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ABSTRACT 
 
The aspiration of gastric contents into the respiratory tract has been associated 
with the development and progression of multiple respiratory diseases in humans. In 
veterinary medicine the term “aspiration” is considered synonymous with “aspiration 
pneumonia” which, while frequently encountered, does not accurately reflect the breadth 
of aspiration associated respiratory syndromes (AARS). In the clinical veterinary 
literature, the effect of alimentary dysfunction on respiratory disease (aerodigestive 
disease) is rarely investigated despite evidence in the human literature, animal models, 
and some studies and case reports linking alimentary and respiratory disease in clinical 
small animal patients.  Aerodigestive disease is rarely investigated in veterinary medicine 
due to lack of clinical recognition and limitations in available diagnostics. Furthermore, 
AARS may be precipitated by several potentially occult alimentary disorders. Current 
methods of investigating aerodigestive diseases in veterinary patients are limited by 
sensitivity, specificity, potential for bias, cost, and availability. This necessitates 
investigations into advanced diagnostics to identify a potentially underrecognized patient 
population with AARS. Additionally, similarities in anatomy, physiology, and several 
pathologic disorders between dogs and humans, make experimental and naturally 
occurring canine models integral to translational research. Thus, evaluating dogs with 
aerodigestive disease may represent an area of substantial clinical relevance in human as 
well as veterinary medicine. 
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CHAPTER 1 
 
AERODIGESTIVE DISEASE: PATHOPHYSIOLOGY, PATHOGENESIS 
AND THE NEED FOR NOVEL DIAGNOSTICS  
 
 
Introduction  
Aerodigestive disorders in people encompass a wide range of conditions 
reflecting the complex interrelationship between swallowing and respiration. That these 
two systems should be intimately related should come as no surprise given their common 
embryological origins, anatomy and innervation.(1) In humans, aerodigestive diseases 
have been implicated in the pathogenesis and progression of several acute and chronic 
respiratory conditions. For example, gastroesophageal reflux (GER) is a frequent source 
of acute and chronic pulmonary disease in human medicine with a prevalence of 50% in 
patients with chronic cough, asthma and chronic obstructive pulmonary disease 
(COPD).(2-6)  GER and extra-esophageal reflux (EER) are defined as the movement of 
gastric contents into the esophagus and from the esophagus to the pharynx respectively. 
Clinical signs resulting from GER and EER are considered gastroesophageal reflux 
disease (GERD) and extra-esophageal reflux disease (EERD) respectively. These 
conditions represent a diagnostic challenge because many patients present with an 
absence of gastrointestinal signs.(7-9) Despite the prevalence of GER in the 
aforementioned respiratory conditions, up to 45% of humans with confirmed GERD are 
asymptomatic for alimentary tract signs.(10)  This makes clinical recognition of the 
relationship between the alimentary and respiratory tracts critically important as 
uncontrolled reflux in humans is known to lead to progression of respiratory disease and 
exacerbations of clinical signs, and increase patient morbidity and treatment costs.(11) 
2 
 
Treatment of GERD and EERD has been demonstrated to reduce the frequency of disease 
exacerbations and slow the rate of decline in lung function in humans with COPD.(2)  
Although aspiration pneumonia is the best recognized example of aerodigestive 
disease in dogs, the spectrum of possible conditions associated with reflux with or 
without aspiration is far broader.(12) Animal models and clinical case reports and case 
series have demonstrated bronchoconstriction, laryngeal dysfunction, and micro-
aspiration in response to experimental or naturally occurring reflux.(12-16) A case series 
in dogs treated for gastrointestinal tract disease prior to brachycephalic airway surgery 
found a decreased complication rate and improved prognosis.(17) This suggests that a 
subpopulation dogs with respiratory disease, like humans, have reflux and may respond 
to treatment targeting the gastrointestinal tract.  
Advanced diagnostics available for the detection of reflux and aspiration 
associated respiratory syndromes (AARS) in humans include protein biomarkers, high 
resolution impedance manometry, and ambulatory pH monitoring. These are not routinely 
used in veterinary medicine due to limitations in sensitivity, specificity, potential for bias, 
expense, necessity for clinical expertise, and in some cases extremely limited 
availability.(8, 18-20)  This necessitates investigation into more readily available 
advanced diagnostics to identify patients with ARRS. This review will provide an 
overview of respiratory and swallow coordination, aspiration associated airway 
inflammation, risk factors for aspiration, AARS recognized in veterinary medicine, the 
currently available diagnostics for identification of aerodigestive disease in veterinary 
3 
 
patients, as well as areas of future interest.   
Physiology of Swallowing  
 Swallowing is both a feeding behavior and an airway protective behavior.  The 
latter occurs by clearing material from the pharynx and disposing of material removed 
from the airways by mucociliary clearance.(21) A swallow is classically divided into 
three sequential phases; the oral/preparatory phase, pharyngeal phase, and esophageal 
phase. The oral/preparatory phase is largely voluntary and responsible for prehension, 
mastication, and conduction of a formed food bolus to the vallecullae located between the 
elevated epiglottis and base of the tongue.(22, 23)  
Unlike the oral/preparatory phase, the pharyngeal and esophageal phases of 
swallowing are involuntary and irreversible once triggered. The pharyngeal swallow may 
occur spontaneously (reflexive swallow) or be triggered by mechanical or chemical 
stimulation of the pharynx and larynx.(21, 24) Stimulation of laryngeal and pharyngeal 
structures is relayed by the cranial laryngeal nerve, and to a lesser degree the 
glossopharyngeal (CN 9) and recurrent laryngeal nerves to the brainstem and nucleus 
tractus solitarius (NTS) and nucleus ambiguous (AMB) to initiate downstream 
contraction of the pharyngeal and mylohyoid muscles which propel the bolus through the 
upper esophageal sphincter (UES).(22, 23) The cranial laryngeal and recurrent laryngeal 
nerve are branches of the vagus nerve (CN 10).   
Pharyngeal stimulation triggers the esophageal phase of swallow by triggering a 
primary esophageal contraction. Subsequent contraction of the esophageal musculature 
conducts the bolus into the stomach through an open lower esophageal sphincter (LES) 
followed by LES closure to prevent reflux. Normal esophageal peristalsis may be 
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modified during multiple rapid swallows where primary esophageal peristalsis is 
inhibited and the LES remains relaxed until the end of the last pharyngeal swallow before 
returning to baseline. (25) It is important to note that motor endplates of esophageal 
skeletal muscle differ from skeletal muscle elsewhere in the body and reflects a complex 
point of integration between extrinsic vagal cholinergic, intrinsic nitrergic, peptidergic, 
and monaminergic neurons. Co-innervation allows modulation of esophageal skeletal 
muscle by myenteric neurons and may reflect a mechanism for common diseases, such as 
megaesophagus, that are observed between species despite differences in esophageal 
muscle composition. Different species show significant variability in the proportion of 
skeletal to smooth muscle in the body of the esophagus. The canine esophagus is 
composed entirely of skeletal muscle compared to where smooth muscle is the dominant 
muscle type, particularly in the distal esophagus.  (26)    
The opening of the LES in response to a pharyngeal swallow is important as 
defects in this process have been implicated in the pathogenesis of spastic esophageal 
disorders in humans including LES achalasia.(26) Swallow-induced LES relaxation is a 
vagally-mediated process with nitric oxide acting as the dominant neurotransmitter. Co-
innervations by peptidergic capsaicin sensitive neurons are thought to play a modulatory 
role in maintaining LES tone with substance P antagonism causing a decrease in basal 
LES tone in a canine model. (26, 27)     
Airway Protective Mechanisms  
Swallowing and respiration require shared use of multiple structures. For 
example, the pharyngeal musculature must dilate to allow airflow during breathing while 
also facilitating bolus conduction to the upper esophageal sphincter during pharyngeal 
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swallow. As such, critical protective mechanisms must exist to prevent aspiration. (Figure 
1) These include respiration/swallow coordination, i.e. “gate keeping,” in addition to 
basal and response mechanisms.(23, 28)  
 “Gate keeping”  
Gate-keeping refers to the centrally-mediated coordination of swallow and 
respiration. In healthy people, breathing is a regular stereotyped behavior that may be 
interrupted by conscious ingestion of food or liquid, or unconsciously by swallowing of 
secretions.(29)  Swallowing and breathing are under the regulation of central pattern 
generators located in the brainstem: the swallow central pattern generator (swCPG) and 
respiratory central pattern generator (rCPG), respectively. Stimulation of the swCPG 
results in sequential contraction of swallow effector muscles. Cross communications 
between the swCPG and rCPG coordinates swallowing and breathing such that 
swallowing occurs preferentially during specific phases of the respiratory cycle, and 
corresponds with the generation of swallow-apnea, a “swallow breath” which is a breath 
just prior to the onset of swallow, and respiratory phase resetting.(23, 29)   
Swallowing preferentially occurs during specific phases of the respiratory cycle. 
Timing of swallow varies with species. In humans, swallows are initiated during the post-
inspiratory and expiratory phases even if the swallow stimulus was delivered during 
inspiration.(23, 30) In both anesthetized and in awake, spontaneously swallowing dogs, 
nearly 80% of swallows occurred during the inspiratory phase.(31) Interestingly, 
respiratory swallow coordination may be impacted by posture. When humans adopt a 
feeding position more like dogs, swallowing occurs more frequently in the inspiratory 
phases in the breathing cycle.(32)  Increases in inspiratory phase swallowing have been 
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documented in the elderly and in patients with dysphagia. Both populations are at 
increased risk of aspiration.(33) Inspiratory phase swallowing has also been documented 
in humans with chronic respiratory disease, linking disordered respiration and swallow 
coordination with increased risk of AARS.(23, 29, 34)  
Another means of airway protection during swallowing is swallow-apnea.(23) 
Studies in humans, as well as small and large animal models have documented a drop in 
airflow nearly to zero corresponding with pharyngeal swallow. This occurs as a result of 
powerful laryngeal adduction and restriction of diaphragmatic contraction.(23, 35, 36) It 
should be noted that despite airflow decreasing to zero, some small-amplitude discharges 
are observed in electromyograms and neurograms of the diaphragm and phrenic nerve 
respectively.(23) It has been hypothesized that a “swallow breath” immediately before a 
breath-hold maintains a positive subglottic pressure permitting expiratory airflow after a 
swallow and clearance of residual secretions from the airway.(23) Multiple swallows in 
series prolongs swallow apnea. This places increased stress on patients with respiratory 
disease and is associated with disordered coordination of respiration and swallow. This 
may increase risk of aspiration in patients with existing respiratory disease contributing to 
disease exacerbations.(34)  The disruption of the normal respiratory phase to 
accommodate a swallow causes the introduction of a new respiratory rhythm. Following 
apnea, the next breath is brought forward or delayed depending on the phase of the 
respiratory cycle when the swallow was initiated.(37, 38) Therefore, swallow affects not 
only the breath just following the swallow but all subsequent breaths as well.  
Basal mechanisms 
Basal mechanisms are barriers to aspiration which are present independent of 
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stimulation. The specific mechanisms encountered depend on the source of aspiration 
(i.e., gastroesophageal or oropharyngeal). In GER, gastric contents must span the length 
of the esophagus to reach the pharynx. In doing so, the refluxate must cross 2 high-
pressure zones: the LES and UES. The LES is a high-pressure zone at the distal 
esophagus comprised of intrinsic and extrinsic components. The intrinsic component 
consists of circular smooth or skeletal muscle fibers, depending on species. In humans 
and dogs this is a band of smooth muscle at the junction between the distal 
esophagus.(39, 40) The extrinsic component consists of external pressure from the 
diaphragm. These combined sources of pressure act as a barrier to reflux and must be 
overcome to allow bolus passage into the stomach from the esophagus. Basal pressure of 
the LES in non-anesthetized dogs is approximately 30 mm Hg which, like in humans, has 
been demonstrated to be variable with body position and is reduced in patients under 
anesthesia.(41, 42)  The UES serves as a barrier between the proximal esophagus and the 
pharynx. The role of the UES is to accommodate an anterograde swallowed bolus while 
preventing retrograde esophago-pharyngeal reflux and aspiration. The primary muscle 
responsible for closure of the UES is the cricopharyngeus (CP) muscle. The CP has 
several distinct characteristics compared to other striated muscles including increased 
density elastic connective tissue and sarcolemma. Because of these structural features, the 
UES maintains basal tone without active contraction. This tension increases with the 
degree of distention and allows a greater closing force to be applied behind a swallowed 
bolus.(43) The esophagus itself also has the capacity to contain refluxate until it can be 
cleared without allowing it to escape to the pharynx. Upon reaching the pharynx both 
GER and oropharyngeal aspiration encounter the same barriers to aspiration. The 
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pharynx, like the esophagus, can contain certain volumes before it overflows into the 
airways.  Within the airways and lungs, mucociliary clearance and innate immunity 
represent additional basal barriers to AARS by mitigating the impact of aspirated material 
on the respiratory tract. (28, 29) The immune response to aspiration will be discussed 
later in this chapter.  
Response mechanisms 
Like the basal mechanisms, response mechanisms involve the pharynx, larynx, 
glottis, UES, esophageal body, LES, and airways. Unlike basal mechanisms, response 
mechanisms become active in response to mechanical or chemical stimulation. These can 
be subcategorized into 4 categories: (1) reflexes that clear volume from the pharynx and 
esophagus, (2) reflexes that accentuate the upper esophageal pressure barrier, (3) reflexes 
that induce closure of the larynx, and (4) clearing reflexes that remove aspirated material 
from the airways, i.e., cough and throat clear.   
Reflexes that clear volume from the pharynx and esophagus include the reflexive 
pharyngeal swallow (RPS) and secondary peristalsis.(44, 45)  The RPS acts as a major 
airway protective behavior by removing debris and residue from the entrance to the 
respiratory tract.(44) These responses have been demonstrated in large and small animal 
models by stimulation of the pharyngeal wall, epiglottis, larynx, or by injection of water 
into the pharynx in humans.(24, 44, 46, 47) This response is presumed to protect against 
spillage of oral contents into the pharynx during the oral/preparatory phase of 
swallowing, or in response to refluxate from the stomach. Unlike primary swallows, the 
RPS is not preceded by an oral/preparatory phase and lacks lingual peristalsis.(44) 
Otherwise RPS are indistinguishable from primary swallows. It has been documented that 
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a larger volume is needed to trigger RPS in the elderly and that the rate of spontaneous 
swallow is lower which may predispose them to aspiration.(48) These swallows also play 
a significant role in airway protection during sleep in cases of  nocturnal reflux.    
Secondary peristalsis refers to peristalsis activated by distention. These occur in 
response to retained volume within the esophagus following primary peristalsis or in 
response to refluxed materials from the stomach. Distention activates a vagally-mediated 
reflex that leads to sequential activation of the esophageal musculature, relaxation of the 
LES and variable changes in UES pressure. Unlike primary peristalsis, secondary 
peristalsis is not preceded by a pharyngeal swallow. In this way, secondary peristalsis is 
similar to RPS.(45)  
Reflexes that increase the upper esophageal pressure barrier include the esophago-
UES contractile reflex, the pharyngo-UES contractile reflex, and the laryngo-UES 
contractile reflex.(49, 50) The UES maintains a high-pressure zone between the 
esophagus and pharynx that relaxes in response to a pharyngeal swallow. However, the 
magnitude of pressure exerted by the UES is variable in response to level of arousal, 
degree of esophageal distention, location and rate of distention (slow vs. rapid, proximal 
vs distal esophagus), the type of distending material (gas vs. liquid, acidic vs. non-acidic), 
and body orientation.(49-52) Upper esophageal sphincter reflexes are mediated by 
complex circuitry that depends on the type, number and location of mucosal, submucosal 
and muscular receptors.  In response to slow esophageal dilation, the UES responds by 
increasing tone.(51)  This reflex is most pronounced by distention near the LES and is 
augmented by esophageal peristalsis to clear esophageal volume. Rapid esophageal gas 
distention however, results in UES relaxation.(49, 50) These responses are also 
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influenced by body position and arousal. In humans, the upright position is associated 
with UES relaxation, rapid proximal esophageal distention, and is commonly associated 
with gas (eructation). UES contraction however, is more common during recumbancy, 
slow distal esophageal distention, and is associated with liquid refluxate.(53) This reflex 
also varies with arousal and is nearly abolished during deep sleep.(52) Studies 
investigating esophageal reflex responses in cats have demonstrated that the UES 
contractile response is mediated by vagal afferent fibers interacting with activated 
mucosal and mechanoreceptors.(54)  
The pharyngo-UES contractile reflex has been documented with mechanical 
pharyngeal stimulation in cats (54) and water stimulation in humans, whereby water is 
injected into the pharynx to induce a response in the UES.(48) In both cases, stimulation 
resulted in increased UES tone. It is presumed that activation of this reflex prevents 
further leakage of gastric contents into the pharynx. This reflex response is nearly always 
followed by RPS. Topical anesthetics applied to the pharyngeal mucosa ablates this 
reflex.(55) The laryngo-UES contractile reflex describes increases in basal UES tone in 
response to laryngeal stimulation. While peripheral and central pathways are different 
between the pharyngo- and laryngo- UES contractile reflexes, both are thought to act to 
prevent additional GER from escaping into the pharynx. Interestingly, paradoxical and 
absent UES responses have been documented in people with UES dysphagia and those 
with reflux-induced laryngeal and pulmonary disorders demonstrating how reflux may 
perpetuate disease by diminishing airway protective mechanisms.(56)   
Reflexes that induce laryngeal closure include the esophago-laryngeal closure 
reflex, pharyngo-laryngeal adduction reflex, and laryngeal adductor reflex. The 
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esophago-laryngeal closure reflex occurs in response to esophageal distention. Abrupt 
distention of the esophagus is seen in response to reflux, vomiting and regurgitation. 
Studies in both animal models and people have documented reflexive adduction of the 
larynx in response to abrupt esophageal distention as a protective mechanism against 
aspiration.(57, 58)  Unlike the esophago-UES reflex, abrupt esophageal distention 
triggers laryngeal closure regardless of location. Esophageal stretch receptors in the 
esophageal body and vagal motor fibers have been implicated as the afferent and efferent 
arms of this response respectively.(58)  The role of this response is presumed to be a 
protective mechanism in response to belching, reflux, regurgitation and vomiting.(59) 
Experimental feline models have demonstrated that esophagitis significantly reduces the 
strength and frequency of this response.(55) Additionally, treatment with topical lidocaine 
or capsaicin, or removal of the esophageal mucosa significantly inhibits this protective 
reflex. This suggests that mucosal stimulation plays a significant role in the induction of 
this reflex.(60)  
 The pharyngo-laryngeal adduction reflex refers to the brief closure of the larynx 
in response to pharyngeal stimulation.(61, 62) This reflex has been stimulated with 
experimental injection of water into the pharynx and in dysphagic patients with 
demonstrated overflow of ingesta into the pharynx during the oral/preparatory phase. The 
adduction of the larynx is believed to reduce the risk of significant aspiration by 
decreasing the diameter of the glottal opening of the larynx during swallowing. This 
response is absent in dysphagic patients with predeglutitive aspiration (i.e. aspiration 
prior to pharyngeal swallow), supporting the role of this reflex as an airway protective 
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behavior.(63)   
The laryngeal adductor reflex occurs in response to stimulation of the larynx 
mediated by the cranial laryngeal nerve. The reflex is activated by mechanical, chemical, 
or thermal stimuli. Importantly small animal experimental models and human studies 
have demonstrated suppression of this response with increased anesthetic depth 
suggesting that diminished laryngeal reflexes may result in increased risk of aspiration 
during sedation and anesthesia and that it may be possible to modulate the degree of 
impact on airway protective mechanisms by careful selection of anesthetic protocols .(64)  
The most easily recognized and evaluated airway protective mechanisms are 
cough and throat clear (TC). Cough and TC play an important protective role that 
facilitates clearance of particulate matter, irritants, debris, and/or fluid from the 
respiratory tract.(65) Cough, when excessive, may also become harmful to the airways 
and negatively impact the quality of life for both dog and client.(65-67) This highlights 
the need to balance targeted therapy allowing adequate airway protection while not 
allowing cough to become detrimental. Cough can be subdivided into 3 phases: an 
inhalation phase, a pressurization phase, and an expulsion phase that forcefully ejects air 
against a closed glottis. A TC lacks an inhalation phase but otherwise serves a similar 
role. Both cough and TC are stimulated by chemical or mechanical stimuli.(68, 69) 
Cough is triggered by stimulation of the pharynx, larynx, trachea, carina, and bronchi 
while TC is typically associated with stimulation of the pharynx, larynx, and cervical 
trachea only.(67, 69) 
Induction of cough in humans and animal models, including dogs, is thought to 
arise from a dual sensory system. C-fibers are mechanically insensitive but respond to a 
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wide variety of chemical mediators including prostanoids, bradykinin, and ions. These 
also contain tachykinin-expressing neurons including transient receptor potential 
vanilloid 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1).(1, 70-72) The 
second sensory arm of cough involves mechanically sensitive myelinated vagal afferent 
fibers that are localized to the trachea, and mainstem and segmental bronchi.(73) Though 
these are largely considered chemically insensitive due to the absence of TRPV1 and 
TRPA1 ion channels, they are activated by protons by another unknown acid sensing ion 
channel. These receptors are responsive to touch-like mechanical stimulation. Peripheral 
terminals are confined to the space between the epithelial cell layers and smooth 
muscle.(1)  Pulmonary stretch receptors are critical in determining lung volume but they 
are not thought to participate directly in cough beyond modulating sensitivity to tussive 
stimuli and determining pre-cough inspiratory volumes.(74)   
Central mechanisms regulating cough include synergistic reflex bronchospasm as 
a result of vagal afferents converging in the caudal brainstem.(75) Further C-fiber 
activation has been demonstrated to have a sensitizing effect on cough receptors via a 
central nervous system dependent mechanism, echoing central pain sensitization in 
somatic tissues.(76)  In people, cough can also be generated from extra-pulmonary 
structures including the ear, nose, pharynx, and esophagus.(1) While extrapulmonary 
cough has been presumed in dogs, the same degree of characterization has not been 
performed compared to other AARS.(12, 77-79)  Clinical recognition of extra-pulmonary 
sources of cough is particularly important as disease may be missed by routine thoracic 
imaging.(80) The source of cough in these regions is theorized to be multifactorial with 
both direct stimulation of sensory afferents and secondary sensitization being implicated. 
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Cough secondary to esophageal stimulation has been demonstrated both in people and in 
animal models. While aspiration of refluxate has been demonstrated, this is not necessary 
to generate cough. Shared vagal innervation between the esophagus and airways result in 
increased mucous secretion and bronchospasm which may generate cough without 
aspiration.(81)  
Aspiration and Respiratory Inflammation 
 Aspiration has been implicated in extra-pulmonary (i.e., laryngeal, pharyngeal, 
middle ear, etc.), airway, and pulmonary parenchymal disorders through the action of 
acid, digestive enzymes, and aspiration of foreign material into the airways.(12, 28, 82-
84) As 50% of healthy people aspirate during sleep without clinical significance,(85) it is 
likely that the development of disease depends on the content and volume of the aspirated 
material rather than the act of aspiration itself. Aspiration may be witnessed or occult and 
may be oropharyngeal or gastroesophageal in origin.(86)   
 In people, the inhalation of low pH gastric fluid, digestive enzymes, and/or 
particulate material frequently leads to sterile aspiration pneumonitis which may or may 
not develop a secondary bacterial complication (aspiration pneumonia).(86, 87) However, 
lack of clinically distinguishing features leads to over-diagnosis of secondary bacterial 
pneumonia and potentially inappropriate treatment.(86, 87) This distinction is rarely 
made in veterinary medicine and may contribute to antimicrobial overuse in veterinary 
patients. In people, large volume aspiration may lead to a severe form of acute respiratory 
distress syndrome (ARDS). In people with aspiration pneumonitis, one third of patients 
develop a severe prolonged disease course associated with ARDS.(86, 88, 89) 
Alternatively, chronic aspiration of small volumes (micro-aspiration) may lead to diffuse 
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aspiration bronchiolitis and has been speculated by some to lead to disease exacerbations 
in, if not the development of, idiopathic pulmonary fibrosis. (89)  
 Inflammation in acidic aspiration is frequently modeled by instillation of 
hydrochloric acid into the trachea of small animal models.(90) In rodent models, the 
response to acid instillation is characterized by a bi-phasic inflammatory response where 
an immediate response involving capsaicin sensitive TRPV-1 neurons and direct damage 
to the respiratory epithelium, is followed 4-6 hours later by IL-6 and IL-8 mediated 
neutrophilic inflammation. Subsequent extravasation of fluid and protein into the alveoli 
and airways due to loss of pulmonary vascular integrity increases work of breathing and 
airway resistance, decreases lung compliance, impedes diffusion of oxygen, and 
interferes with pulmonary surfactant.(86, 90-93)  Decreasing airway and pulmonary pH 
has additional negative effects on normal immunologic responses. Antimicrobial peptide 
activity, cytokine expression, and macrophage activity have all been demonstrated to 
decrease in response to acidic conditions.(86)  
 Like acid, digestive enzymes play a role in respiratory inflammation following 
aspiration. Pepsinogen is produced in the chief cells of the gastric mucosa and undergoes 
conversion to pepsin in response to a low pH. Deactivation begins at a pH of 6.8 before 
becoming irreversibly deactivated at pH 7.5. A human bronchial epithelial cell model 
found pepsin to be directly cytotoxic and induce an inflammatory response. An in vivo 
study in rabbits demonstrated erosive esophageal lesions secondary to pepsin exposure 
were caused by destruction of junctional molecules.(94) Similar lesions have been 
identified in airways following aspiration of gastric fluid.(9, 94) Importantly for the role 
of pepsin in the development of upper airway disease, pepsin sensitive receptors have 
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been demonstrated in human laryngeal tissue.(95, 96) After binding, pepsin is taken up 
into endocytic vesicles where the pH is approximately 5. At this pH pepsin that is not 
irreversibly denatured may become re-activated.(96) Pepsin at a pH of 5 has 
demonstrated 40% of its maximal proteolytic activity.(86, 97) Epithelial damage to 
endocytosed pepsin in the upper airways has been demonstrated in people and highlights 
the role of non-acidic, extra-esophageal reflux in the pathogenesis of upper airway 
inflammation.(9, 95, 96)  Bile acids (BA) have been documented in BALF fluid in human 
patients with reflux-associated respiratory disease and in dogs with pulmonary 
fibrosis.(98-100) Studies have implicated BA aspiration in pulmonary infections by 
Pseudomonas aeruginosa. BA aspiration is associated with increased expression of IL-8 
and tumor necrosis factor alpha (TNFa) in animal models though the complete 
inflammatory mechanism is incompletely understood.(86)  
 Small non-acidified gastric particles (SNAPs) also induce inflammation in the 
respiratory tract. In small animal models, tracheal instillation of small (<10 um) particles 
lead to neutrophilic inflammation at 4-6 hrs.(97) A lack of pulmonary edema 
distinguishes SNAP induced inflammation from neutrophilic inflammation secondary to 
aspiration of acidic gastric contents.(97) In small animal models, monocytic influx occurs 
after 48 hours initiating the formation of granulomatous inflammation by a monocyte 
chemoattractant protein-1 (MCP-1) mediated process.(97) Importantly, the combination 
of acidic aspiration and SNAP aspiration appears to have a synergistic effect. Albumin 
concentrations in BAL fluid, which serves as a marker of alveolar capillary membrane 
integrity, are significantly higher in animal models with combined acid and SNAP 
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aspiration compared either acid or SNAP alone. (86, 97) 
Risk factors for aspiration  
 Increased risk for developing AARS have been reported for human patients with 
altered consciousness, impaired airway protective mechanisms, and conditions capable of 
overwhelming barriers to aspiration.(97) These risk factors are mirrored in dogs where 
level of consciousness, body position during anesthetic recovery, duration of anesthesia, 
vomiting and regurgitation, seizures, cranial nerve deficits and the presence of 
megaesophagus are independent risk factors for developing aspiration pneumonia 
following surgery.(101, 102) More than 1 disorder may occur concurrently with dogs 
having 1, 2 and 3 associated disorders in 68%, 26%, and 6% of cases respectively.(102) 
The most common underlying disorders included esophageal disease (39.8%), vomiting 
(38.6%), neurologic disease (27.3%), laryngeal disease (18.2%), and post-anesthetic 
aspiration (13.6%).(102) Of those with esophageal disease, megaesophagus (ME) was 
identified in 71.4% of dogs. The remaining dogs were diagnosed with non-ME 
esophageal dysmotility, hiatal hernia, and an unknow disorder in 17.1%, 2.8%, and 8.6% 
of dogs respectively.(102)  Though focusing specifically on aspiration pneumonia, these 
studies highlight the role of alimentary disease, particularly esophageal disease, in the 
development of aspiration. Given the breadth of aspiration syndromes, the role of 
alimentary dysfunction in the development of respiratory disease may be even greater 
than these studies suggest and warrants further study.  
Recognized Aspiration Related Respiratory Syndromes in Dogs  
The ultimate prevalence of aerodigestive disease in dogs is currently unknown, 
however they represent a significant source of morbidity and mortality in human patients 
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and are associated with disease progression, exacerbations of clinical signs, and treatment 
costs.(103) As dogs are susceptible to many of the same conditions as people a similar 
spectrum of disorders should be expected with number of similar conditions being 
reported in individual case reports and case series.(12, 79, 104-106) An extensive review 
has been performed previously and is beyond the scope of this manuscript,(12) however 
for a brief overview aspiration associated respiratory syndromes reported in dogs and in 
people are presented in Table 1.  
Diagnostic Testing for Aerodigestive Disorders  
Thoracic radiographs are often considered the first line diagnostic for patients 
presenting evidence of respiratory disease. Though widely available, radiographs are 
poorly sensitive for aerodigestive disease where signs are elicited by stimulation of the 
esophageal-bronchial reflexes as well as mechanical/chemical stimulation of the pharynx 
and larynx which are poorly imaged by standard thoracic radiography.(107-111) 
 Adjunctive diagnostic and monitoring strategies for GER and EER in veterinary 
medicine incorporate a combination of client surveys, treatment trials with proton pump 
inhibitors (PPIs), esophagoscopy, and rarely esophageal manometry and ambulatory pH 
probes.(19, 112-119) However, these have significant limitations. Client reporting is 
inherently prone to bias due to variable client vigilance, and a failure to recognize 
episodic, subtle clinical signs. Treatment trials with antacid therapy may be associated 
with a large and variable placebo effect. In people, randomized control trials that included 
a placebo arm have documented improvement in 1% to 40% in the placebo group, often 
meeting statistical significance.(120, 121) Diagnostic tests relying upon esophageal or 
pharyngeal pH fail to recognize reflux in human patients treated with PPIs or those with 
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non-acidic reflux, which is being increasingly implicated in disease representing up to 
90% cases in some human studies.(9, 122-124) Diagnostics requiring anesthesia impart 
increased risk of aspiration events due to decreased airway protective mechanisms.  In 
human studies endoscopy identified abnormalities in less than 50% of patients with 
known disease.(116) High resolution manometry and pH probes are significantly limited 
by availability, cost, and the need for substantial operator training.(18, 19) As such, 
additional diagnostic and monitoring strategies are needed.   
 The current methods of evaluating aerodigestive disease in veterinary patients are 
limited necessitating investigation into novel strategies. Several avenues of potential 
investigation exist both for diagnosing aerodigestive disease and for objective disease 
monitoring. These include videofluoroscopic swallow studies (VFSS), reflux 
scintigraphy, biomarker development, and acoustic wave analysis.  
Videofluoroscopic swallow studies  
Videofluoroscopic swallow studies (VFSS) are considered the criterion standard 
for the evaluation of dysphagia in dogs.(125) Historically, these have been performed 
with dogs held in lateral recumbancy and force-fed. This has limited its use in several 
disorders due to unacceptable risks of aspiration. Recent studies have proposed an 
alternative which, by allowing free-feeding, reduces risk of aspiration to what would be 
expected from feeding at home. Natural feeding position and standardized food items 
with rheological properties objectively consistent with commercially available products, 
further increases the physiologic relevance of VFSS in dogs. (125) Utilizing this 
technique for evaluation of aerodigestive disorders in dogs may provide valuable 
information for dogs with occult aerodigestive disease, or help identify patients at risk for 
20 
 
developing an ARRS.  Chapter 2 describes our investigation of VFSS in dogs with cough 
lacking alimentary tract signs.  Chapters 3-4 detail investigations of a novel cause for 
canine megaesophagus and associated directed therapy.  
Scintigraphy  
Nuclear scintigraphy, which has been employed to measure mucociliary clearance 
in dogs,(126)  is also capable of measuring reflux and cumulative small volume 
aspiration.(127-129) It does not rely on pH, is non-invasive, and can be performed 
without anesthesia.(127-131) This technique is considered safe and has been used to 
evaluate pulmonary aspiration in fragile human infants.(127, 130) In adults, cough and 
laryngospasm were strongly correlated with positive reflux/aspiration scintigraphy.(130) 
Further, patients who were positive for reflux on scintigraphy had symptomatic response 
to surgical treatment. (130)  Adaptation of this technique in dogs may allow detection of 
microaspiration, which may not be detectable by conventional imaging modalities. 
Before placing pathologic significance on findings in clinically affected dogs, normative 
data is needed. Chapter 5 describes our use of reflux scintigraphy to evaluate for GER, 
EER, and aspiration in heathy dogs.  
Biomarkers of Reflux  
Biomarkers are used to diagnose, prognosticate, and identify populations at risk 
for disease. In recent years biomarkers had a progressively larger impact in companion 
animal medicine.(132)  Biomarkers have the potential to advance our understanding of 
disease pathogenesis and allow objective investigation of efficacy of novel therapeutics in 
various disease states. Biomarkers have been used reliably to provide evidence of reflux 
and aspiration in human patients.(100, 122, 133) Though not used routinely in veterinary 
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medicine, there is evidence that aspiration may be detected in respiratory secretions in 
veterinary patients.(98) Further evaluation of potential biomarkers is warranted to detect 
patients with reflux associated respiratory syndromes. Chapter 6 describes our study 
characterizing the gastric fluid proteome of dogs as well as the oropharyngeal proteome 
in healthy, coughing, and vomiting or regurgitating dogs. This pilot discovery study is 
indented to evaluate for potential protein biomarkers of reflux and aspiration.  
Acoustic cough monitoring  
Cough represents both a critical defense mechanism for the respiratory tract as 
well as a marker for disease control. Cough additionally represents a significant source of 
frustration for both patient and client. Unfortunately, management of cough in veterinary 
medicine is often suboptimal and based on subjective response rather than objective 
evidence. Acoustic wave analysis incorporating spectral and waveform evaluation has 
provided an objective means of detecting cough in people but has not yet been adapted 
for veterinary use.(134-139) This may provide a means of objectively evaluating cough 
frequency in veterinary patients and bridge the gap between subjective monitoring and 
objective assessment. Chapter 7 describes our study characterizing the canine cough 
acoustic wave form and comparison to other acoustic behaviors to determine its potential 
utility as an objective disease marker in dogs with cough.   
Conclusions  
 Aerodigestive diseases are the result of discordant respiration and swallow and 
are currently underdiagnosed in our canine patients. The close inter-relationship between 
these two antagonistic processes represents a broad range of diagnostic and clinical 
challenges.  Further investigation into these conditions in dogs requires advancing 
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respiratory diagnostics beyond thoracic radiography to include dynamic and functional 
imaging as well as objective monitoring strategies to identify a potentially under-
recognized patient population. Identification and characterization of patients with 
aerodigestive disease may further opens the doors for the development of novel targeted 
interventions. The following chapters detail our contributions to this endeavor.  
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CHAPTER 2 
 
AERODIGESTIVE DISORDERS IN DOGS EVALUATED FOR COUGH 
USING RESPIRATORY FLUOROSCOPY AND VIDEOFLUOROSCOPY 
SWALLOW STUDIES  
 
 
Introduction 
Aerodigestive disorders in people represent a broad spectrum of diseases that 
emphasize the complex interrelationship between respiration and swallowing.(140, 141) 
Unfortunately, diagnosis is challenging as these conditions frequently present without 
gastrointestinal signs.(142) Aerodigestive disease(s) (AeroD) are infrequently 
investigated in dogs due a combination of poor clinical recognition and limitations in 
available diagnostics. Aspiration pneumonia (AP) is the most well recognized example of 
AeroD in dogs. However, in humans and less commonly dogs, macro-aspiration and 
chronic micro-aspiration have also been associated with upper and lower airway 
dysfunction, bronchiolar diseases, interstitial lung disease, and aspiration pneumonitis.(5, 
14, 143, 144) Reflux is a common source of chronic microaspiration in people, resulting 
in acute and chronic pulmonary disease. The prevalence of reflux in chronic cough, 
asthma and chronic obstructive pulmonary disease (COPD) is 50%.(2, 5, 13, 14) 
Comparable studies in dogs with respiratory symptoms are lacking.  
Thoracic radiographs are often considered a first line diagnostic test for dogs with 
respiratory disease. Though widely available, radiography is insensitive compared to 
alternative imaging modalities for a number of respiratory syndromes.(109-111) This may 
be especially true for those with AeroD, where cough may be elicited by stimulation of 
the esophageal-bronchial reflex. This reflex, which involves vagally-mediated 
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bronchoconstriction secondary to acidic stimulation of the distal esophagus, underscores 
the interplay of acid reflux with respiratory clinical signs. Mechano- and/or 
chemoreceptor stimulation of the pharynx, larynx, and cervical trachea can also trigger 
cough which is not well evaluated by standard thoracic radiography.(107, 108)   As such, 
alternative diagnostics are frequently required.(145, 146) 
The association between reflux, aspiration, and airway dysfunction has not been 
thoroughly evaluated in veterinary medicine, though the link has been supported by a 
number of clinical case reports and experimental canine models.(15, 17, 79, 144)  
Identifying patients affected by AeroD could prove important as uncontrolled reflux in 
people leads to disease progression, exacerbations of clinical signs, increased patient 
morbidity, and treatment costs.(11) Patients with a history of  cough which worsens 
during eating and drinking, or those with concurrent regurgitation/vomiting may prompt 
consideration of AeroD. However, a subpopulation with occult alimentary disease may 
prove clinically important by identifying new therapeutic targets and/or by providing a 
diagnosis in dogs with persistent cough despite unremarkable conventional diagnostics 
(i.e., idiopathic cough). 
Videofluoroscopic swallow studies (VFSS) are the criterion standard for 
evaluating dysphagia in dogs.(147) It is unknown if VFSS could identify subclinical 
pathology in dogs without dysphagia or vomiting, but with cough. The objective of this 
study was to evaluate dogs presenting exclusively for cough using respiratory 
fluoroscopy (RF) and VFSS to detect occult AeroD. We hypothesized that a subset of 
dogs presenting exclusively for cough would have documentable evidence of AeroD 
despite the absence of esophageal or gastrointestinal signs.  
25 
 
Materials and Methods  
Case Selection and Criteria  
 Medical records for dogs presenting to the University of Missouri Veterinary 
Health Center (MU-VHC) between April 2015-December 2017 with RF and VFSS were 
retrospectively reviewed. Dogs were included if they had a primary complaint of cough 
without esophageal and gastrointestinal signs, had thoracic radiographs and complete 
medical records. When thoracic radiographs were performed with a referring veterinarian 
and unavailable for review, a radiology report from a boarded radiologist was considered 
adequate for a final radiographic diagnosis. Our exclusion criteria were dogs with cough 
of cardiac origin or esophageal/gastrointestinal signs including dysphagia, regurgitation, 
and vomiting within the preceding 6 months. A terminal retch, after a paroxysm of cough, 
was not considered evidence of gastrointestinal disease and therefore did not meet our 
exclusion criteria.  
Data extracted from the medical record  
 Demographic data, body weight (BW) (kg), body condition score (BCS), head-
conformation, other clinical signs aside from cough, duration of cough, radiographic 
diagnosis, and final clinical diagnosis were acquired from the medical record. The results 
from laryngeal function examination, bronchoscopy, bronchoalveolar lavage fluid 
(BALF) cytology, and culture results were reported when available.   
Respiratory fluoroscopy and videofluoroscopic swallow study   
Dogs meeting our inclusion criteria had their RF and VFSS evaluated by two 
internal medicine specialists (MG, CR) and a board-certified radiologist (IM) for 
standardized outcome parameters. (Table 2) Criteria for evaluation are displayed in 
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Tables 3 and 4. Studies were performed at 30 frames/sec using a GE Advantx or GE OEC 
9900 Elite Mobile C-Arm system (GE Heathcare, Chicago, IL) at the MU-VHC. 
Respiratory fluoroscopy preceded the VFSS. The VFSS was performed as previously 
described.(147, 148) Briefly, after a 12-24 hour fast dogs were placed in a polycarbonate 
kennel appropriate for their body size: small/toy (≤35 lbs), medium (>35 lbs ≤ 65 lbs), 
large (> 65 lbs to ≤85 lbs), and giant breed dogs (≥85 lbs). Dogs were fed three 
standardized food consistencies containing a contrast agent: puree (25% iohexol (350 
mg/mL)), liquid (25% iohexol (350 mg/mL)), and kibble (barium 40% w/v).  
Final Diagnosis  
Canine chronic bronchitis (CCB), eosinophilic bronchitis (EB), AP, laryngeal 
paresis/paralysis, epiglottic retroversion (ER), bronchomalacia (BM), bronchiectasis 
(BE), and hypoplastic trachea (HT) were diagnosed as previously described.(149-155) 
Specific diagnostic criteria are available in Table 5. Non-respiratory or “alimentary” 
cough was diagnosed where there was a VFSS abnormality supportive of an AeroD in the 
absence of an inflammatory or architectural respiratory disorder based on the diagnostics 
performed. 
Statistics  
 Descriptive statistics were performed where appropriate. A Wilcoxon rank-sum 
test or a one-way ANOVA on ranks was performed to detect significant differences in RF 
and VFSS parameters for demographic data, BW (kg), BCS and head-conformation. A p 
< 0.05 was considered significant. Post-hoc analysis (Dunn's method for multiple 
comparisons) was performed where appropriate.  
Results  
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Animals 
 One hundred and thirty VFSS were performed between April 2015 and December 
2017 with 31 dogs meeting criteria for further evaluation. Demographic and clinical data 
are presented in Table 6.  
Diagnostic Evaluation  
Multiple ancillary respiratory diagnostics were performed. With each test, some 
dogs had more than one abnormality identified. Results are presented in Table 6.  
 With respect to VFSS, abnormalities were detected for 25/31 (81%) dogs, 
including 9/11 (82%) dogs with unremarkable radiographs. Six of 11 (55%) dogs with a 
bronchial pattern on radiographs and 6/9 (67%) dogs with sterile neutrophilic and/or 
eosinophilic inflammation on BALF had VFSS abnormalities. All dogs with BE (n=5) 
and BM (n=5) had VFSS abnormalities. Five of 7 (71%) dogs with radiographic evidence 
of AP had abnormalities detectable on VFSS, including all of those with a history of 
recurrent AP.  
Oral-preparatory phase defects were found in 6/25 dogs. Penetration was 
observed in 5 and aspiration in 3 dogs with both penetration and aspiration in 2 of those 
dogs. (Figure 3) Penetration of the larynx was exclusively by kibble. All aspiration events 
occurred with puree and/or liquid. Both were commonly in conjunction with pharyngeal 
dysfunction (pharyngeal hypomotility (PH), n=4; pharyngeal spasticity, (PS) n=1). 
Pathologic reflux was noted in 36% of dogs with abnormal VFSS.  
Epiglottic retroversion was identified in 2 dogs by RF; only 1 of these dogs was 
also identified by functional oral/laryngeal function examination. A laryngeal polyp was 
identified in one dog via RF and was associated with aspiration and pathologic GER.  In 
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6/7 dogs (85.7%) with LarPar, an abnormal VFSS was present. Abnormalities included 
PH (3/7), GER (3/7), penetration + aspiration (2/7), and EH (1/7). No significant 
differences were found for any VFSS based on demographic data, BW (kg), BCS, or 
head-conformation. A summary of all VFSS findings are presented in Table 7.   
Final clinical diagnoses  
Diagnosis of more than one disease was frequently made in dogs with either 
respiratory cough or non-respiratory alimentary cough. (Table 7) Respiratory cough 
without VFSS evidence of alimentary disease was found in 4/31 (13%) dogs. Respiratory 
cough with concurrent VFSS abnormalities was found in 17/31 (55%) dogs. Alimentary 
cough was identified in 8/31 (26%) dogs. Neither a respiratory nor alimentary source of 
cough could be identified in 2 dogs.   
Discussion 
 In dogs presenting for cough without clinical evidence of alimentary disease, 
VFSS documented abnormalities in 81% of cases highlighting the common link between 
the respiratory and alimentary tracts (i.e., AeroD). Identifying dogs with disorders of the 
pharynx, esophagus and stomach as a primary source of or contributor to their respiratory 
signs may enhance our understanding of the pathogenesis of chronic respiratory disease 
in dogs, opening the door for evaluation of novel, targeted therapies.  
 Aerodigestive disorders span a broad range of diseases reflecting defects in 
respiratory-swallow coordination. These represent a diagnostic challenge because many 
patients present without gastrointestinal signs. Importantly, GER occurs commonly in 
healthy, asymptomatic humans and physiologic reflux been documented in up to 41% of 
asymptomatic dogs using VFSS.(147) Pathologic and physiologic reflux differ in volume, 
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timing and location within the esophagus. In people, pathologic reflux often remains 
occult until patients develop deleterious sequelae: esophagitis, laryngeal dysfunction, 
regurgitation and a wide spectrum of respiratory diseases. The association between 
reflux, aspiration, and airway dysfunction has not been thoroughly evaluated in dogs, 
despite several supportive clinical case reports, experimental canine models, and a review 
of aspiration-related respiratory disorders.(15, 17, 79, 144, 149) Detection of reflux and 
aspiration is possible by several imaging modalities including VFSS. 
Videofluoroscopic swallow studies are sensitive for identifying human patients 
with aspiration secondary to dysphagia.(156)  Historically, the use of VFSS for dogs with 
esophageal dysphagia (e.g., ME), a risk factor for aspiration, has been limited. This is 
largely due to the historical VFSS protocol of restraint in lateral recumbancy and force-
feeding which carry unacceptable risks of aspiration.(157, 158) By allowing free-feeding 
in unrestrained dogs, the risk of AP is no more than would be expected when feeding at 
home and allows evaluation of patients for which a VFSS would have been previously 
contraindicated.(147) Additionally, the upright and free-feeding protocol allows for a 
more physiologic reflection of (often subclinical) alimentary defects that can contribute 
to a wide variety of respiratory diseases. 
In our study, VFSS abnormalities were detected in 81% (25/31) of dogs 
presenting with cough with no owner-reported alimentary tract signs. This demonstrates 
that, like people, AeroD presents in the absence of dysphagia, regurgitation or vomiting. 
This study emphasizes a previously under-recognized and common canine population 
with alimentary tract disease causing or contributing to cough. Approximately 26% of 
dogs in this study were diagnosed with alimentary or “idiopathic cough” based on their 
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diagnostic evaluation.  Respiratory cough with VFSS abnormalities was found in 17/31 
(55%) of dogs, reflecting the complex relationship between respiratory and alimentary 
disease; it is likely that each contributes to disease progression.(159) For example, reflux 
contributes to laryngeal dysfunction, a known risk factor for aspiration.(79, 160) 
Likewise, cough induces reflux in humans likely contributing to a self-perpetuating cycle 
in some patients.(161) Therefore, treatment in dogs with mixed respiratory and 
alimentary disease is likely to be multimodal reflecting the contribution of alimentary 
tract disease in such cases. Given the percentage of dogs with alimentary or mixed 
alimentary and respiratory disease, AeroD should be investigated in dogs with chronic 
cough and not solely in those with evidence of AP.  Identifying dogs with AeroD is 
important as failing to treat occult GI disease may, as in people, allow for progression of 
disease and contribute to patient morbidity and mortality.(5, 108, 117, 140, 162, 163) 
Based on our study, evaluation of alimentary tract disorders using VFSS should be 
considered as a part of the clinical evaluation of coughing dogs.  
 Supportive respiratory and/or neurologic signs may further increase our index of 
suspicion for AeroD. In our study, all dogs with historical recurrent AP had VFSS 
abnormalities. Such historical information may increase the index of suspicion for AeroD 
in patients. Additionally, 6/31 (19%) of dogs had a history of worsening clinical signs 
during eating and drinking. As such, specific lines of questioning emphasizing the 
relationship between the respiratory and alimentary tracts may be helpful in identifying 
patients with AeroD. Concurrent nasal disease (sneezing, nasal discharge and reverse 
sneezing) were also encountered,  paralleling human studies where extra-esophageal 
reflux (EER) results in nasopharyngeal as signs as well as cough.(4, 117, 164) Four dogs 
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had neurologic deficits on physical examination. Though this was identified in a 
relatively small number of patients, this study and others support a relationship between 
neurologic dysfunction, dysphagia, and respiratory disease.(149, 165) As such, studies 
evaluating patients with neurologic dysfunction for occult AeroD may be warranted.  
Thoracic radiographs are considered a first line diagnostic in patients with chronic 
cough.(145, 146) However, thoracic radiographs fail to identify the source of disease 
especially when it is dynamic (intermittent or changes are dependent on phase of 
respiration), extra-thoracic in origin, subacute to acute where radiographic lesions lag 
behind clinical signs, or with certain small or subtle lesions.(145, 146, 166) In this study, 
35% of dogs had unremarkable radiographs despite nearly 82% having detectable 
abnormalities on VFSS. This speaks to a lack of sensitivity for detecting the source of 
AeroD by radiographs alone and underscores the utility of VFSS as an adjunctive tool in 
dogs with cough, particularly in the face of unremarkable thoracic radiographs.   
A bronchial pattern on radiographs, which was found in 11 dogs, is considered 
non-specific evidence of lower airway disease.(111) In isolation, this finding provides 
little information to aid in clinical decision making without additional diagnostics 
including BALF cytology/culture. In our study 7/11 patients with a bronchial pattern 
were later diagnosed with inflammatory airway disease based on BALF cytology. Six of 
those 7 dogs had abnormalities detectable on VFSS. Investigating a link between chronic 
inflammatory disease and repetitive microaspiration is warranted. Though markedly 
under diagnosed by thoracic radiographs, BE and BM were each detected in 5 dogs in 
this study. Microaspiration has been implicated in the pathogenesis of sterile airway 
inflammation in people,(167) and is a known contributor to the development of BE and 
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BM.(168-170)   Four of 5 cases of BE and BM were associated with VFSS abnormalities 
including laryngeal penetration, reflux, and pharyngeal/esophageal dysmotility 
suggesting that, like people, AeroD may contribute to airway inflammation and 
architectural remodeling. Aspiration pneumonia is the most widely recognized AeroD in 
dogs. Radiographic evidence of AP was present in 23% of patients in our study including 
2 dogs with a concurrent diffuse bronchial pattern. The majority (71%) of these dogs had 
abnormalities on VFSS suggesting that dogs with chronic clinical signs (>2 mo) and 
radiographic evidence of AP may warrant a more thorough investigation than radiographs 
alone. As such, a thorough diagnostic evaluation of respiratory disease in veterinary 
medicine should be multimodal with clinical consideration for AeroD.  
  Laryngeal dysfunction was abnormal in 12 dogs despite only 3 presenting with 
dysphonia. Laryngeal erythema was found in 80% of dogs that underwent a laryngeal 
function examination including all dogs with evidence of pathologic reflux. While 
laryngeal erythema has been previously discussed as a non-specific finding of chronic 
cough,(105) based on the findings of this study, a contribution from EOR would be 
strongly suspected. Laryngeal paralysis, a known risk factor for AP, is not considered a 
consequence of chronic cough but has been associated with reflux diseases as well as 
other dysphagic disorders.(149, 160)  These findings were supported by our study where 
6/7 dogs with laryngeal dysfunction has concurrent swallow study abnormalities, 
including PH, penetration, and aspiration. Common innervations to pharynx, larynx, and 
proximal esophagus through the recurrent larnygeal nerve may explain this spectrum of 
dysfunction, and may suggest an increased risk of aspiration in these patients beyond 
laryngeal dysfunction alone.(165) Penetration or aspiration was witnessed in 6 dogs (8 
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total incidences). Two dogs with documented aspiration exhibited no attempts to clear the 
aspirated material from the trachea (Penetration-aspiration score of 7). In both cases 
aspirated material extended past the thoracic inlet within the trachea suggesting 
diminished airway protective mechanisms.  While evidence of aspiration during VFSS 
helps confirm the link between an abnormal swallowing and respiration, absence of 
witnessing aspiration during the limited period video clips are obtained does not rule it 
out. Patients with penetration of kibble without aspiration on VFSS were considered at 
high risk for future macro-aspiration events (171) and possibly microaspiration. Micro-
aspiration is not detectable via VFSS. 
Fluoroscopy has advantages over thoracic radiography in that VFSS capture data 
over a longer period and dynamic processes are captured. However, intermittent 
abnormalities may be missed using this modality. Thus, an important limitation of this 
study is the duration of data collection. Additionally, VFSS for detection of dogs with 
occult AeroD is not widely available requiring referral; not all referral centers use 
unrestrained free-feeding protocols.  The retrospective nature of this study is another 
limitation wherein not all dogs received the same diagnostic evaluation. Future 
prospective studies are warranted. 
Conclusions 
Aerodigestive diseases occur in dogs in the absence of esophageal and 
gastrointestinal signs and in the face of normal thoracic radiographs. Identifying this 
under-recognized patient population opens doors for treatment targeting alimentary tract 
disease in dogs with what may have previously been considered “idiopathic cough.” This 
study highlights the need for multimodal evaluation incorporating VFSS in dogs 
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presenting with cough, regardless of presence of alimentary tract signs and particularly 
for those with unremarkable thoracic radiographs.  
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CHAPTER 3 
 
VIDEOFLUOROSCOPIC SWALLOW STUDY CHARACTERIZATION 
OF LOWER ESOPHAGEAL SPHINCTER ACHALASIA SYNDROME 
(LES-AS) IN DOGS 
 
Introduction  
 
Canine megaesophagus (ME) is a motility disorder of the esophagus carrying a 
poor long-term prognosis with death frequently reported secondary to aspiration 
pneumonia, malnutrition, and euthanasia due to poor quality of life.(172-174)  
Classically, ME is described as congenital or acquired and as idiopathic or secondary to a 
number of underlying etiologies including hypoadrenocortisolism and myasthenia gravis 
(MG).(175-177) However, identification of an underlying disease fails to reveal if a 
functional outflow obstruction of the esophagus is causing ME. This distinction is 
critically important in people where lower esophageal sphincter (LES) disorders causing 
functional obstruction, LES achalasia, are rare causes of ME that respond to targeted 
therapy designed to address esophago-gastric outflow obstruction.(178-180) This 
condition is considered distinct from conditions that cause esophageal hypomotility 
without functional LES obstruction. Achalasia, a primary esophageal motility disorder in 
people, results from a selective loss of inhibitory myenteric neurons leading to a failure 
of the LES to relax in response to pharyngeal swallow and impaired esophageal 
peristalsis.(181)  While sporadic cases of  functional LES obstruction have been 
suspected in dogs, comparable etiologic information is lacking. Functional LES disorders 
in dogs are rarely diagnosed due to limitations in currently available testing used in 
dysphagia evaluation.(182-185) However, functional LES disorders may represent an 
important, yet undetected, subpopulation of dogs with ME, perhaps responsive to targeted 
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intervention and with a different long-term prognosis.  
In people, high-resolution manometry (HRM) is considered the gold standard for 
the diagnosis of functional LES disorders such as LES-achalasia. Understanding the 
limitations of HRM in dogs, which include cost, availability, and patient compliance, our 
goal was to use a free-feeding VFSS protocol(125) to characterize VFSS features of 
functional LES obstruction. We defined a functional LES obstruction as a failure of the 
LES to relax in response to a pharyngeal swallow.  Though a direct comparison between 
dogs and people cannot be made without manometry, we elected to refer to functional 
LES obstruction in our canine patients as LES achalasia-like syndrome (LES-AS) after 
the key pathophysiologic feature of achalasia in humans.(178, 186)  The objective of this 
study was to identify VFSS parameters which could be used to identify LES-AS in dogs. 
We hypothesized that LES-AS could be distinguished from normal dogs using 
standardized VFSS criteria.  
Materials and Methods  
Case Selection and Criteria  
Medical records for dogs presenting to the University of Missouri (MU-VHC) 
between April 2015 and December 2017 for VFSS were retrospectively reviewed. Dogs 
were included if they had a standing, free-feeding VFSS available for review, a complete 
medical record, and evidence of a failure of the LES to relax in response to a pharyngeal 
swallow (LES-AS). Dogs determined to have LES-AS, were further evaluated for 
discriminating criteria between LES-AS, dogs with non-LES-AS ME, and healthy dogs. 
Common features among dogs with LES-AS were assessed to evaluate for discrete 
clinical syndromes.(178, 187)  Standardized assessment and diagnostic criteria were 
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developed and validated by calculating agreement between a panel of investigators at MU  
College of Veterinary Medicine and a blinded expert reviewer with expertise in the area 
of swallowing disorders (CPG) based on diagnostic criteria and characteristic features of 
disease identified in people. These criteria were inclusive of failure of the LES to relax in 
response to pharyngeal swallow, esophageal motility, retained ingesta/oral secretions 
within the esophagus, “bird-beak”, reflux, and the absence of mechanical obstruction 
(178, 180, 188, 189) As objective metrics for determining ME involve comparisons to the 
cervical vertebrae or thoracic inlet, which may be out of view during parts of the VFSS, 
subjective assessment of dogs with all dogs with ME on VFSS was objectively evaluated 
by comparing the ratios of distal esophageal diameter (DeD) to the height of the 12th 
thoracic vertebral body compared to healthy dogs. For those with focal ME the distal 
most portion of the esophagus orad to the obstruction was used to calculate the DeD.   
 Dogs receiving prokinetic medications or opioids and those with focal ME or 
VFSS evidence of mechanical obstruction (including hiatal hernia and esophageal 
strictures) were excluded. Additional testing for hypothyroidism, MG, and 
hypoadrenocortisolism were performed in most dogs at the discretion of the attending 
clinician based on supporting clinical evidence. Dogs with a positive diagnosis of 
hypothyroidism, MG, and/or hypoadrenocortisolism were not excluded from further 
evaluation. Swallow studies were compared against archived normal data from a previous 
publication (n=20).(125) Control dogs were considered healthy based on physical 
examination and the absence of either respiratory or gastrointestinal signs, including oral, 
pharyngeal, and esophageal dysphagia, for the 6 months prior to the VFSS.  
Demographic Data 
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Demographic data, clinical features, duration of clinical signs, incidences of 
aspiration pneumonia, and body condition scores were acquired from the medical record.  
Videofluoroscopic Swallow Study Protocol 
VFSS was performed in accordance with a previously validated free-feeding VFSS 
protocol.(125) Briefly, after a 12 hour fast, dogs were placed in 1 of 4 polycarbonate 
kennels designed to accommodate small/toy ( ≤ 16 kg), medium (> 16 kg - ≤ 30 kg), large 
(>30 kg - ≤39 kg), and giant breed (≥ 39 kg) dogs. These kennels were designed to permit 
upright free feeding behavior, direct patient visualization, and contrast videofluoroscopy. 
The dogs were fed 3 standardized food consistencies containing a contrast agent; puree 
(25% iohexol (350 mg/mL), liquid (25% iohexol (350 mg/mL), kibble (barium 40% 
w/v)). Studies were performed at 30 frames/sec using a GE Advantx or GE OEC 9900 
Elite Mobile C-Arm system at the MU-VHC.   Studies were considered complete if they 
included VFSS views as described in Table 8. VFSS for functional LES-AS was 
considered diagnostic only if the LES could be evaluated in response to pharyngeal 
swallowing using multiple food/liquid consistencies containing oral contrast. The LES 
was actively challenged (contrast abutting the LES) during active swallowing with the 
dog in a sitting and/or standing position to mitigate the effect of esophageal weakness on 
the passage of contrast through the LES. Evaluation was also performed when the dog 
was not actively swallowing to assess for bolus passage secondary to hydrostatic 
pressure. Some dogs were asked to sit during active swallows to add extra challenge to 
the LES.  
Statistics  
Statistical analysis was performed using MedCalc data analysis software (version 
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18.5). Descriptive statistics were performed where appropriate. Non-parametric analysis 
was performed on objective swallow metrics due to the small sample size. Data are 
presented as median and interquartile range (IQR). A 95% CI was calculated for common 
VFSS features of LES-AS.  A ROC curve analysis was performed to determine the 
sensitivity and specificity for detection of ME using a ratio between the maximal distal 
esophageal diameter and the height of the T12 vertebral body. Kappa/weighted kappa 
coefficients were calculated to assess for agreement between the MU panel and the 
independent reviewer (CPG) for criteria discriminating between LES-AS and normal 
dogs and the assigned LES-AS subtype for each dog. Weighted kappa coefficients were 
weighted linearly.  A P value of ≤ 0.05 was considered significant.  
Results  
Animals  
One hundred thirty dogs underwent VFSS at the MU-VHC between April 2015 
and December 2017.  Twenty-nine patients were found to have ME based on VFSS. 
Megaesophagus was described as ether generalized (n=23) or focal (n=6). Those with 
generalized ME without LES-AS (n=9) were characterized by diffuse esophageal body 
hypomotility without LES obstruction. In these cases, a food bolus passed unimpeded 
into the stomach once presented to the LES. Timing of LES relaxation was coordinated 
with a pharyngeal swallow. Videofluoroscopic swallow study diagnosis for the 130 cases 
reviewed are available in Figure 4.  
Out of 130 VFSS, 19 patients including 61% of those with generalized ME, met 
entry criteria for further evaluation by having a failure of the LES to relax in response to 
pharyngeal swallow. For those with LES-AS, ages ranged from 5 weeks to 12 years, with 
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a median (IQR) age of 2.5 years (0.9-6.7 years). Seven dogs were spayed females, 2 were 
intact females, 8 were castrated males, and 2 were intact males. Breeds represented 
included Mixed breeds (n=4), Australian Shepherd (n=3), Chihuahua (n=2), Golden 
Retriever (n=2), Miniature Schnauzer (n=1), Miniature Dachshund (n=1), Doberman 
Pinscher (n=1), German Shepherd Dog (n=1), Irish Wolfhound (n=1), Boston Terrier 
(n=1), German Shorthair Pointer (n=1), and English Cocker Spaniel (n=1).  The median 
(IQR) body condition score on a 9-point scale was 3 (2-5) with 4-5/9 being considered 
ideal.   
Out of 19 dogs with LES-AS, presenting complaints included regurgitation 
(n=14), regurgitation and cough (n=4), and cough alone (n=1). The duration of clinical 
signs prior to presentation ranged from 5 weeks to 4 years, with a median (IQR) of 7 
months (4-16 months). Hypothyroidism was ruled out in 17/19 dogs by total T4/TSH. 
Hypoadrenocortisolism was ruled out in 17/19 dogs by either baseline cortisol (>2սg/dL, 
>55nmol/L) or ACTH stimulation test. Acetylcholine receptor antibody testing was 
performed in 14/19 dogs. Testing was confirmatory for MG in 1 dog. In the remaining 
dogs, clinicians elected to forgo testing based on lack of supporting clinical signs.  A 
previous history of aspiration pneumonia was reported in 5/19 dogs. No dog underwent 
anesthesia within 30 days of presentation to the VHC.  
Archived VFSS from twenty research and companion dogs were included in our 
study as healthy controls (n=20). Dogs were determined to be healthy based on history 
(no evidence of dysphagia, gastrointestinal or respiratory signs within 6 months of the 
VFSS) and physical examination. Ages ranged from 4 weeks to 14 years, with a median 
(IQR) age of 4.9 years (2.0-9.0 years).  Eleven dogs were spayed females and 9 dogs 
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were castrated males. Breeds represented included Pembroke Welsh Corgis (n=6), long 
haired Dachshunds (n=5), Chinese Crested and Beagle mix (n=5), large mixed breeds 
(n=2), Jack Russell Terrier (n=1), and German Shepherd Dog (n=1).  
Videofluoroscopic Swallow Studies 
MU Results 
The VFSS metrics for evaluation are described in Table 9. Functional obstruction of 
the LES was diagnosed if there was failure of the LES to relax in response to a 
pharyngeal swallow during active challenge of the LES. VFSS videos were initially 
evaluated by a panel of trained reviewers including 2 board certified internal medicine 
specialists (MG, CR), a PhD and board-certified speech-language pathologist specializing 
in translational deglutology (TL), and a senior radiology resident (JS). Panel results were 
achieved by consensus. An MD gastroenterologist considered an expert in esophageal 
motility disorders (CPG) independently reviewed each study using the standardized 
criteria in Table 9. The independent reviewer (CPG) was blinded to the findings of the 
MU panel. The results of the MU panel and the independent reviewer were evaluated for 
agreement in order to validate our VFSS criteria for diagnosis and classification.  
Multiple criteria for evaluation were used based on esophageal motility studies performed 
in people based on standardized criteria (bellow):(188, 190, 191)  
1)  Megaesophagus: Dogs were assessed for the presence/absence of generalized 
esophageal dilation. Subjective evaluation was subsequently compared to 
objective parameters (esophageal diameter at its widest point comparted to the 
height of the T12 vertebral body). T12 was selected for ease of visualization 
relative to the LES.  (Figure 5) 
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2) Timing of ingesta entry into the stomach: Movement of the contrast bolus from 
the distal esophagus into the stomach was assessed to determine if bolus passage 
was in response to active pharyngeal swallowing, secondary to hydrostatic 
pressure (i.e., gravity-dependent and not during swallowing), or due to a 
secondary peristaltic wave. 
3) Baseline fluid line: Prior to administering contrast-laden food or liquid, the 
esophagus was assessed for the presence/absence of fluid retention within the 
esophagus after a prolonged fast (≥ 12 hours). This is distinguished from reflux by 
evaluating for persistence/lack of clearance. Ventrally dependent fluid within a 
diverticulum was not considered positive for a fluid line.  (Figure 6) 
4) LES “bird-beak”: The distal esophagus and LES were assessed for the 
presence/absence of a dilated distal esophagus terminating in an elongated taper 
(“bird-beak”) though the LES during active pharyngeal swallowing. (Figure 7) 
5) Esophageal peristalsis (contraction and propulsion): The esophagus was assessed 
for presence/absence of the following clinical features:   
a. Primary peristalsis was defined as a wave of bolus movement beginning in 
the proximal esophagus, initiated by a pharyngeal swallow. 
b.  Secondary peristalsis was defined as a wave initiated by esophageal 
distention, evaluated while the dog was not actively eating/drinking to 
avoid confounding by concurrent primary peristalsis and clearance 
initiated by a subsequent food bolus. 
c. Esophageal contraction referred to the inward movement of the dorsal and 
ventral esophageal walls.  
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d.  Propulsion refers to the ability of either primary or secondary peristaltic 
activity to conduct a food bolus aborally towards the LES.  
6) Narrowed (spastic) distal esophagus: The distal esophagus was assessed for the 
presence/absence of a transient segmental decrease in diameter of the distal 
esophagus, proximal to the LES, resulting in a narrowed contrast column. A lack 
of robust contractions against a closed LES distinguishes this finding from a 
hypermotile esophagus. (Figure 8a, b) 
7) Hypermotile distal esophagus: The distal esophagus was assessed for the 
presence/absence of robust contraction against a closed LES, during or between 
pharyngeal swallows.  
8) Reflux: Presence/absence of orad movement of contrast from the stomach into the 
esophagus was evaluated passively and during forced abdominal compression. 
During abdominal compression, a licensed veterinarian wearing appropriate 
personal protective equipment applied abdominal pressure to a standing dog in 
order to induce reflux and/or sliding hiatal hernia.  
9) Hiatal hernia: Presence/absence of herniation of the stomach into the thoracic 
cavity (through the esophageal hiatus of the diaphragm) was assessed either 
passively or in response to abdominal pressure by a licensed veterinarian.  
ME was present in 14/19 dogs with LES-AS.  The ratio of the maximum distal 
esophageal diameter (DeD):height of T12 vertebral body being significantly greater in all 
dogs with subjective ME (n=29) (median:6.4 IQR:6.0-7.3) compared to healthy dogs 
(median 3.8 IQR: 3.3-4.0; p <0.001). No statistically significant differences were 
identified between LES-AS and non-LES-AS dogs with ME for the DeD: height of T12. 
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A DeD:T12 ratio greater than 4.8 was 94% sensitive and 100% specific for ME compared 
to normal controls.  In dogs with LES-AS, a baseline esophageal fluid line was present in 
68.4% (95% CI, 47.5-89.3%). An LES “bird-beak” was present in 63.2% (95% CI, 41.5-
84.8%) of dogs with LES-AS. These features were not present in any dog with ME that 
did not also have LES-AS. Additional discriminatory VFSS criteria for LES-AS 
compared to controls available in Table 10.  
For primary peristalsis, the esophagus was subjectively graded by the MU panel 
as acontractile (n=8), hypomotile (n= 8), or hypermotile (n=3) compared to normal 
controls. Normal primary peristaltic propulsion was not identified in any LES-AS dog. 
Apart from 1 dog, in dogs with acontractile or hypomotile primary peristalsis, decreased 
secondary peristalsis was also observed.  Normal secondary contractions (n=4) diffuse 
throughout the length of the esophagus were observed in dogs with hypermotile primary 
peristalsis and in the distal esophagus of 1 dog with hypomotile primary peristalsis. 
Reflux was identified in 1/19 dogs with achalasia-AS compared to 8/20 of healthy 
controls. In healthy dogs, physiologic reflux occurred commonly during feeding but 
tended to be restricted to the distal esophagus and was rapidly cleared by a subsequent 
food bolus. In our clinical experience, clinical patients where reflux is thought to be 
pathologic, reflux tends to be spontaneous (not during feeding), may span the length of 
the esophagus, or is retained in the esophagus for a longer period. The one dog with LES-
AS with reflux appeared to have physiologic reflux, excepting that reflux events occurred 
spontaneously (i.e., not during feeding).  This dog was later diagnosed with a distal 
mechanical obstruction of the esophagus (pseudoachalasia).  Post-procedural aspiration 
pneumonia was not reported for any dog undergoing VFSS. 
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In evaluating VFSS in dogs with LES-AS, classification criteria for three discrete 
syndromes was developed, and a case of pseudoachalasia was identified. While each 
syndrome was characterized by failure of the LES to relax in response to pharyngeal 
swallowing, there were differences in the degree and type of peristaltic dysfunction, as 
well as the degree of gastric filling and esophageal dilation.  
Type 1 LES-AS (n=8 dogs) showed ME with acontractile primary peristalsis and 
absent secondary contraction.  Abnormal LES relaxation (failure to relax in response to 
pharyngeal swallowing) was observed in response to all food/liquid types, resulting in 
minimal gastric filling.   
Type 2 LES-AS (n=7 dogs) was characterized by hypomotile primary peristalsis with 
or without ME. Of note, increased hydrostatic pressure (achieved by sitting, upright 
feeding, or significant accumulation of food within the esophagus) facilitated gastric 
filling.  
 Type 3 LES-AS (n=3 dogs) demonstrated a spastic distal third of the esophagus or a 
hypermotile distal esophagus against a closed LES, with or without ME.  
a. Spasticity was defined as a transient, segmental decrease in diameter of the distal 
esophagus, proximal to the LES, resulting in narrowed contrast column. 
b. Hypermotility was defined as robust contractions against a closed LES, during or 
between pharyngeal swallows. 
Pseudoachalasia (n=1) was defined as mechanical esophageal-gastric junction 
outflow obstruction. In the dog in this report it was due to a circumferential 
adenocarcinoma.  
Objective (DeD:T12) and subjective interpretations of ME were found to have 
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perfect agreement. After agreement was achieved among the X panel, discriminatory and 
sub-classification criteria were compared to the review performed by the MD 
gastroenterologist to calculate agreement. Specific kappa values, standard error, and 95% 
confidence intervals are presented in Table 11.    
Discussion  
This study has demonstrated that a subpopulation of dogs with ME have a 
functional obstruction of the LES (LES-AS), which may open the door to additional 
therapeutic opportunities. A lack of understanding of disease pathogenesis and limitations 
in available diagnostics play a role in the poor prognosis associated with ME. This 
manuscript details VFSS characterization of functional LES obstruction, termed LES-AS 
in dogs. The identification of a previously overlooked subpopulation of dogs with 
esophageal dysphagia provides hope to these patients, as humans with analogous diseases 
may respond to interventions targeting functional obstruction of the LES including 
injection of the LES with botulinum toxin A, pneumatic LES dilation, or surgical LES 
myotomy. Though further research is needed, the identification of similar clinical 
syndromes between dogs and people may suggest utility for dogs with LES-AS as a 
translational model for humans with LES achalasia.  As knowledge is bi-directional, 
successful treatment protocols for humans may also benefit our canine species and merit 
evaluation in clinical trials.   
The gold standard for evaluation of LES achalasia in people is HRM, which 
evaluates esophageal motor function by detecting esophageal and LES pressure 
profiles.(178-180, 192) In humans, this technique allows the detection and 
subcategorization of obstructive LES disorders based on their pathophysiologic profiles. 
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(179) This technique is rarely utilized in companion animals due to limited availability, 
high cost, and variable patient tolerance.(18, 193, 194) Conventionally, evaluation of 
dysphagia in dogs has relied upon historical information, physical examination findings 
and radiography including VFSS, all of which are considered the gold standard in 
veterinary medicine.(125) In people, swallow studies were used prior to the development 
of HRM to detect LES achalasia and have more recently been proposed as the method of 
choice for detecting recurrence of functional LES obstruction after therapy.(180, 188, 
191) The barium esophagram is an established protocol for detecting LES achalasia and 
is considered an alternative initial approach in humans where LES achalasia is 
suspected.(178, 180, 191)  Standardized dynamic contrast studies, such as the “timed 
barium swallow,” allows clinicians to detect the degree of esophageal bolus 
retention.(188) Despite only moderate sensitivity, these tests are considered specific for a 
diagnosis of LES achalasia.(191) Prior to our VFSS-based study, there had been no such 
standardized protocols developed for evaluating functional LES obstruction in dogs. In 
part, this may be due to the paucity of VFSS in dogs with ME and other forms of 
dysphagia, for which the historical protocol of restrained recumbency and force feeding 
of contrast has unacceptable risks of aspiration.(195, 196) However, allowing upright 
free-feeding in unrestrained dogs dramatically diminishes the risk of aspiration to no 
more than what would be encountered during feeding at home and allows the study of 
any type of dysphagia (i.e., oral, pharyngeal, and/or esophageal).(125) This technique 
also allows the investigator to assess the timing of LES relaxation in response to 
pharyngeal swallow allowing investigators to distinguish between LES-AS and other 
forms of ME. These are broadly characterized by esophageal hypomotility/weakness 
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without functional obstruction of the LES. This distinction is critically important as the 
functional obstruction at the level of the LES is what determines candidacy for targeted 
therapeutic intervention. In our clinic, no dog having undergone a free feeding VFSS 
developed post-procedural aspiration pneumonia.  Our VFSS findings represent a 
substantial departure from a prior study where VFSS performed in lateral recumbency 
failed to identify any dog with functional LES obstruction compared to 61% of our 
patients with ME (Figure 4).(196) Our findings suggest that this procedure can be 
performed safely in dogs with ME and esophageal dysphagia to identify dogs with 
functional LES disorders.   
Abnormal relaxation of the LES in response to pharyngeal swallowing is 
recognized as the key pathophysiologic feature in LES achalasia.(178-180, 192) This 
highlights the need for evaluation of the LES during active swallowing in order to assess 
for inappropriate failure of the LES to relax. Several swallows should be evaluated for 
each food/liquid consistency, as LES achalasia may not occur with every swallow. 
Common features of LES achalasia in people undergoing dynamic imaging include ME, 
the distal esophagus/LES “bird-beak”, a lack of primary peristalsis, and a persistent 
contrast column above the LES.(180) As a result of this functional obstruction, the 
esophageal body can lose tone and dilate, retaining both ingesta and oral/respiratory 
secretions. In our study, these clinical features were also identified in dogs with LES-AS. 
Interestingly, though ME was commonly identified, 5/19 dogs with LES-AS had 
objectively and subjectively normal esophageal diameter compared to controls. As such, 
the absence of ME does not rule out LES-AS in dogs and should be considered as a 
differential in dogs with signs of esophageal dysphagia despite the absence of ME. Serial 
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evaluation of these dogs would be warranted to determine if they progress to 
development of ME. Based on this study subjective and objective assessment of ME in 
dogs compared to healthy dogs had perfect agreement suggesting that objective 
calculations are not always necessary to confirm diagnosis of ME and objective 
measurement may be reserved for cases where ME may be considered borderline. 
However, the lack of a gold standard measurement for ME is a limitation in calculating 
specificity for dogs in this study. A baseline fluid line and bird-beak were frequently 
identified in patients with LES-AS and was absent in normal dogs and in our population 
of dogs with other forms of ME. This may suggest that fluid line and bird-beak could 
discriminate LES-AS from forms ME, though further study is needed. Two cases of 
seropositive MG were identified in our population. One with LES-AS and the other with 
diffuse esophageal hypomotility without LES obstruction. A previously published case 
report used manometry to confirm a  functional LES obstruction in a pug with 
seronegative MG.(194)  This suggests that functional obstruction of the LES may be a 
feature of ME in some, but not all patients with MG. However, too little data exists to 
speculate on the pathophysiology of ME in these patients.    
   In humans, LES achalasia represents a family of syndromes grouped by 
variations in esophageal contractility rather than a single disorder characterized by a sole 
discrete phenotype.(178-180) The subtype of LES-AS in people does not determine 
candidacy for targeted intervention. It may however be used to help determine which 
means of LES disruption is selected (e.g. pneumatic dilation vs. BTA injections, or 
surgery) as different subtypes may have different response rates.(179, 186, 187, 192) 
Three phenotypes were characterized in our canine patient population which share 
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similarities to the syndromes described in people. (178-180) As in people, Type 1 was 
considered end stage with absence of esophageal motility, and presence of esophageal 
dilation and minimal gastric filling. Type 2 was characterized by esophageal 
hypomotility. Retention of some esophageal tone and biophysical processes which 
allowed for improved esophageal emptying and gastric filling compared to Type 1, 
especially gravity-dependent increases in hydrostatic pressure. Type 3 LES-AS 
demonstrated impaired distal esophageal and LES relaxation in response to a food bolus 
resulting in esophageal bolus retention despite vigorous esophageal contraction upstream 
to the LES.(179) Like HRM, VFSS may result in a false positive diagnosis for patients 
with a distal mechanical LES obstruction (i.e. pseudoachalasia). In this study, one dog 
who was initially classified as having Type 3 achalasia was later identified to have a 
circumferential LES adenocarcinoma, resulting in a mechanical LES obstruction. 
Interestingly, this was also the only clinical dog with detectable reflux compared to 8/20 
asymptomatic healthy controls. Though speculative, pseudoachalasia may have resulted 
in an LES with a fixed diameter that simultaneously impeded gastric filling and permitted 
small volumes of spontaneous reflux. This form of pseudoachalasia has been previously 
identified in humans(197) and underscores the need for adjunctive diagnostics such as 
esophagoscopy to evaluate for occult mechanical obstructions which may mimic LES-AS 
prior to targeted intervention.(192)  
Given the clinical importance of ME and esophageal dysphagia in dogs, it is 
critical that patients who may be receptive to targeted therapy be accurately identified. 
For this reason, VFSS images were interpreted by a blinded, independent MD reviewer 
who participated in the international working group for disorders of gastrointestinal 
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motility and function to develop the consensus statement on achalasia syndromes in 
humans. Our goal was to adapt this diagnostic criteria and gauge the ease by which it 
could be applied to clinically affected dogs.(186) Agreement between the MU panel and 
the MD reviewer was perfect for 6/17 VFSS parameters, near perfect agreement for 5/17 
parameters, substantial for 4/17 parameters, moderate for 1/17 parameters, and fair for 
1/17 parameters.(198) (Table 11) This suggests that with training, these criteria could be 
applied by others to detect the subpopulation of dogs affected by LES-AS, thus 
broadening the ability of veterinarians to detect patients that may respond to targeted 
intervention.  It should be noted that only fair agreement was reached for the frequency of 
abnormal swallow events (failure of the LES to relax in response to pharyngeal swallow). 
This finding supports our earlier recommendation that multiple swallow events should be 
evaluated because, depending on the LES-AS subtype and observer, aberrant swallowing 
events may appear variably frequent. However, this did not impact the agreement 
between the MU panel and the independent reviewer (CPG) for the final diagnosis of 
LES-AS for any dog.  
Conclusions  
Due to its inherent limitations, HRM for diagnosis of LES-AS does not currently 
have significant clinical utility outside of a few veterinary research centers or tertiary care 
facilities. The morbidity and mortality of ME in dogs necessitated developing a more 
accessible diagnostic test for identifying dogs that may respond to targeted intervention. 
Compared to HRM, VFSS is relatively accessible, inexpensive, and with training, easy to 
perform. In keeping with our stated objective, this study demonstrates that functional 
LES obstructions (LES-AS) can be identified by VFSS. We have also demonstrated that 
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VFSS could identify discrete achalasia syndromes as are appreciated in humans. 
Interpretation will require high quality diagnostic studies and practice, with the guidelines 
developed herein highlighting important features of LES-AS. Identifying this previously 
unrecognized patient population allows future exploration of treatments focusing on 
relieving functional obstruction of the LES to reduce morbidity and mortality associated 
with canine ME and esophageal dysphagia.   
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CHAPTER 4 
 
MECHANICAL DILATION AND BOTULINUNM TOXIN A (BTA) 
INJECTIONS FOR TREATMENT OF LOWER ESOPHAGEAL 
SPHINCTER ACHALASIA-LIKE SYNDROME IN DOGS  
 
Introduction  
Megaesophagus (ME) in dogs is a motility disorder of the esophagus that carries a 
poor long-term prognosis with death frequently reported secondary to respiratory 
complications,  malnutrition or both, or euthanasia because of poor quality of life.(172-
174) For dogs with idiopathic ME, interventions are limited in part because of a lack of 
understanding of the underlying disease mechanisms. Recently, using a free-feeding 
videofluoroscopic swallow study (VFSS) protocol(125), we identified a subpopulation of 
dogs with functional obstruction of the lower esophageal sphincter (LES) analogous to 
LES achalasia in people.(148) In people, LES achalasia is diagnosed by high resolution 
manometry (HRM) and is characterized by a failure of the LES to relax in response to 
pharyngeal swallowing.(178) This functional obstruction results in esophageal dilation, 
retention of ingesta and oral secretions in the esophagus, loss of esophageal motility, and 
associated clinical signs of esophageal dysphagia.(178, 179, 199) Like achalasia in 
people, dogs with LES-AS lacked  LES relaxation in response to pharyngeal swallow on 
VFSS.(148) Identifying LES achalasia in dogs is critically important because, in people, 
it may respond to treatment targeting the LES and esophageal outflow obstruction.(178, 
180, 187, 200-202)  The analogous functional LES obstruction in dogs, LES achalasia-
like syndrome (LES-AS), likewise may represent a condition responsive to targeted 
intervention, though therapeutic studies in this population are critically lacking.   
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In people, achalasia is subcategorized into a spectrum of different disease 
phenotypes by HRM. Unfortunately, routine use of HRM in veterinary patients is 
impractical because of high cost, limited availability, poor patient compliance, and the 
need for substantial operator expertise.(18, 193) These limitations led to VFSS being 
successfully evaluated as a surrogate for the diagnosis of functional LES obstruction in 
dogs.(148)  In people, regardless of clinical phenotype or method of diagnosis, the core 
treatment objective is to relieve the esophageal obstruction by mechanical disruption of 
the LES or lowering LES tone. In people, positive clinical responses are seen after 
mechanical dilation (pneumatic dilation or bougienage), botulinum toxin A (BTA) 
injections, LES myotomy with fundoplication or some combination of these.(178, 180, 
187, 200-202) Given the positive response to targeted therapy in people with LES 
achalasia, our objective was to evaluate the response of dogs with LES-AS to targeted 
intervention with mechanical dilation and LES botulinum toxin A (BTA) injections, with 
or without surgical myotomy with fundoplication. We hypothesized that clinical and 
VFSS features of LES-AS would improve after treatment targeting the LES and 
esophageal outflow obstruction. 
Materials and Methods  
Case Selection and Criteria  
 Dogs presented to the University of Missouri Veterinary Health Center (MU-
VHC) between April 2015 and December 2017 had medical records retrospectively 
reviewed. Dogs were included if they had complete medical records, were diagnosed with 
LES-AS by free-feeding VFSS and underwent targeted treatment by mechanical LES 
dilation (pneumatic dilation or bougienage), LES BTA injections, with or without LES 
55 
 
myotomy with fundoplication.  Dogs receiving prokinetics or opioids, those with a 
secondary form of ME, and those with focal ME or evidence of mechanical obstruction 
(e.g. pseudoachalasia, stricture, hiatal hernia) at the time of diagnosis were excluded. For 
most dogs, additional testing for relevant endocrinopathies (hypothyroidism, 
hypoadrenocortisolism) and myasthenia gravis was performed at the discretion of the 
attending clinician, based on supporting clinical evidence. Dogs meeting inclusion 
criteria were evaluated for a number of clinical and VFSS outcome variables to determine 
response to treatment (Table 1). The VFSS features at the time of diagnosis were used to 
compare post-treatment VFSS outcomes for each dog. Dogs with positive response to 
LES mechanical dilation with BTA injections were considered candidates for and offered 
the option of surgical intervention (LES myotomy with fundoplication) as a longer-term 
treatment.  
Data Extracted from the Medical Record  
 Demographic data, clinical features, prior medical management for ME, duration 
of clinical signs, clinical perception of post-treatment disease control (positive or 
negative treatment response), body weight (BW), body condition score (BCS), frequency 
of regurgitation and complications after treatment were retrieved from the medical record 
or from follow-up calls to clients. Body condition score was evaluated according to the 
American Animal Hospital Association guidelines. Clients were requested to quantify 
frequency of regurgitation (episodes per day) before treatment as part of pre-treatment 
evaluation and after treatment as part of follow-up evaluation.  No changes were made to 
the patient’s pre- treatment regimen after targeted intervention to avoid confounding 
treatment effects.  
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Videofluoroscopic Swallow Studies  
 Videofluoroscopic swallow studies were performed both to confirm diagnosis of 
LES-AS and 2-3 weeks post-mechanical dilation and BTA injection as previously 
described.(125) Briefly, after being fasted for 12 hours, dogs were placed in 1 of 4 
kennels selected according to patient body size. The polycarbonate kennels are designed 
to accommodate small or toy (≤ 35 lbs), medium (> 35 lbs to ≤ 65 lbs), large (>65 lbs to 
≤85 lbs), and giant breed (≥ 85 lbs) dogs. These kennels were designed to permit 
unrestrained free-feeding behavior, maximize ease of patient visualization, and perform 
contrast videofluoroscopy. Dogs were fed 3 standardized food consistencies containing a 
contrast agent: puree (25% iohexol [350 mg/mL]), liquid (25% iohexol [350 mg/mL]), 
and kibble (barium 40% w/v). Studies were performed at 30 frames/sec using a GE 
Advantx or GE OEC 9900 Elite Mobile C-Arm system (GE Heathcare, Chicago, IL) at 
the MU-VHC. VFSS videos were evaluated by a panel of trained reviewers including 2 
board certified internal medicine specialists (Megan Grobman, Carol Reinero), a PhD and 
board-certified speech-language pathologist specializing in translational deglutology 
(Teresa Lever), and a senior radiology resident (James Schachtel). The VFSS was 
considered diagnostic for LES-AS if a lack of LES relaxation was observed in response 
to pharyngeal swallowing. The LES was actively challenged (contrast abutting the LES) 
during active swallowing with the dog in a sitting or standing position or both to mitigate 
the effect of esophageal weakness on the passage of contrast through the LES. Evaluation 
also was performed when the dog was not actively swallowing to assess bolus passage 
secondary to hydrostatic pressure. Some dogs sat during active swallows to add 
additional challenge to the LES. The VFSS parameters used for pre- and post-treatment 
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comparisons were selected based on studies in humans showing improved gastric filling, 
improved ME, and improved esophageal motility after treatment for achalasia.(180, 188, 
203) The VFSS outcome parameters are provided in Table 12.  
1) ME: Dogs were assessed pre- and post- treatment for subjective changes in 
esophageal diameter.  
2) Esophageal motility and peristalsis (contraction and propulsion): The esophagus 
was assessed for presence or absence of the following clinical features:   
a. Primary peristalsis, defined as a wave of bolus movement beginning in the 
proximal esophagus, initiated by a pharyngeal swallow. 
b. Secondary peristalsis, defined as a wave initiated by esophageal 
distention, evaluated while the dog was not actively eating ordrinking to 
avoid confounding by concurrent primary peristalsis and clearance 
initiated by a subsequent food bolus. 
c. Esophageal contraction referred to as the inward movement of the dorsal 
and ventral esophageal walls. Dogs without VFSS evidence of contraction 
were referred to as “acontractile.” 
d.  Propulsion referred to the ability of either primary or secondary peristaltic 
activity to conduct a food bolus aborally towards the LES.  
e. Amotile: referred to dogs without evidence of primary or secondary 
peristalsis  
f. Hypomotile: referred to dogs with evidence of primary and/or secondary 
peristaltic waves that are unable to conduct a food bolus aborally toward 
the LES.  
58 
 
g. Hypermotile: referred to spastic or excessive esophageal motility  
i. Spasticity: transient segmental decrease in the esophageal 
diameter, proximal to the LES and resulting in a narrowed contrast 
column. 
ii. Excessive motility: robust contraction against a closed LES, during 
or between pharyngeal swallows. 
h. Normal motility: referred to normal primary and secondary peristalsis that 
transferred swallowed boluses unimpeded to the LES.   
3) Gastric filling: Passage of ingesta into the stomach in response to pharyngeal 
swallowing or hydrostatic pressure (sitting or standing). If residual food or 
contrast remained in the esophagus, dogs were held upright for 5 minutes to 
increase hydrostatic pressure and facilitate emptying into the stomach.  
a. The extent of gastric filling was evaluated pre- and post- treatment and 
graded as small (<25%), medium (25-75%), or large (>75%).  
Targeted Intervention for LES-AS 
All procedures requiring general anesthesia (endoscopy, mechanical disruption of 
the LES [pneumatic dilation and bougienage], BTA injections of the LES, and LES 
surgery) were performed a minimum of 12 hours after VFSS. Anesthetic protocols and 
monitoring were performed under the direction and supervision of a board-certified 
anesthesiologist.   
Endoscopy 
 Esophagoscopy and abbreviated gastroscopy were performed using a Fujinon EG-
450HR, 10.7 mm gastroscope (Fujifilm,Wayne, New Jersey). Endoscopy was performed 
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before to mechanical dilation and BTA injections to evaluate for evidence of an occult 
mechanical obstruction of the LES. Esophagoscopy included evaluation of the 
esophageal body for wall defects, mucosal changes, and residual food or fluid. The LES 
and cardia were assessed for a distal esophageal stricture and to determine the ease of 
passage of the endoscope through the LES. Strong resistance to passage of the endoscope 
was considered suspicious for mechanical obstruction of the LES (pseudoachalasia).(204) 
A “J maneuver” was performed to evaluate for pseudoachalasia capable of causing 
esophageal outflow obstruction. Because a diagnosis of LES-AS was made based on a 
failure of LES relaxation in response to pharyngeal swallowing, an open LES observed 
under anesthesia was not considered to contradict a VFSS diagnosis of LES-AS nor was 
it a contraindication to targeted therapy. Fluid and food were suctioned from the 
esophagus to permit visualization before mechanical LES dilation and BTA injections.   
Mechanical Dilation  
 Mechanical dilation was performed either by pneumatic dilation (CRE TM Pro 
Wireguarded Balloon Dilation Catheter, Boston Scientific, Marlborough, MA) or 
bougienage.  Balloon diameter, ranging from 1-3 cm, was subjectively adjusted according 
to patient size to prevent overdistension and perforation.  Under endoscopic guidance, the 
balloon was passed through the LES (205) making sure to span the entire length, inflated, 
and then held in place for 90 seconds. This process was repeated 2-3 times. Blanching of 
the mucosa at the LES was observed through the transparent balloon (Figure 9). The 
endoscope did not simultaneously span the LES during deployment of the balloon to 
allow uniform radial force to be applied to the LES. In 1 dog, after the only appropriately 
sized available balloon was determined to be damaged, rubber bougies (40-50 French) 
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were inserted sequentially through the LES and each held in place for 90 seconds. This 
process was repeated twice. Confirmation of bougie placement and mucosal blanching 
were performed as for pneumatic dilation.  
BTA Injection 
After mechanical dilation, BTA (Botox [onabotulinumtoxinA] ®, Allergan, 
Madison, NJ) diluted to 40 U/mL in 0.9% sterile saline was administered using an 
endoscopic injection needle (InterjectTM Sclerotherapy Needle,  Boston Scientific, 
Marlborough, MA) at 8 sites around the LES (4 U/site) (Figure 10a, b). The first 4 
injections (Set 1) were made circumferentially at 90° intervals at the esophagogastric 
junction. The second 4 injections (Set 2) were made 1 cm distal to Set 1, also 
circumferentially at 90° intervals. Set 2 was rotated 45° from Set 1, as shown in Figure 
10b. A small bleb was visible after each injection with no visually detectable losses.  
Surgical LES Myotomy with Fundoplication   
Surgical myotomy of the LES (Heller procedure) was performed followed by Dor 
fundoplication as previously reported in the human surgical literature.(206) A standard 
ventral midline celiotomy was performed and the LES was isolated from its attachments 
within the crus of the diaphragm. The definitive location of the LES was determined by 
intra-operative endoscopy (5 mm ₓ 65 mm Storz Bidirectional Intubation Fiberscope, 
Tuttlingen, Germany) and marked with monopolar electrosurgery on the serosa of the 
stomach at the esophagogastric junction. A full thickness myotomy of the LES was 
performed extending 3 cm orad in the esophagus and 3 cm aborad in the stomach. 
Complete myotomy of the LES was confirmed by retromucosal illumination via intra-
operative endoscopy to assess for residual muscle fibers overlying the submucosa. After 
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completion of the myotomy, a Dor fundoplication was performed using polypropylene 
suture. The right and left crura of the diaphragm were apposed and residual air within the 
thoracic cavity was removed by suction. Finally, adequate patency of the LES was 
confirmed by endoscopic visualization before closure. A gastric tube was placed to 
facilitate feeding as needed during recovery. Post-operative analgesic protocols were 
carried out at the discretion of the attending clinician. All dogs were treated post-
operatively with omeprazole (1 mg/kg PO q 12h) for 10-14 days.  
Statistics 
 Statistical analysis was performed using SigmaPlot data analysis software 
(version 14.0). Descriptive statistics were performed where appropriate. Non-parametric 
analysis was performed because of the small sample size. Wilcoxon Signed Rank tests 
were performed on pre-and post-treatment variables of BW, BCS, and frequency of 
regurgitation. Pre-treatment data was collected from dogs with LES-AS at the time of 
diagnosis. Post-treatment data was collected at the time of the first evaluation after 
mechanical dilation and BTA injections. Data are presented as median and interquartile 
range (IQR). A p value of ≤ 0.05 was considered significant. 
Results 
Animals 
One-hundred and thirty VFSS were performed at the MU-VHC between April 
2015 and December 2017 (Figure 4). Nineteen dogs were diagnosed with LES-AS based 
on VFSS criteria and 14/19 met inclusion criteria for the study. Ages ranged from 5 
weeks to 12 years with a median (IQR) age of 2.5 years (0.9-5.8 years). Five dogs were 
spayed females, 3 were intact females, 2 were castrated males, and 4 were intact males. 
Breeds represented included mixed breeds (n=3), Australian Shepherd (n=2), Chihuahua 
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(n=1), Golden Retriever (n=1), Miniature Schnauzer (n=1), Miniature Dachshund (n=1), 
Doberman Pinscher (n=1), German Shepherd Dog (n=1), Irish Wolfhound (n=1), German 
Shorthair Pointer (n=1), and English Cocker Spaniel (n=1).  
 Presenting complaints included regurgitation (n=11), regurgitation and cough 
(n=2), and cough alone (n=1). The duration of clinical signs before presentation ranged 
from 5 weeks to 4 years with a median (IQR) of 8 months (4-18 months). Twelve of 14 
dogs had ≥ 2 weeks medical management for regurgitation before presentation including 
upright feeding and treatment with proton pump inhibitors with or without other 
gastroprotectants. Thirteen of the 14 dogs had ME at the time of diagnosis for LES-AS. 
Hypothyroidism was ruled out in 12/14 dogs by total thyroxine (T4) and thyroid 
stimulating hormone (TSH) concentrations. Hypoadrenocortisolism was ruled out in 
12/14 dogs either by baseline serum cortisol concentrations (>2 μg/dL, >55 nmol/L) or 
ACTH stimulation test. Acetylcholine receptor antibody testing was performed and found 
to be negative in 12/14 dogs. In the remaining dogs, clinicians elected to forgo testing 
based on lack of supporting clinical signs.  A previous history of aspiration pneumonia 
was reported in 5/14 dogs.  
Endoscopy  
Esophagoscopy and abbreviated gastroscopy were performed uneventfully in all 
14 dogs. Esophageal diverticula were identified at the thoracic inlet in 2/14 dogs 
corresponding to lesions observed on VFSS. Bone fragments and ingesta were present in 
the dependent region of the diverticulum in 1 dog. Despite being fasted ≥ 12 hours, 
esophageal fluid was present in all 14 dogs. Roughened texture and esophageal 
hyperemia were observed in all 14 dogs. According to our inclusion criteria, no evidence 
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of mechanical obstruction was identified in any dog.  
Post- Mechanical Dilation and BTA Injection (Clinical Variables) 
Dogs were presented for follow-up a median (IQR) of 21 days (14-25 days) post-
treatment. Total post-treatment follow-up was a median (IQR) of 3.5 months (2-4.8 
months). At the time of the first post-treatment evaluation, 100% of owners described 
subjective clinical improvement. Body weight was significantly (P <0.001) increased 
post-treatment. Median (IQR) pre- and post- treatment body weights (kg) were 7.3 kg (5-
15.8kg) and 8.1 kg (4.7-23.25kg), respectively.  Median (IQR) percent increase in body 
weight was 20.4% (12.7-25). No dog lost weight during the evaluation period. Median 
body condition score also was significantly (P<0.001) increased after treatment. Median 
(IQR) pre- and post-treatment BCS (9 point scale) were 3 (3-3.5) and 5 (4-5) respectively. 
Frequency of regurgitation was significantly (P<0.001) decreased post-treatment. The 
median (IQR) decrease in regurgitation as recorded by owners was 80% (50-85%). 
Median (IQR) duration of effect was 40 (17-53) days. 
Post- Mechanical Dilation and BTA Injection (VFSS Parameters) 
 Pre- and post- treatment VFSS findings are presented in Table 13. After LES 
mechanical dilation with BTA, all 14 dogs lacked detectable change to esophageal 
diameter or motility. Gastric filling was markedly improved in 12/14 dogs following 
treatment (Figure 11 a,b). 
Complications Post-BTA Injection with Mechanical Dilation  
 Complications following BTA and mechanical dilation were reported for 2/14 
dogs. One dog developed post-treatment aspiration pneumonia. This dog responded well 
to medical management and recovered uneventfully. No long-term consequences related 
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to aspiration pneumonia were identified. Improvement in clinical signs and VFSS were 
observed for this dog after recovery from aspiration pneumonia. In another dog, a 
gastroduodenal-esophageal intussusception with a Type IV hiatal hernia was identified 3 
weeks after mechanical dilation with BTA injections (Figure 12 a-d). The dog underwent 
surgery in which the stomach, spleen and a portion of the duodenum and pancreas were 
identified in the distal esophagus. The hernia was surgically corrected during exploratory 
celiotomy and left-sided gastropexy. Substantial improvement in clinical signs had been 
recorded for this dog before it developed complications.  
Heller Myotomy and Dor Fundoplication 
 Dogs with documented improvement after mechanical dilation with BTA 
injections were considered candidates for surgical intervention. Six of 14 dogs underwent 
surgery (Heller myotomy with Dor fundoplication). The median (IQR) follow-up for 
patients undergoing Heller myotomy with Dor fundoplication was 7 months (1-21 
months). In all 6 dogs, post-surgical clinical signs and VFSS features were similar to 
those at the first evaluation after mechanical dilation and BTA injections (i.e. improved 
over baseline). In addition, 2 dogs had improvement in esophageal diameter and 
esophageal motility as measured by VFSS > 6 months postoperatively, indicative of a 
delayed positive functional response to surgery. Of the dogs that showed improved 
motility, 1 dog was considered to have an amotile esophagus and the other a hypomotile 
esophagus.  Evaluation of response with respect to patient age, duration of clinical signs, 
and LES substage could not be performed because of to our small sample size.  
Discussion 
Idiopathic ME in dogs is a disorder with high morbidity and mortality that 
historically has lacked effective targeted treatment. A subgroup of these dogs with LES-
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AS have excellent clinical responses to mechanical dilation and BTA injections, with 
surgery being a more definitive, long-term option. To identify which dogs with ME may 
benefit from these targeted treatments, use of a free-feeding VFSS protocol is crucial to 
identify functional LES obstruction.(148) In people with LES achalasia, relieving the 
esophageal-gastric outflow obstruction significantly improves clinical signs.(178-180, 
201, 207) Comparably, significant clinical improvement, based on our previously 
described outcome variables, was observed in our population of dogs with LES-AS that 
underwent targeted intervention using mechanical dilation and BTA injections, although 
the response was temporary and shorter than is typical in people.(192, 205, 206)  Surgery 
provided sustained clinical improvement  compared to baseline, despite not resolving the 
ME and esophageal motility defects detected by VFSS. In all dogs, VFSS showed 
improvement in gastric filling after surgery.  By promoting gastric filling, improvement 
in the aforementioned outcome variables (body weight and body condition score as well 
as decreased regurgitation frequency) would be expected even with continued defects in 
esophageal motility. Our data suggest that targeted intervention in dogs with LES-AS 
may provide substantial clinical benefit in this patient population, providing hope for 
dogs that are refractory to traditional medical management.(208)   
Megaesophagus is characterized by diffuse dilation of the esophagus with 
decreased peristalsis. Unless, and sometimes even if, an underlying cause can be 
identified, treatment is largely supportive and carries a guarded to poor prognosis. 
Reported median survival times range from 1 to 3 months with an overall fatality rate of 
74%.(172, 174) Unfortunately, the majority of cases of ME are idiopathic with no clear 
understanding of an underlying pathologic process. (172)  In humans, esophageal motility 
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disorders are better classified allowing for identification of patients with conditions that 
may benefit from targeted intervention.(190) Achalasia, a primary esophageal motility 
disorder in people, results from a selective loss of inhibitory myenteric neurons leading to 
a failure of the LES to relax in response to pharyngeal swallowing and impaired 
esophageal peristalsis.(181)  It represents a rare cause of ME that responds to targeted 
intervention and is considered distinct from conditions that cause esophageal 
hypomotility without functional LES obstruction. This condition has been suspected in 
dogs, with a few case reports over the last 4 decades and most presumptive diagnoses 
being made without manometry or dynamic imaging studies. (182, 207, 209-213)  The 
lack of recognition of this syndrome in dogs may in part be a consequence of limitations 
in available diagnostic tests. High resolution manometry is considered the gold standard 
for diagnosis of LES achalasia in people. Unfortunately, this modality is not routinely 
performed in veterinary medicine because of limited availability, high cost,  need for 
operator expertise, and patient compliance.(182, 194)  However, before the adoption of 
the HRM in people, contrast swallow studies were used to diagnose LES achalasia and 
although only moderately sensitive, were considered highly specific for this 
condition.(188, 199, 214) Few manometric studies in dogs with ME have been 
performed, and these did not identify LES achalasia to the extent documented in our 
study. (194, 215) The response to treatment in our patient population makes misdiagnosis 
unlikely, and this discrepancy between our study and previous studies may reflect 
limitations in available diagnostic tests at the time those studies were performed. 
Alternatively, it may highlight the point that this condition reflects subpopulations of 
dogs and not all dogs with ME, making accurate diagnosis critically important.  
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Videofluoroscopic swallow studies, have long been considered the gold standard 
for evaluation of dysphagia in veterinary medicine, but because VFSS traditionally have 
been performed with dogs in lateral recumbency, and often by force-feeding, the risk of 
aspiration made such studies relatively contraindicated in dogs with ME, a diagnosis that 
could be made by routine thoracic radiography. However, thoracic radiography provides 
essentially no information regarding esophageal motility, which that has previously 
limited our understanding of the pathogenesis of the disease in dogs with ME. Using a 
protocol that allows dogs to stand and free-feed, we documented that 61% of dogs with 
ME that would have been classified as “idiopathic” had underlying LES-AS. These 
findings contrast with those of a  large study of 216 dysphagic dogs in which VFSS 
performed with dogs in in lateral recumbency failed to identify any dogs with  functional 
LES obstruction and historical manometric studies that failed to identify functional LES 
obstruction.(196, 215) Furthermore, the use of unrestrained and free-feeding VFSS 
protocols decreases the risk of aspiration to no more than would be expected in the dogs 
at  home. To date, no dog at our institution has developed aspiration pneumonia after 
these unrestrained free-feeding VFSS, including those with ME.  Thus, expanding the 
population that can be evaluated safely by VFSS has allowed identification and 
characterization of dogs with LES-AS, permitting specific treatment.(148)  
The primary goal in treating LES-AS is early patient identification and treatment 
of esophageal-gastric outflow obstruction. In people, this goal is achieved either by 
mechanical disruption of the LES by dilation or surgical myotomy or by lowering LES 
tone. Sildenafil has been used with variable effect in humans to lower LES tone.(216) A 
recent study indicated improved clinical signs in puppies with congenital ME treated with 
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sildenafil (without documentation of functional LES-obstruction), perhaps supporting the 
role of increased LES tone in the pathogenesis of ME in dogs.(185) In people, treatment 
is dictated largely by clinical variables, patient risk factors, and LES achalasia sub-
classification.(186, 217) Sub-classifications for LES achalasia in people are based on 
HRM, and treatment responses have been shown to vary based on achalasia subtype.(186, 
218) Although subtypes have been identified in dogs with LES-AS based on fluoroscopy 
(148), numbers of affected animals are insufficient to attempt treatment based on sub-
classification. Furthermore, because achalasia subtypes in people are established by HRM 
rather than fluoroscopy, direct comparisons between subtypes in humans and dogs are not 
possible. As such, a combination of mechanical dilation and BTA injections was selected 
to maximize the likelihood of a response, and any dog with a positive response then 
subsequently was offered surgical intervention as a more lasting treatment.  
In this study, treatment for LES-AS resulted in significant clinical and VFSS 
improvement after therapy targeting LES functional obstruction. Clients perceived 
clinical improvement in 100% of dogs by 2-3 weeks after mechanical dilation and BTA 
injections. This finding is crucial, considering the degree to which perception of quality 
of life impacts treatment decisions in veterinary patients.(219) Although placebo effect 
may have played some role, this perceived clinical improvement is supported by pre- and 
post- treatment BW, BCS, frequency of regurgitation, and extent of gastric filling. All of 
the aforementioned metrics were significantly improved from baseline making a 
substantial placebo effect unlikely. Videofluoroscopic swallow studies documented 
improvement in passage of food from the esophagus to the stomach in the majority of 
dogs despite the persistence of ME and abnormal esophageal motility. This finding 
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suggests that clinical improvement is secondary to relieving the functional LES 
obstruction, and supports the role of functional LES obstruction in the pathogenesis of 
ME in a subpopulation of dogs. The persistence of ME and esophageal dysmotility in 
these patients may reflect the short time frame between treatment and evaluation. 
Alternatively, irreversible structural changes may have occurred secondary to chronic 
dilatation. As such, clients should be informed that complete resolution of ME, 
esophageal dysmotility or both may not occur with targeted treatment but, this does not 
diminish the importance of the often dramatic clinical improvement. Two of 14 dogs did 
not show improved gastric filling after mechanical dilation and BTA injection despite 
improvement of other clinical variables. This finding has also been reported in people 
with achalasia following treatment, and in 1 study was predictive of long term treatment 
failure. (220) More study is needed before conclusions regarding this finding can be 
made in dogs with LES-AS.  
Despite strongly positive responses to mechanical dilation with BTA injections, 
the relatively short duration of effect precludes their use as definitive (permanent) therapy 
for LES-AS. The increased risk of aspiration under general anesthesia makes multiple 
repeated endoscopic treatments less appealing. As such, mechanical dilation with BTA 
may be best reserved as a test for definitive surgical intervention, for temporary treatment 
for patients considered too high risk for myotomy (e.g. poor wound healing due to 
malnutrition), or as a temporary measure before surgery, particularly in young dogs 
before reaching skeletal maturity.  
 Although more data is needed, our study suggests that surgical intervention may 
provide sustained clinical improvement in dogs with LES-AS and that mechanical 
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dilation and BTA injections may help identify patients that may benefit from surgical 
intervention. Interestingly, 2 dogs showed delayed (>6 months later) evidence of 
decreased esophageal diameter and improved esophageal motility after surgical 
intervention compared to their initial VFSS evaluation. This observation is supported by 
findings in the human medical literature that suggest that esophageal pathology is 
secondary to increased LES tone, and treatment may result in a return to peristalsis in 
some patients without permanent damage. (221, 222)  
The age range of dogs with LES-AS was wide and inclusive of dogs with both 
congenital and acquired ME. Surgical intervention cannot be recommended until dogs 
reach skeletal maturity because gastric motility may be impacted by surgery, and final 
position of anatomic structures cannot be predicted in a growing animal. For these dogs, 
repeated treatment with mechanical dilation and BTA merits further evaluation. In people, 
mechanical dilation of the LES and injections of BTA can be repeated but submucosal 
fibrosis may occur with repeated treatment, potentially complicating future surgical 
intervention. (223, 224)   
Overall treatment complications in people with achalasia are approximately 6.3% 
with a peri-procedural mortality of 0.1%.  The most commonly reported complications 
after mechanical dilation and BTA injections in people include chest pain and mild 
heartburn, managed by antacids.(225, 226) Of note, chest pain and heartburn cannot be 
specifically detected in dogs. More serious complications in people including 
mediastinitis, allergic reactions to BTA and LES perforation are rare.(226) Complications 
after mechanical dilation with BTA in dogs included aspiration pneumonia and a Type IV 
hiatal hernia. Review of medical records could not reveal a potential cause of the 
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complications in the dog with the hiatal hernia, but concurrent diffuse gastrointestinal 
dysmotility should be considered.  
In people, LES mechanical dilation and BTA injections are performed as 
independent interventions.(202, 204, 218) However, despite combining these 2 
procedures in dogs, the duration of effect was considerably shorter than has been reported 
in people for either procedure alone. (200, 202, 205, 227) Dosing of BTA for achalasia is 
variable in people but ranges between 20-100 units.(228) A total of 32 U (4 U/site) was 
selected based the smaller size of dogs compared with humans and to minimize the risk 
of complications associated with excessive administration.(225) Although doses were 
uniform for all dogs regardless of size, and the study was not powered to detect a dose-
dependent response.  Additional studies would be needed to determine if higher doses 
result in a longer duration of effect.(229) Another explanation for the shorter duration of 
efficacy in dogs may involve anatomic differences between the canine and human 
esophagus. The entire canine esophagus is comprised of skeletal muscle compared to 
humans where the distal two-thirds of the esophagus is comprised of smooth muscle. 
Botulinum toxin A acts by interacting with several proteins including synaptosomal-
associated protein (SNAP) 25 in the nerve terminal to prevent vesicle fusion and 
inhibiting the release of acetylcholine.(230) Differences in regional expression of SNAP-
25 in the esophagus have been reported in other species and could account for differences 
in treatment response.(231) Upregulation of SNAP-25 mRNA also has been identified in 
rats after BTA injections into skeletal muscle. (232)  This finding suggests a possible role 
for SNAP-25 in functional muscle recovery and could account for variable responses if 
species differences are documented. Alternatively, differences in collagen composition, 
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due either to species variation or extent of fibrosis at the time of diagnosis, may impact 
local diffusion of BTA and subsequent response to treatment.  
Anatomic differences also may contribute to a shortened response to mechanical 
dilation. The purpose of mechanical dilation is to weaken the LES by tearing muscle 
fibers.(204) Differences in collagen versus muscle content may have made the extent of 
radial pressure applied by pneumatic dilation insufficient to achieve a sustained treatment 
response. Given the sustained treatment response seen after surgical myotomy, a greater 
extent of LES disruption may be needed. Mechanical dilation in adults is most commonly 
performed with balloons ranging from 3 to 4 cm in diameter. Smaller balloons are 
recommended in children, with balloons >3.5 cm being reserved for children > 8 years of 
age.(233)  In our population, the balloon and bougienage diameter were selected based on 
patient size but ranged between 1-3 cm. Selecting balloon size based on patient size was 
performed to decrease the risk of LES perforation. Blanching of the mucosa surrounding 
the LES was observed in all patients, suggesting resistance across the LES in response to 
balloon dilation and bougienage. Multiple dilation cycles were performed for each dog to 
maximize disruption of the LES. Multiple dilations with progressively increasing balloon 
diameter may result in a more sustained response, but may be associated with increased 
risk of LES perforation. 
Conclusions 
Dogs with LES-AS experienced marked clinical improvement after targeted 
intervention with mechanical dilation and BTA injections of the LES. Although the 
response was temporary, this finding establishes the role of functional LES obstruction in 
the pathogenesis of ME and esophageal dysphagia in dogs. Preliminary results from dogs 
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with LES-AS following surgical myotomy, suggest that a positive response to mechanical 
dilation with BTA may identify dogs that could benefit from surgery, and that surgery 
may provide lasting clinical benefit despite persistence of ME. These interventions allow 
for often dramatic clinical improvement (improved quality of life, decrease episodes of 
regurgitation, weight gain, improved BCS) in a subpopulation of dogs with ME 
associated with LES-AS.  
  
74 
 
CHAPTER 5 
 
DOCUMENTING SILENT REFLUX AND MICROASPIRATION 
EVENTS USING NUCLEAR SCINTIGRAPHY IN HEALTHY DOGS  
 
Introduction   
Reflux is a known source of acute and chronic respiratory disease in people (2-6).  
Importantly, both reflux and microaspiration are also known to occur in healthy adult 
humans without obvious clinical consequence (5, 14). Clinically silent microaspiration 
highlights the importance of normative data before ascribing significance to reflux and/or 
microaspiration in the pathogenesis of canine respiratory disease. Repetitive 
microaspiration is a strong contributor to respiratory diseases in people (82, 234, 235). 
Importantly, treatment of GER and extra-esophageal reflux (EER), reflux extending 
beyond the esophagus, reduces frequency of disease exacerbations and slows the rate of 
decline in lung function in people with asthma, chronic obstructive pulmonary disease, 
and idiopathic pulmonary fibrosis (2). As in people, a relationship between reflux, 
microaspiration, and respiratory disease is suspected in dogs based on a few clinical 
studies, case reports, and studies in animal models (12, 17, 79, 98, 236-238).  However, 
the frequency of reflux and microaspiration in healthy dogs has not been clearly 
established.  The prevalence of gastroesophageal reflux (GER) in healthy, free-feeding 
dogs was found to be 41% by videofluoroscopic swallow study (VFSS) (239). However, 
this technique lacks the sensitivity to detect reflux associated with microaspiration. The 
ability to document reflux and microaspiration in dogs with respiratory disease may open 
doors for novel avenues of therapeutic intervention. As such, characterizing reflux and 
aspiration in normal dogs, and subsequently in dogs with aspiration associated respiratory 
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disease (AARS), is an area of significant clinical relevance.   
Current diagnostic methods for reflux and aspiration in dogs lack sensitivity and 
specificity due to intermittent reflux events, variable client vigilance, small volumes of 
refluxate, and the presence of non-acidic refluxate, which may account for as many as 
90% of events in people (19, 112, 113, 117, 121). Nuclear scintigraphy has potential to 
address many of these limitations and has been used successfully to detect reflux and 
aspiration people (127-131). For example, this technique has been used to safely evaluate 
pulmonary aspiration in medically fragile human infants (127, 130). In dogs this 
technique is postulated to be able to detect reflux events missed by owner observation 
and that may be missed by VFSS due to small volume. Scintigraphy may also detect non-
acidic reflux events, broaden effective time of data collection by looking at additive 
radio-nuclide activity in several anatomic regions, and help establish the normative data 
necessary to determine the significance of positive results obtained in clinical patients 
(127-131).  Nuclear scintigraphy may therefore represent a novel and sensitive means to 
help in the diagnosis of elusive reflux and AARS in dogs. 
The objectives of this study are to characterize and determine the prevalence of 
reflux and aspiration events in healthy mesocephalic dogs and to obtain clinically 
relevant normative data to allow further exploration of nuclear scintigraphy as a 
diagnostic tool for dogs with suspected reflux and AARS.  We hypothesize that healthy 
dogs will commonly have GER and a proportion of these dogs will have EER with silent 
aspiration into their respiratory tract.    
Materials and Methods  
Animals 
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Twelve clinically healthy, adult, mesocephalic companion dogs were enrolled 
with informed consent (University of Missouri ACUC #9871). Dogs were determined to 
be healthy based on normal physical examinations and the absence of clinical respiratory 
and GI disease within the preceding 6 months. Brachycephalic breeds and dogs receiving 
prokinetic medications were excluded.  
Reflux Scintigraphy  
After a 12-hour fast, dogs were free-fed a standardized meal impregnated with 
(111 MBq) colloidal 99m-technetium phytate (99TcP) (Mid-America Isotopes, Ashland 
MO). Each meal was followed by water (10-20 mL) to ensure clearance of radioactive 
material from the pharynx and esophagus. During data collection, non-invasive 
temporary markers were placed at the level of the mandible and stomach to ensure 
regions of interest (ROI) were maintained in the area of detection. Images were collected 
using a gamma camera with 140 keV parallel hole collimator (Equistand, Middlesex, NJ) 
with Mirage computer system (Medical Imaging technologies, Akron, OH) at 2 
seconds/frame (240, 241). Dynamic studies were collected over 5 minutes in left-lateral 
and dorsal recumbancy (n=6) or in dorsal recumbancy alone (n=6). Data were collected 
5- and 30-min post-ingestion of 99TcP. Static studies were collected for all 12 dogs in 
dorsal recumbancy in order to visualize both lung fields (right and left).  Static data were 
collected over 2 minutes at 2- and 18-hours post ingestion of 99TcP. No abdominal 
pressure was applied. Dogs were housed in accordance with University of Missouri 
Environmental Health and Safety regulations between scans. All studies were performed 
without anesthesia or sedation. 
Data analysis 
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Data analysis was performed using 3DSlicer (version 4.10.1) and Fiji 
(ImageJ)(242) analysis software. For dynamic and static studies performed in dorsal 
recumbancy, ROI were drawn over the pharynx; proximal, middle, and distal esophagus; 
stomach; and right and left lung fields. (Figure 13a) For dynamic studies performed in 
left lateral recumbancy, lung ROI were not evaluated due to summation of the right and 
left lung fields. (Figure 13b) For dynamic studies, time-activity-curves (TAC), maximal 
reflux margination, volume, frequency, and duration were evaluated for each ROI (241). 
Reflux events (displayed on TAC) were defined as counts ≥ 200% background activity 
with a concurrent decrease in gastric counts (130). (Figure 14) Reflux TAC were 
subcategorized as rising (i.e. repeated reflux events with failure of clearance), flat (i.e. no 
reflux or reflux events with return to baseline between events) or falling (i.e. reflux with 
delayed clearance) (130). (Figure 15) Dogs with rising TAC were determined to have 
cumulative reflux events even if an exact number could not be quantified provided 
cumulative counts exceeded 200% of background. Maximal reflux margination was 
recorded as the maximal distance traveled (i.e. most distal ROI from the stomach) by 
reflux for each dog. Reflux volume was calculated as previously described (243). Reflux 
volume was depicted as the percent of gastric counts refluxed during each event. Reflux 
frequency was calculated as the number of discrete events occurring over the 5-minute 
collection period. Reflux duration was determined by the number of seconds counts 
remained ≥ 200% background. Static studies were used to confirm complete clearance of 
reflux after feeding (i.e. baseline), persistent ROI contamination and aspiration.  
Aspiration was defined as counts ≥ 200% baseline though a concurrent a drop in gastric 
counts were not considered necessary for diagnosis (130). 
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Statistical evaluation  
Statistical analysis was performed using SigmaPlot (version 14.0) data analysis 
software.  Descriptive statistics were applied where appropriate. Between group 
comparisons were made using a One-Way ANOVA on Ranks or Wilcoxon signed-rank 
test with a p ≤ 0.05 significance level. Post-hoc analysis (Dunn’s analysis for multiple 
comparisons) was performed where appropriate.  
Results  
Animals 
 Twelve healthy companion dogs were enrolled with informed consent. Breeds 
represented included mixed breed (n=3), beagle dog (n=2), Labrador retriever (n=2), and 
one each for miniature Dachshund, Jack Russel terrier, Brittany spaniel, Feist terrier, and 
West Highland white terrier. Seven dogs were castrated males and 5 were spayed females. 
Ages ranged from 3-13 years with a median (IQR) age of 9.5 years (6-10.25 years). 
Weights ranged from 7.1-26.0 kg with a median (IQR) weight of 9.6 kg (8.2-20.4 kg). 
Body condition score (9-point scale) ranged from 4 to 6 with a median (IQR) BCS of 5 
(5-5). 
Scintigraphy 
Baseline scans demonstrated complete clearance of 99TcP from the pharynx and 
esophagus at the start of the study. Reflux events were detected in all 12 dogs using 
reflux scintigraphy. A total of 144 TAC curves were further characterized as rising 
(n=27), flat (n=105), and falling (n=12).  No significant differences were detected for 
demographic data (age, weight, or BCS), recumbancy (left lateral or dorsal), collection 
time (5 min or 30 min), or ROI for TAC subcategory, maximal reflux extension, reflux 
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frequency (events/5 minutes), or reflux duration (sec) (p > 0.05 for all). As such, groups 
were combined for further evaluation. Thirty-three discrete esophageal and 6 pharyngeal 
reflux events were identified.  Pharyngeal reflux was identified in 5/12 dogs. Reflux 
marginated maximally to the pharynx (5/12 dogs), proximal esophagus (2/12 dogs), 
middle esophagus (3/12 dogs), and distal esophagus (2/12 dogs). The total number of 
discrete reflux events identified within the esophageal ROI were 4/33, 6/33, and 23/33 for 
the proximal, middle, and distal esophagus respectively. The median (IQR) reflux 
volumes for esophageal and pharyngeal ROI are displayed in Table 1. Distal esophageal 
reflux volume was significantly greater than for pharyngeal reflux volume (p <0.001). 
Reflux events detectable in the middle and proximal esophagus were not significantly 
greater in volume than pharyngeal reflux (p >0.05). Median (IQR) frequency of reflux 
was 2 events/5 minutes (1-3.25 events/5 minutes). Median (IQR) duration (sec) of reflux 
was 6 seconds (4-9 seconds). Static scans showed no evidence of persistent 
contamination (counts ≥ 200% of background) within the pharyngeal or esophageal ROI 
for any dog regardless of timepoint (2hrs or 18hrs). Likewise, lung ROI showed no 
evidence of pulmonary aspiration for any healthy dog regardless of time-point (2hrs or 
18hrs). 
Discussion  
In this pilot study, reflux scintigraphy was used to successfully identify and 
characterize reflux events in clinically healthy mesocephalic dogs. Reflux (GER and 
EER) but not pulmonary aspiration was a common finding in healthy dogs. This provides 
important normative data allowing further investigation into the role of reflux in the 
pathogenesis of respiratory disease. Investigating the relationship between reflux and 
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aspiration is important as this may ultimately open new avenues of therapeutic 
intervention in affected dogs with a variety of respiratory disorders. Furthermore, since 
dogs and humans both have clinical manifestations of GER and EER, using a One Health 
approach will increase the opportunity for bidirectional advancement in research related 
to aspiration-associated respiratory syndromes (AARS). 
People may have both reflux and aspirate without apparent clinical consequence 
due to the presence of functional protective and clearance mechanisms (5, 14, 29). 
Interestingly reflux is also associated with the pathogenesis and progression of 
respiratory disease in human medicine with a prevalence of 50% in patients with chronic 
cough, asthma, COPD and pulmonary fibrosis (2-6). Therefore, the development of 
pathology is likely dictated by frequency, margination, volume, duration and content of 
reflux and aspiration rather than the presence or absence of such events. As such, data 
documenting the prevalence of reflux and aspiration in normal dogs and objective 
characterization of these events is necessary prior to ascribing pathologic significance to 
reflux and aspiration in clinically affected patients.  
Airway-associated reflux can be subcategorized into GER and EER. Extra-
esophageal reflux is considered a supra-esophageal manifestation of GER with a 
demonstrated correlation between the severity of GER and prevalence of EER (244). 
Extra-esophageal reflux also increases risk of macro- and micro-aspiration, laryngeal 
dysfunction and exacerbation of pulmonary pathology (244, 245). Importantly, treatment 
of GER and EER has been demonstrated to reduce the frequency of disease exacerbations 
and slow the rate of decline in lung function in patients with airway and pulmonary 
parenchymal disease (2). A study in brachycephalic dogs likewise demonstrated that 
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treatment for reflux prior to brachycephalic airway surgery resulted in decreased post-
operative complications (17). Treatment for GER and EER may therefore reflect a 
potential avenue of therapeutic intervention for dogs with AARS. Unfortunately, studies 
evaluating the relationship between GER, EER, aspiration and the development of 
respiratory disease are conspicuously absent in the veterinary literature. This due in part 
because diagnostics capable of identifying dogs with naturally occurring GER, EER, and 
microaspiration are lacking.  
Reflux scintigraphy with 99TcP is considered a safe and sensitive means to detect 
reflux and microaspiration in people (127-130). Because 99TcP is not absorbed 
systemically, the presence of increased counts in the esophagus and pharynx, as well as 
the lungs after initial clearance into the stomach are diagnostic for reflux and aspiration, 
respectively. In adult people, cough and laryngospasm were strongly correlated with 
positive reflux/aspiration scintigraphy (130). Further, patients who were positive for 
reflux via scintigraphy had symptomatic response to surgical treatment: 90% of cases had 
resolution of clinical symptoms suggesting a high predictive value for scintigraphy 
findings (130).  
In this study, reflux was identified in 100% of dogs. This is greater than the 41% 
reported in healthy dogs evaluated by VFSS (239). This may be attributed to the 
increased sensitivity of scintigraphy compared to fluoroscopy for small volume reflux as 
well as the longer collection period of scintigraphy compared to VFSS (246). Increased 
intragastric pressure during recumbancy may also be contributory and clinically relevant 
(i.e., it would be common for a dog to lay down after eating).  Decreased numbers of 
transient lower esophageal sphincter relaxations have been demonstrated in dogs and 
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people in supine compared to upright posture (247-249). As such, increased frequency of 
transient lower esophageal sphincter relaxations, due to dorsal and lateral recumbancy are 
unlikely to contribute to the increased number of dogs with reflux observed in this study. 
The majority of dogs in this study had an ideal or near ideal body condition score which 
was similar to the population of dogs evaluated in the aforementioned VFSS study (239). 
As such, body condition is unlikely to contribute to the increased prevalence of reflux 
noted with scintigraphy. The presence of detectable reflux in 100% of healthy dogs 
evaluated by reflux scintigraphy highlights the need for additional parameters to 
discriminate between healthy dogs and those with pathologic reflux.   
The use of time activity curves (TAC) allows for quantification of repeat reflux 
events and are routinely evaluated in reflux scintigraphy studies in people (130, 250). The 
presence of a rising TAC is considered supportive of cumulative reflux events though 
individual reflux events cannot necessarily be visualized due to superimposition. 
Individual reflux events were determined by counts ≥ 200% with concurrent drops in 
gastric counts (Figure 2). However, reflux events were not always tracible to their 
maximal extent in each ROI (e.g. reflux events detectable in ROI E1 and E3 but not E2). 
This was likely attributable to rapid transit times compared to sampling rate. Similarly 
discontinuous tracings may be seen in people with reflux detected by impedance 
manometry as well as scintigraphy (251, 252).  Such discontinuous tracings precluded 
correlation of total reflux volume with extent of margination. As such, reflux volume was 
calculated according the volume calculated within each ROI. A higher frame rate may 
improve detection of individual reflux events and additional studies in dogs are needed to 
establish a correlation between severity of GER and the presence of EER as is seen in 
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people (240, 241, 244). Despite this limitation, the frame rate selected for this study is 
otherwise considered sufficient. Sampling rates 1-6 seconds/frame are used for pediatric 
gastric scintigraphy studies. Further, esophageal pH studies have demonstrated that 
increased sampling rate did not correlate with increased acid exposure time, and it has 
been postulated that brief reflux events are less likely to be clinically relevant than 
prolonged esophageal contact with refluxate (131, 241, 253, 254). As a rising TAC curve 
is indicative of esophageal exposure to gastric contents, the sampling rate in this study is 
not considered a significant limitation. In this study all TAC subcategories (rising, flat 
and falling) were represented. The presence of EER in this study was not associated with 
a rising TAC as has been demonstrated in some studies in people though the influence of 
type 2 error cannot be ruled out (130). Studies in clinically affected dogs are needed to 
determine the significance of flat and falling TAC. 
Pharyngeal reflux (i.e., EER) was identified in nearly 42% (5/12) of dogs 
representing approximately 15% of total discrete reflux events detected. This mirrors 
findings in people where EER events were detectable in 10-30% of asymptomatic adults 
evaluated by impedance manometry (255).  Extra-esophageal reflux is clinically 
important as laryngeal structures are susceptible to damage by acid and digestive 
enzymes (256-258). In the esophagus, up to 40 reflux episodes per day is considered 
normal in people; however, as few as 3 reflux episodes reaching the larynx are sufficient 
to cause detectable damage (258).  In dogs without EER, maximal esophageal 
margination for the proximal, middle, and distal esophagus was approximately 16.7% 
(2/12), 25% (3/12), and 16.7% (2/12) accounting for 70% (23/33), 18% (6/33), and 12% 
(4/33) of detected individual esophageal reflux events respectively. This is a departure 
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from VFSS where the majority of reflux events appeared to be contained within the distal 
esophagus (239).  In healthy adults, proximal esophageal reflux was identified in 34% of 
upright reflux events by esophageal impedance pH monitoring. Additional studies 
evaluating the reflux margination in people with gastroesophageal reflux disease (GERD) 
and extra-esophageal reflux disease (EERD)  suggest that symptomatic patients have a 
higher median proximal margination of reflux events, larger reflux volumes, and longer 
reflux durations than healthy controls (259).  
The volume of refluxate is considered important as it reflects the total amount of 
potentially damaging substances. Absolute quantification of reflux volumes is technically 
challenging but may be performed by calculating the percent of gastric counts that are 
detected in the esophagus during reflux events. Large volume reflux events (> 4%) were 
occasionally detected in this population. The volume of reflux in the distal esophagus was 
considerably greater than in the other esophageal and pharyngeal ROI suggesting 
decreasing volumes of refluxate with increased margination from the stomach. Frequency 
and duration of reflux events were able to be characterized by reflux scintigraphy 
suggesting utility in clinical patients, however controlled studies comparing objective 
parameters in healthy and clinically affected dogs are needed.  
Interestingly, aspiration was not identified in any healthy dog, which is in 
opposition to the human literature. Species differences may account for this variation, 
however, type 2 error cannot be ruled out and further studies are needed. Lack of 
sensitivity for detecting aspiration is considered unlikely. Computer acquisition of data 
demonstrated that as little as 0.1 MBq of activity aspirated into the lungs can be detected 
by the gamma camera (260). This suggests that microaspiration is likely to be detected 
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where present.  
Limitations of this study include small sample size. Further, not all dogs were 
evaluated both in left-lateral and dorsal recumbancy. Importantly, no differences were 
identified with recumbency, which is important as dorsal recumbency allows independent 
visualization of the right and left lung fields. Ultimately these do not alter the conclusion 
that reflux scintigraphy represents a viable adjunctive diagnostic for dogs with reflux and 
AARS especially when repetitive microaspiration is suspected. Finally, only 
mesocephalic dogs were evaluated in this study. Given the presumed predisposition of 
brachycephalic for reflux and AARS, additional studies specifically evaluating this 
population is needed.  
Conclusions  
 Gastric reflux to the level of the esophagus and pharynx, but not pulmonary 
aspiration, were common findings in healthy mesocephalic dogs evaluated by nuclear 
scintigraphy.  The results of this study support further exploration of reflux scintigraphy 
as an adjunctive diagnostic in dogs with aerodigestive disorders. The normative data 
presented here may help in the interpretation of future studies in dogs with suspected 
AARS.  
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CHAPTER 6 
 
PROTEOMIC BIOMARKERS IN REGURGITATION, VOMITING, AND 
COUGH: PROTEOMIC CHARACTERIZATION OF CANINE GASTRIC 
FLUID BY LIQUID CHROMATOGRAPHY MASS SPECTROMETRY 
(LC-MS) 
 
Introduction  
Biomarkers diagnose, prognosticate, monitor, and identify populations at risk for 
disease. Development and implementation of biomarkers has been making an 
increasingly large impact in companion animals. Biomarkers have the potential to 
advance understanding of disease pathogenesis, allow objective investigation of 
efficacy of novel therapeutics, and advance translational research through animal 
models of human disease (132, 261-264). 
Reflux of gastrointestinal contents is a source of acute and chronic pulmonary 
disease with a prevalence of 50% in humans with chronic cough, asthma, chronic 
obstructive pulmonary disease and idiopathic pulmonary fibrosis (2-6). Reflux is 
subcategorized into gastroesophageal reflux (GER) and extraesophageal reflux 
(EER). Gastroesophageal reflux refers to reflux of gastric contents into the esophagus 
while EER refers to refluxate reaching structures beyond the esophagus including the 
oro-and nasopharynx, larynx, and airways (245).  Severity of GER and prevalence of 
EER are correlated (244). In people, EER increases risk of macro- and micro-
aspiration, laryngeal dysfunction and exacerbation of pulmonary pathology (244, 
245). Importantly, treatment of EER in people reduces frequency of disease 
exacerbations and slows rates of decline in lung function (2). This makes identifying 
patients with reflux-associated respiratory disease critically important. 
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Reflux and aspiration are implicated in canine respiratory disorders including 
rhinitis, laryngeal dysfunction, and upper/lower airway and pulmonary parenchymal 
diseases (12, 79, 98). Despite the implied association between reflux, aspiration, and 
respiratory disease, a non-invasive widely available means of detecting EER in dogs 
is needed. Human gastric fluid (GF) has been extensively characterized allowing for 
identification of reflux biomarkers outside the gut (265-267). Gastric pepsin (pepsin 
A), a component of refluxate identified in humans with EER, is a biomarker in oral 
and respiratory secretions with improved sensitivity (100%) over ambulatory 
esophageal pH monitoring (63%)(9, 115, 266-268).  Though proteomic evaluation has 
been performed for several biological fluids in dogs, (264, 269) characterization of 
the canine GF proteome has not been performed previously.  
The objectives of this pilot study were 2-fold. The first was to perform a 
comprehensive characterization of the protein composition of canine GF using liquid 
chromatography mass spectrometry (LC-MS) and to compare the GF proteomic 
profile to that of the oropharynx in healthy, vomiting/regurgitating, and coughing 
dogs to evaluate for potential biomarkers of EER. The second objective was to 
evaluate potential biomarkers for stability by evaluating samples after storage at -
20°C for ≤ 2 weeks and 6 months. We hypothesized that using high coverage 
proteome analysis we could identify stable proteins relevant as potential biomarkers 
of canine EERD.  
Materials and Methods  
Animals  
Twenty-three companion dogs presenting to the University of Missouri Veterinary 
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Health Center were prospectively enrolled with informed owner consent (University of 
Missouri ACUC 240). Residual canine GF was collected directly via nasogastric or 
orogastric tubes in patients for whom these interventions were deemed medically 
necessary by the attending clinician. Oropharyngeal swabs were collected from healthy 
dogs, dogs with a history of regurgitation/vomiting, and coughing dogs. Heathy dogs had 
an unremarkable physical examination and no clinical evidence of gastrointestinal (GI) or 
respiratory disease within the preceding 6 months. Regurgitating/vomiting dogs were 
enrolled if they had a documented episode of regurgitation or vomiting within 12 hours of 
sample collection. Coughing dogs were enrolled if they had a history of cough for greater 
than 2 weeks without clinical evidence of gastrointestinal disease (e.g., vomiting, 
regurgitation). Exclusion criteria included dogs with mixed clinical evidence of 
respiratory and GI disease and dogs that were currently receiving pro-kinetics, 
antibiotics, or probiotics at the time of sample collection.  
Sample Collection 
Two mL of GF were collected via nasogastric or orogastric tube and placed in a 
sterile red top tube. Oropharyngeal swabs, collected by vigorously rubbing this region in 
each gently restrained dog meeting our inclusion criteria, were placed in 2 mL of sterile 
saline in a sterile red top tube as above. The samples were gently vortexed, and even 
aliquots distributed into 2 polypropylene conical bottom Eppendorf tubes (Fischer 
Scientific, Chicago, IL). Paired samples were frozen at -20°C; 1 aliquot was evaluated 
within 2 weeks and the other was evaluated 6 months after sample collection.   
Proteome Analysis  
Protein was extracted using 4 volumes of ice-cold acetone.  Following washing 
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with 80% acetone (in water) the pellet was re-suspended with 6 M urea, 2 M thiourea, 
and 100 mM ammonium bicarbonate. Protein was quantified using the EZQ assay 
according to the manufacturer’s instructions (Invitrogen/Life technologies). After 
quantification, protein amount normalized across all samples by dilution in the urea 
buffer, and 25 µg protein from each sample were digested with trypsin.  The resulting 
peptides were desalted using C18 pipette tips (Peirce/Thermo), lyophilized, and re-
suspended in 25 µl of acetonitrile/formic acid (0.1%). Ten ug of the re-suspended 
peptides was loaded on a C8 trap column (Thermo PepMap 100, 5cm x 300um) and then 
separated using a 400 nL/min 70 min gradient on a self-packed C18 column (75 um x 20 
cm x 1.7 um particles – Waters BEH C18) at 50 °C in the CaptiveSpray nanospray 
source.  The mobile phase consisted of 0.1% formic acid in water (A) and 0.1% formic 
acid in acetonitrile (B) and the LC gradient was for B: Initial 2%, followed by 26 min 
ramp to 17%, 17-25% over 36 min, 25-37% over 15 min, gradient of 37- 80% over 6 
min, hold at 80% for 7 min with a total run time of 90 min. MS + MS/MS data were 
acquired on a Proxeon Easy nLC system attached to an TQ Orbitrap mass spectrometer or 
Bruker timsTOF-PRO using the PASEF(1) method over the 90min gradient.  Capillary 
voltage was set to 1600V, tims-on, PASEF-on (10 PASEF frames, overlap of 5; i.e. 
between MS acquisition), 100-1700 m/z mass range. Cycle time for 1 MS and 15 PASEF 
= 1.8 sec (approximately 120 MS/MS acquired per cycle).  Repeated acquisition: 
threshold 4X within 0.4 min (if same peptide precursor is observed at a 4X intensity 
within the RT threshold, re-acquire MSMS).  Active exclusion: release after 1 min 
(exclude from MS/MS the same peptide mass, notwithstanding the criteria above, and 
release after 1 min of elution).  MS data were collected over an m/z range of 100 to 1700. 
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During MS/MS data collection, each trapped ion mobility spectrometry (tims) cycle 
included 1 MS + an average of 10 parallel Accumulation Serial Fragmentation (PASEF) 
MS/MS scans. 
Samples stored at -20°C 
 During the 6-month storage period, the MU proteomics core underwent a systems 
upgrade. Samples were processed as previously described; however, peptides were 
acquired using the Bruker timsTOF pro (Bruker Scientific Billerica, MA).  
Data Analysis  
The acquired data were submitted to the PEAKS DB search engine (version X, 
Bioinformatics Solutions Inc.) for peak picking and protein identification using NCBI 
database limited to dog sequences (81,077 entries, last update 3/1/2019) or cat sequences 
(45,259 entries; last update 5/1/2019). Database search parameters were as follows: 
parent mass tolerance: 50 ppm; fragment mass tolerance: 0.1 Da; precursor mass type: 
monoisotopic; enzyme: trypsin; max # cleavages: 2; non-specific cleavage: 1 (consider 
peptides with one end that is tryptic); fixed modification: carbamidomethyl Cys; variable 
mods: Met oxidation and deamidation.  FDR estimation enabled (a reversed decoy 
database is created and searched simultaneously).  Differential abundance of proteins was 
determined using PEAKS LFQ (label-free quantitation) based on the MS1 peak 
integration approach with the following parameters: algorithm: PEAKS-Q; retention time 
tolerance: 1 min; mass tolerance: 40 ppm.  Data were then filtered for 1% protein FDR 
with ≥1 unique peptide and ≥2-fold change. Spectral counting was used to determine 
differential protein abundance using the following criteria: data were then filtered for 1% 
protein FDR with ≥1 unique peptide and then >4 spectral counts per protein (mean of 
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replicates). Protein abundance is described using the normalized spectral abundance 
factor (NSAF). Biological function was determined for the 200 most abundant proteins 
per group (GF, normal, vomiting/regurgitation, coughing) as determined by NSAF. 
Biomarker candidates were evaluated according to their abundance in GF, tissue 
specificity, low or absent concentrations in normal dog OP, and increased concentrations 
in vomiting/regurgitating compared to normal dog OP. Candidate proteins were then 
assessed in coughing dogs to look for evidence of EERD. 
Statistical Analysis  
Statistical analysis was performed using Past (version 3.21) and SigmaPlot 
(version 14.0) data analysis software. Descriptive statistics were applied where 
appropriate. Differences in patient demographics between groups (GF, healthy, 
vomiting/regurgitation, and cough) were evaluated by Wilcoxon signed rank test with p ≤ 
0.05 significance level. Principle component analysis (PCA) was performed for all 
proteins identified across groups. Differential abundance of proteins between groups 
based on pairwise comparisons were evaluated by Fischer Exact test with p <0.0004 
considered significant. Coefficient of variation was calculated for each protein 
demonstrating differential abundance between groups. A one-way Analysis of Similarity 
(ANOSIM) using a Bray-Curtis similarity index was used to test for similarity between 
groups based on the biological function of detected proteins with p ≤ 0.001 significance 
level. Normality was evaluated by Shapiro-Wilk test. Post-hoc analysis (Dunn’s method 
or Bonferroni correction for multiple comparisons) was applied where appropriate. Due 
to differences in sensitivity between collection methods (TQ Orbitrap mass spectrometer 
at the early time point vs. Bruker timsTOF pro at the 6-month time point), exact 
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comparisons before and after storage could not be performed. Candidate biomarkers 
identified in the initial run were therefore described as present or absent following 6 
months of storage of -20°C. 
Results  
Animals 
Twenty-three companion dogs were prospectively enrolled with informed 
consent. Breeds represented included mixed breed (n=5), Labrador retriever (n=3), 
Yorkshire terrier (n=2), standard poodle (n=2), and one each for Australian shepherd, 
Welsh corgi, basset hound, Jack Russel terrier, beagle dogs, golden retriever, German 
Shepherd dog, Boston terrier, bull terrier, miniature poodle, and Catahoula leopard dog. 
Twelve dogs were spayed females, 7 were castrated males, 2 were intact males, and 2 
were intact females. No significant differences were detected between groups (GF (n=5), 
healthy (n=6), vomiting/regurgitation (n=7) and cough (n=5)) for age, weight, or body 
condition score (BCS). These results were therefore grouped and displayed as range and 
median (IQR). Ages ranged from 6 months to 13 years with a median (IQR) age of 9 
years (7-10 years). Weights ranged from 1.7-43 kg with a median (IQR) weight of 16.6 
kg (9-29 kg). Body condition score (9-point scale) ranged from 4 to 8 with a median 
(IQR) BCS of 5 (5-6).  
Proteomic analysis  
From all samples, a total of 504 individual proteins were identified. Within group 
evaluation showed no significant differences for the total number of proteins identified. 
The median (IQR) number of proteins (per sample) per group were GF: 122 proteins 
(110-230), healthy: 259 proteins (203-209), vomiting/regurgitation: 231 proteins (203-
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240) and cough: 258 proteins (254-325).  No significant differences between groups were 
found for the total number of proteins identified. Principal components analysis 
demonstrated overlap between GF, vomiting/regurgitation, and cough but not normal OP 
(Figure 16).   
Three pairwise comparisons were performed to identify differentially abundant 
proteins between groups: 1) normal vs GF, 2) normal vs vomiting/regurgitation, 3) 
normal vs cough. 
Normal vs GF: One hundred thirty proteins showed significant differential abundance 
(p<0.0004). Seventy proteins were significantly greater in abundance in GF; 60 were 
significantly greater in OP swabs from normal dogs. Coefficients of variation between 
dogs ranged from 16.9- 244.9 for the differentially abundant proteins.  
Normal vs Vomiting/Regurgitation: Twenty proteins showed significant differential 
abundance (p<0.0004). Thirteen proteins were significantly greater in abundance in 
OP swabs from vomiting/regurgitating dogs; 7 were significantly greater in OP swabs 
from normal dogs. Coefficients of variation between dogs ranged from 45.5-264.6 for 
the differentially abundant proteins. 
Normal vs Cough: Twenty-two proteins showed significant differential abundance 
(p<0.0004). Twelve proteins were significantly greater in abundance in OP swabs 
from coughing dogs; ten were significantly greater in OP swabs from normal dogs. 
Coefficients of variation between dogs ranged from 41.7-244.9 for differentially 
abundant proteins.  
For the biologic function of proteins, all groups were found to be dissimilar on 
ANOSIM with p ≤ 0.05 (Figure 17).  Metabolic and immune proteins were over-
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represented in GF compared to normal dog OP swabs (p ≤0.05). Seventy-three percent of 
gastric metabolic proteins were pancreatic in origin which is over-represented compared 
to salivary (14%), gastric (10%) and intestinal (3%) proteins (p ≤ 0.05). Pancreatic 
metabolic proteins were also increased in overall abundance compared to salivary, gastric 
and intestinal metabolic proteins by NSAF. Pepsin A was identified in GF from all dogs 
but was less abundant compared to other non-gastric metabolic proteins (Table 15). 
Metabolic proteins were likewise over-represented in OP swabs in vomiting/regurgitating 
dogs compared to healthy dogs (p <0.05), as were proteins with immunologic function (p 
<0.05). Coughing dogs had increased numbers of proteins involved in cellular 
differentiation and stimulus response compared to normal and regurgitating/vomiting 
dogs (p <0.05). After 6 months of storage at -20°C, 54/70, 11/13, and 8/12 proteins 
demonstrating differential abundance compared to healthy dog OP in the first run were 
still detectable for GF, vomiting/regurgitation and coughing dogs respectively.    
Discussion 
 In this pilot study, untargeted LC-MS was used to successfully characterize the 
canine GF proteome and identify several candidate biomarker proteins demonstrating 
differential abundance in health and disease in the dog. The proteome of gastric fluid 
showed statistically significant differences compared to healthy dog OP. This suggests the 
possible utility of protein biomarkers as screening tool for dogs with EERD and 
aspiration. Reflux and aspiration contribute significantly to the pathogenesis and 
progression of respiratory disease in people (2, 3, 5, 6, 236). A similar relationship is 
suspected in veterinary patients, and although a readily available diagnostic test capable 
of detecting EERD and aspiration is lacking (17) a proteomics approach shows promise. 
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Though further studies are needed, significant between-dog variability may suggest 
improved utility of biomarker panels over individual proteins. Detection of candidate 
biomarkers was possible after storage at -20 for 6 months which provides important 
preliminary data for those engaged in clinical research requiring sample banking.  
Understanding the link between reflux and aspiration in clinical patients is critically 
important as people with reflux-associated respiratory disease have demonstrated 
reductions in disease exacerbation and decline in lung function following treatment 
targeting GERD and EERD (2).  A similar targeted therapeutic approach may be beneficial 
in dogs with airway, interstitial and/or pulmonary parenchymal diseases. In experimental 
canine models, a link between respiratory disease, reflux and aspiration in dogs has been 
demonstrated with bronchoconstriction, laryngospasm, laryngeal paresis/paralysis, and 
microaspiration occurring in response to application of acid and digestive enzymes to the 
esophagus and larynx (13-16). In pet dogs, this association is less clear. In brachycephalic 
dogs, an animal model for obstructive sleep apnea in people, treatment for presumptive 
GERD/EERD significantly improved clinical signs of brachycephalic airway syndrome 
(BAS) and minimized post-surgical complications (17, 236, 237). As such, treatment for 
EERD may also benefit other dogs with other naturally developing respiratory disorders in 
which reflux and repetitive microaspiration play a role in disease development, 
progression and exacerbation (12). Furthermore, similarities in anatomy, physiology and 
several pathologic disorders makes experimental and naturally occurring canine models 
integral to translational research in humans (270-273).  
Identifying dogs with naturally occurring GERD and EERD poses a diagnostic 
challenge as reliable, inexpensive, minimally invasive diagnostic tests are lacking.  In 
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people, biomarkers have been effectively utilized as a part of a multimodal approach to 
diagnosing reflux and aspiration-associated respiratory syndromes (AARS) (3, 9, 123, 
266).  Though biomarkers have been utilized effectively for a number of diseases in dogs, 
investigation into biomarkers of reflux and aspiration have been rarely performed (98, 
132, 262, 269, 274).  In this study, LC-MS was successfully used to generate a proteomic 
profile of canine GF to identify potential biomarker candidates. Principal component 
analysis demonstrated complete separation with a CI of 95% of the GF proteome and 
normal dog OP proteome suggesting that these two sites significantly different with 
respect to their protein composition. This is a key initial finding supporting in absence of 
reflux there are no gastric proteins in the healthy dog OP and sets the stage to identify 
biomarker gastric proteins in this location in disease states. 
Statistically significant differential abundance for multiple proteins was identified 
between all groups compared to normal dogs. This finding suggests that the canine 
proteome differs not only by the site of collection (GF vs. OP (normal)) but also in health 
and disease (vomiting/regurgitation or cough vs. normal). Principal component analysis 
demonstrated overlap between GF, vomiting/regurgitating, and coughing proteomes. No 
overlap was identified between GF and normal dog OP. Though further studies are 
needed, this supports hypothesis that GF biomarkers may be identified in 
vomiting/regurgitating and coughing dogs. The overlap between vomiting/regurgitating, 
coughing and healthy dog OP likely reflect a shared site of collection. Despite this 
overlap, a number of proteins demonstrating statistically significant differential 
abundance were identified.  
Gastric pepsin (pepsin A) is an abundant component of the human gastric 
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refluxate which has been used as a biomarker to identify patients with EER and aspiration 
(9, 266-268, 275). While pepsin A was identified in canine GF, it was low in abundance. 
Further, pepsin was not identified in OP swabs from any dog including those with 
documented regurgitation/vomiting within 12 hours of sample collection. It is possible 
that protein degradation may have reduced the abundance of this protein below our limit 
of detection. The low abundance of pepsin A in GF and lack of detection of pepsin A on 
OP swabs in vomiting/regurgitating dogs suggests this to be a less than ideal protein 
biomarker regardless of cause, and represents a significant departure from the human 
literature (100, 122, 123, 266, 276). Interestingly, pancreatic proteins were highly 
abundant in GF suggesting that gastroduodenal reflux was a frequent occurrence in our 
population and supports a biomarker study which identified bile in bronchoalveolar 
lavage fluid from dogs with pulmonary fibrosis (98). In human gastric fluid pancreatic 
proteins are also identified, however the abundance is insufficient to overshadow pepsin 
A in gastric fluid (275). Salivary proteins were abundant in gastric fluid as well as in dogs 
with vomiting/regurgitation. The abundance of salivary proteins in GF likely reflects 
reflexive swallow of salivary secretions (277). Increased abundance in dogs with 
vomiting/regurgitation may reflect bathing of the OP with concentrated salivary 
secretions from the gastric fluid, ptyalism secondary to nausea, or as a result of the 
esophagosalivary reflex which increases salivary secretions to protect against damage to 
the esophagus by gastric acid/digestive enzymes (278).  
While biomarker candidates based on our criteria were identified in dogs with 
vomiting/regurgitation, evidence of EER was not identified in any coughing dog. This 
likely reflect our small sample size (5 dogs with cough) and larger studies in respiratory 
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patients are needed before drawing conclusions about the prevalence of EER in dogs. The 
presence of gastric proteins demonstrating increased abundance in OP swabs from 
vomiting/regurgitation compared to normal dogs opens doors for future biomarker 
validation studies in dogs with EERD and AARS. Important to future biomarker studies 
was that protein concentrations between dogs was extremely variable echoing similar 
findings in people, suggesting limited utility for individual protein biomarkers in favor of 
biomarkers panels (279-281).   
Biological protein function was determined for the 200 most abundant proteins 
per group and statistical evaluation by ANOSIM demonstrated that OP swabs from 
normal dogs, vomiting/regurgitating, and coughing dogs were statistically dissimilar 
representing discrete functional proteomic profiles. This suggests that the differences in 
composition between groups may be enough to alter the functional resident proteome in 
health and disease. In this case, even though vomiting/regurgitating and coughing dogs 
demonstrated overlap according to PCA, differences in relative abundance were enough 
to change the functional proteomic profile between health and disease, and between 2 
disease states (vomiting/regurgitating and coughing).  In vomiting/regurgitating dogs, 
proteins with metabolic (i.e. enzymatic) functions were found in increased abundance 
compared to normal dogs. This may reflect a contribution from the GF proteome though 
the overall functional proteomic profiles were still considered dissimilar between these 
two groups. Though further studies are needed the functional proteome may reflect an 
additional means to identify dogs affected by GERD and EERD that is less affected by 
individual protein concentrations which vary significantly between dogs.   
Sample banking is an important part of clinical research and human and 
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veterinary medicine (282). Large scale biomarker validation trials reflect collaborative 
interdisciplinary efforts involving both scientists and clinicians with access to variable 
methods of cold storage (283). Banking at -20°C was selected to reflect the most 
common means of sample banking available to general practitioners. Most proteins in 
vomiting/regurgitating and coughing dogs exhibiting differential abundance were present 
after 6 months of storage. However, due to unforeseen differences in instrumentation 
during the time of the current study, absolute degradation could not be determined. 
Additional studies evaluating the degradation of candidate biomarkers is recommended 
before making recommendations regarding long term sample storage.  
 Conclusions  
 Extra-esophageal reflux and aspiration represent a significant contributor to a 
number of acute and chronic respiratory diseases in people. Importantly, therapy targeting 
GER and EER may positively impact management of people with AARS. Proteomic 
characterization of GF and the OP in vomiting/regurgitating dogs identified potential 
candidate proteins for future studies investigating biomarker panels for EER and AARS.  
Unlike in people, pepsin was poorly abundant in gastric fluid and non-detectable in dogs 
with vomiting/regurgitation. Salivary and pancreatic proteins were abundant in GF and 
may reflect potential biomarkers for evaluation of patients with suspected EERD and 
AARS. Short-term sample storage resulted in detectable differences between groups, and 
those proteins could be identified after 6 months.  
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CHAPTER 7 
 
DESCRIMINATION BETWEEN RESPIRATORY AND NON-
RESPIRATORY SOUND WAVEFORMS IN DOGS USING ACOUSTIC 
WAVE RECORDINGS: AN OBJECTIVE METRIC OF COUGH 
 
Introduction 
Cough is a critical defense mechanism of the respiratory system and provides an 
important metric for disease control. Chronic cough may lead to exacerbation of 
structural airway disease through perpetuation of inflammation. In addition, cough 
represents a significant source of frustration for both dog and client, and severe cough is 
associated with a perceived reduction in quality of life (284). Unfortunately, management 
of cough in veterinary medicine is often suboptimal and based on subjective response 
rather than objective evidence. As such, objective metrics of cough are needed.    
The assessment of cough in veterinary medicine currently employs measures 
based on client surveys, visual analogue scale (VAS) scores, and other subjective 
measures of clinical scoring (285, 286). Owner stress associated with witnessing 
coughing episodes may lead to client overestimation of cough severity, while the episodic 
nature of cough and variable client vigilance may lead to underestimation. A study 
evaluating compliance and accuracy of self-reporting in human asthmatics found 23% of 
subjective client-recorded metrics being fabricated (287). These confounding factors, 
combined with the placebo effect, have the potential to alter the conclusions of treatment 
trials, which are critical for management recommendations of chronic respiratory disease. 
Current subjective metrics represent significant challenges and highlight the need for 
objective, independently recorded biometrics to aid in clinical case management as well 
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as placebo-controlled clinical trials.  
In people, cough generates high velocity, non-laminar airflow producing a 
characteristic auditory signal (139, 288). The resulting acoustic waveform can be detected 
and objectively evaluated (139, 288-291). Audio-based cough monitoring in human 
medicine is capable of providing reliable data on the number of coughs by examining 
acoustic waveforms with sensitivity and specificity of 85% and 91%, respectively (139, 
288, 290, 291). We hypothesized that healthy dogs would demonstrate characteristic and 
consistent respiratory waveforms which could be distinguished from other acoustic 
behaviors (AB). The objectives of this study were three-fold. The first was to develop a 
sound recording protocol to capture respiratory waveforms in healthy dogs. The second 
was to discriminate cough events from other AB based on objective acoustic parameters 
(AP). The final objective was to determine if a trained investigator could, when blinded 
to randomized data, correctly identify each AB.  
Materials and methods  
Dogs  
Healthy employee-owned companion dogs were enrolled with informed consent. 
Dogs were determined to be healthy based on clinical history and physical examination. 
Inclusion criteria included being greater than one year of age with no history of 
respiratory or gastrointestinal signs within the preceding 6 months. Patients with a prior 
history of tracheal stenting, laryngeal tie back surgery, and/or current treatment with 
antitussive medications were excluded. Age, sex, body weight, body condition score 
(BCS), and breed were recorded for each dog to evaluate for changes in AB based on 
patient demographics.   
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Acoustic behavior recordings 
A laryngeal microphone (CTA Digital, Brooklyn, NY, USA) was used to record 
eight common AB: cough, chew, lick, bark, whine, drink, growl, and throat clear. Dogs 
were minimally restrained and maintained in a standing position during data collection. A 
recording microphone positioned over the larynx was connected to a laptop computer 
(Figure 18).   Data were collected at a sampling rate of 44.1 kHz. The frequency response 
for the cardioid (unidirectional) microphone was between 20 Hz and 20 kHz. The 
recordings were analyzed using Raven Pro © sound analysis software (version 1.4, 
Cornell Ornithology Laboratory, Ithaca NY). This bioacoustics program is used to 
perform conservation research and as such is adaptable to a wide range of animal AB. 
Nine APs were measured: six temporal and three spectral (Table 16). Feeding AB (lick, 
chew, drink) were produced by offering a compatible food item such as peanut butter, 
kibble, and chicken broth, respectively. Respiratory AB (cough and throat-clear (TC)) 
were produced by light digital palpation of the trachea. Vocalization AB (growl, whine, 
bark) were produced via multiple means including command, having the owner exit the 
collection area, and/or withholding a toy or food item.  
Manual identification of acoustic behaviors  
A trained reviewer (MG) blinded to the data sets evaluated randomized waveform 
and spectral images. Randomized digital images of waveform and spectral data were 
presented to the reviewer. The reviewer then saved each image under its assigned AB. 
Each image was classified as one of eight possible AB (cough, chew, lick, bark, whine, 
drink, growl, or TC). This process was repeated to calculate intra-reviewer reliability. 
Correct group assignment (i.e., feeding, vocalization, or respiratory AB) was also 
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assessed as for each AB.  
Statistical methods 
Statistical analysis was performed using Past (version 3.21), SigmaPlot (version 
14.0) data analysis software, and MedCalc (version 19). Descriptive statistics were 
performed where appropriate. A one-way Analysis of Similarity (ANOSIM) using a Bray-
Curtis similarity index was used to test for similarity between AB with a p <0.001 
significance level. Where AB were found to be dissimilar, within group and between 
group evaluations were performed by a one-way ANOVA on Ranks. P <0.05 was 
considered significant. A Wilcoxon rank-sum test was performed to assess for differences 
in AP between AB induced by tracheal palpation and subsequent coughs when more than 
one cough was produced after a single tracheal palpation. Normality was evaluated by 
Shapiro-Wilk test. Post-hoc analysis (Dunn’s method or Bonferroni correction for 
multiple comparisons) was applied where appropriate. Kappa coefficients were calculated 
to assess intra-reviewer agreement for manual assignment of AB. Accuracy was recorded 
as percent of waveforms correctly identified. 
Results  
Animals 
Ten healthy employee-owned dogs were enrolled in this study with informed 
consent. Ages ranged from 2 to 12 years with a median (IQR) age of 5 years (3-7.5 
years). Body weight (kg) ranged from 4.2 to 28 kg with a median (IQR) body weight of 
8.25kg (5.15-20.4 kg). Body condition score (9 point scale) ranged from 4 to 7 with a 
median (IQR) BCS of 5 (5-5).  Five dogs were spayed females, four were castrated 
males, and one was an intact female. Breeds represented included: Mixed breeds (n=2), 
104 
 
Miniature Dachshunds (n=2), Beagle (n=1), Miniature Pinscher (n=1), Husky (n=1), 
Catahoula Leopard Dog (n=1), Yorkie (n=1), Doberman Pincher (n=1).   
Acoustic behaviors  
Data were recorded from ≥ 3 dogs per AB. Respiratory AB, cough and TC, were 
recorded for 6 and 3 dogs respectively. The total number of waveforms/spectra evaluated 
for each AB are as follows: cough (n=24), chew (n=104), lick (n=73), bark (n=43), whine 
(n=35), drink (n=89), growl (n=17), TC (n=8). Representative examples for each AB are 
presented in Figure 19. Acoustic parameter data pertaining to each AB are found in Table 
16.  An analysis of similarity found cough to be dissimilar (p <0.0001) to all other AB 
with the exception of throat clear (p = 0.09). The vocalization AB, growl and whine, were 
acoustically similar, as were TC and drink, with p values of 0.04 and 0.06 respectively.  
All other AB were significantly acoustically dissimilar (Table 17). No between-subject 
differences were identified between cough and TC groups for any parameter. All other 
behaviors showed statistically significant within-group variation (P< 0.001). Cough and 
TC were found to be distinguishable from every other evaluated AB, with significant 
differences in two or more of the analyzed parameters (P<0.001 for each; Table 18). No 
differences were detected between AB induced by tracheal palpation and subsequent 
respiratory AB for any AP. No significant differences for cough or TC were found for any 
AP based on patient demographics. Randomized AB were correctly assigned by a blinded 
reviewer with 96.5% accuracy. This arm of the experiment was performed twice with 
kappa coefficient calculations being performed for each acoustic behavior and again for 
group assignment: feeding, vocalization, and respiratory behaviors. The kappa coefficient 
for individual behaviors was 0.76 suggesting moderate agreement. For group assignment 
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the kappa coefficient was 0.97 suggesting near perfect agreement. Respiratory behaviors 
were assigned to the correct group 100% of the time with a kappa coefficient of 1.0. 
(Table 19) 
Discussion 
  In this study, we found that mesocephalic dogs generated consistent respiratory 
AB for cough and TC, which could be differentiated from non-respiratory AB using 
temporal and spectral descriptors. Cough and TC are important respiratory protective 
mechanisms acting both as symptoms of disease and important markers of disease 
control. The practical use of cough as a marker of disease control is substantially 
hampered by subjectivity and placebo effect. Non-invasive acoustic monitoring would be 
valuable for future objective assessment of disease control in dogs with chronic 
respiratory disease while opening the door for objectively evaluated placebo-controlled 
clinical trials.  
For many respiratory conditions, cough is the primary marker of disease severity 
and is used by clients and clinicians alike to judge response to therapeutic intervention 
(285, 286). Further, in conditions where structural airway disease represents the primary 
etiology (e.g., collapsing trachea), pharmacologic cough suppression is the cornerstone of 
medical intervention (292, 293). Though the use of antitussives is widespread, there is 
little objective data to support clinical efficacy, instead relying on perceived clinical 
improvement. Unfortunately, these methods of assessment are highly subjective. In 
people, the placebo effect accounts for up to 85% of the efficacy of some over-the-
counter cough medications (294). Studies in people evaluating accuracy of medical self-
reporting have found 23-40% respondents reported fabricated results both for objective 
disease metrics and maintaining interventions initiated in hospital (287, 295). In 
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veterinary medicine, it is possible to introduce an even greater degree of subjectivity and 
bias as patient reporting becomes the responsibility of the client. This is supported by 
studies in human pediatric patients, where patient self-reporting is not possible. In these 
studies the accuracy of cough reporting by care givers was poor compared to objective 
cough monitoring (296, 297). These confounding variables have the potential to 
negatively impact the ability of the clinician and/or researcher to judge disease severity 
and accurately assess response to therapy. This highlights the need for objective 
respiratory biometrics for assessment of clinical patients and for placebo-controlled 
clinical trials.  
In people, assessment of cough acoustic recordings provides an accurate means to 
assess cough frequency, in part because the cough AB has been well characterized (134, 
291, 298, 299). The same has not been previously performed for dogs. In this study, we 
successfully collected respiratory, feeding, and vocalization AB. Dogs were minimally 
restrained during data collection in a quiet room to reduce ambient noise interference as 
ambient noise has been a challenge for AB characterization in people (300). Dogs were 
otherwise encouraged to freely engage in each AB apart from cough and TC, which were 
manually induced. Free-feeding and minimal handling was considered important to 
ensure that the ABs recorded as a part of this study are representative and not unduly 
influenced by restraint or force feeding. For respiratory behaviors, when a single 
palpation event resulted in a series of respiratory AB, the initiating respiratory AB 
(induced by tracheal palpation) and each subsequent respiratory AB in the series were 
evaluated for significant differences in AP. This comparison demonstrated that coughs 
induced by tracheal palpation and subsequent respiratory AB were acoustically 
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indistinguishable in healthy dogs. This mirrors studies in people evaluating spontaneous 
and induced cough and suggests that coughs induced by tracheal palpation are suitable 
for objective evaluation (301, 302). As such, induced respiratory AB were grouped with 
their respective spontaneous AB for further analysis. Though this finding should be re-
evaluated in dogs with respiratory disease, it suggests in-hospital evaluation of cough 
sensitivity may be performed without significantly altering the acoustic profile of 
respiratory AB in dogs.   
This study effectively demonstrates that healthy mesocephalic dogs generate 
respiratory AB that are consistent across dogs. Specifically, in this pilot study respiratory 
AB are not affected by demographic data such as BCS, weight, and breed, and are 
distinguishable from other AB based on objective AP. Though larger validation studies 
are needed to confirm these finding, this consistency suggests potential utility for 
respiratory sound analysis as an objective respiratory biometric. Similar to studies in 
people, TC was found to be qualitatively similar to cough and could not be distinguished 
based on the AP measured (303). Though distinct physiologically, both cough and TC are 
considered respiratory protective behaviors. TC is likely to be considered a “small cough” 
by most lay-evaluators (clients) and still has the potential to suggest the presence of 
diseases such as extra-esophageal reflux or post-nasal drip, which cause cough through 
stimulation of the larynx (304). For this reason, discriminating cough from TC was not 
considered necessary for clinical utility and was therefore not a significant limitation in 
this study.  
 Cough sound processing in people is either performed manually or through 
automatic sound processing algorithms. Automatic processing algorithms are often 
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challenged by the need to distinguish between respiratory sounds and ambient noise and 
talking (305). As such, manual evaluation is still an integral part of acoustic analysis in 
humans.  This study demonstrated that AB in dogs could be identified with 96.5% 
accuracy by a trained reviewer blinded to the data sets. If AB were grouped by function 
(respiratory, vocalization, or feeding behaviors), respiratory AB were correctly identified 
100% of the time. Collectively these data suggest that manual identification of AB in 
dogs is feasible.  
 Limitations of this study included a relatively small sample size. Multiple AB 
were collected for each dog to minimize type 2 error. Also, the current collection protocol 
is limited to the hospital setting with simultaneous induction of the AB and data recording 
over short periods of time. Ambulatory collection devices have been developed for 
people and are useful for longer term monitoring. Ambulatory collection in dogs, 
allowing for spontaneous ABs in natural settings, may prove to be easier than in humans 
as dogs do not generate the same range of vocalization behaviors. Acoustic behaviors 
including sniffing, sneezing, and reverse sneezing were not included in this pilot study. 
When recorded by a microphone positioned over the larynx, sniffing did not reliably 
result in discrete ABs distinguishable from background noise and were therefore 
excluded from objective evaluation in this pilot study.   Sneezing and reverse sneezing 
could not be induced in the healthy dogs in this study but should be included in future 
studies validating acoustic cough recording for clinical use. (139, 288, 306, 307).  
Conclusions  
Objective metrics of cough, an important clinical manifestation of many 
respiratory disorders, are lacking in dogs. Cough frequency has the ability to significantly 
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impact clinical decision making, result in significant patient morbidity, and impact a 
client’s perception of quality of life for their animal. In this study, respiratory AB were 
demonstrated to be statistically distinct based on objective metrics and can be accurately 
identified by manual analysis. This study represents a proof of concept for the objective 
assessment of cough frequency by identifying respiratory AB in healthy dogs.  
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CHAPTER 8 
 
CONCLUSIONS AND FUTURE DIRETIONS 
 
 
 The studies described herein highlight the complex inter-relationship between 
swallowing and respiration. The frequent identification of abnormal swallowing in the 
studied dogs supports a possible contribution from dysphagia, reflux, and aspiration in 
the pathogenesis of canine respiratory disease. This underscores the need for a 
multimodal diagnostic and therapeutic approach in dogs with aerodigestive disease as 
well as well designed, objectively evaluated, prospective studies in the veterinary 
literature. Historically this aim has been hampered by a lack of clinical recognition, 
diagnostic limitations, and a lack of objective monitoring strategies in clinically affected 
patients. This dissertation presents our responses to these limitations. 
The lack of clinical recognition for aerodigestive disease and aspiration associated 
respiratory syndromes (AARS), a subclassification of aerodigestive disease, is 
multifactorial with a likely contribution from an overreliance on thoracic radiography and 
the fact that many affected patients present without clinical evidence of GI disease.(7, 8, 
308) Diagnostic evaluation of respiratory disease in dogs typically begins with thoracic 
radiogaphs. Though radiographs have the benefit of being widely available they lack 
sensitivity when investigating aerodigestive disease and provide almost no functional 
information. (109, 308, 309)  Videofluoroscopic swallow studies (VFSS) represent the 
criterion standard for diagnosis of dysphagia in dogs, however, like radiographs, these 
have significant limitations.(239, 310-312)  The reliance on force-feeding in lateral 
recumbancy carries increased risk of aspiration pneumonia such that it is considered 
contraindicated in certain dysphagic disorders (e.g., megaesophagus). Recently, the 
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validation of an upright free-feeding VFSS protocol has permitted investigation of a 
broader range of dysphagic disorders while limiting the risk of aspiration pneumonia and 
increasing physiologic relevance of the data obtained.(239)   
 This expanded use of VFSS in dogs with chronic cough (Chapter 2) has provided 
important information on the prevalence and breadth of aerodigestive disease in dogs. 
Our studies support aerodigestive disease as a common contributor to chronic cough in 
dogs with nearly 81% (25/31) of patients presenting solely for cough having evidence of 
swallow dysfunction detected by free-feeding VFSS. This included 11 dogs with normal 
thoracic radiographs. Of these 31 dogs, only 7 had evidence of aspiration pneumonia on 
thoracic radiographs. This study emphasizes a previously under-recognized and common 
canine population with numerous different alimentary tract diseases causing or 
contributing to cough. This demonstrates that, like people, aerodigestive disease in dogs 
is diverse and may present in the absence of gastrointestinal signs. These findings also 
suggest that a high index of clinical suspicion is required in addition to a multimodal 
approach for evaluation of respiratory patients due to thoracic radiography being 
insufficient to detect aerodigestive disease. In dogs with both respiratory and GI causes 
for cough (i.e., mixed disorders) each likely contributes to disease progression. As such, 
treatment in dogs with mixed respiratory and alimentary disease is likely to be 
multimodal reflecting the contribution of alimentary tract disease in such cases. Given the 
high prevalence of dogs with VFSS swallow abnormalities in our study, clinical suspicion 
for aerodigestive diseases should be high with consideration being also given to dogs 
with chronic cough and not just those with evidence of gross aspiration.  
 In addition to providing necessary information on the relationship between 
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respiration and swallowing in coughing dogs, the broader clinical use of VFSS has 
resulted in improved characterization of a clinically important dysphagic disorder in 
dogs: megaesophagus (Chapter 3). Using this technique, our group successfully identified 
a subpopulation of dogs with a failure of the lower esophageal sphincter (LES) to relax in 
response to a pharyngeal swallow (i.e., LES achalasia-like syndrome). Similar functional 
obstructions of the LES have been identified in people (i.e., LES achalasia). Identifying 
this condition in dogs was considered critically important as functional LES obstructions 
in people represent one of the only forms of esophageal dysphagia with a demonstrated 
response to targeted intervention. Though the criterion standard for diagnosis in people is 
high-resolution manometry, its use in dogs is significantly limited.(18) Reliance on this 
technique would significantly limit clinical actionability in dogs, as few patients would 
be able to be evaluated. This made finding an alternative more widely available means to 
identify this population of dogs highly clinically relevant. Though interpretation will 
require high quality diagnostic studies and practice, with the guidelines developed herein, 
a diagnosis of LES-AS may be possible for a far greater number of dogs. This is 
especially important because our group later demonstrated that dogs with LES-AS, like 
people with LES-achalasia, respond to intervention directed at relieving the obstruction at 
the LES (Chapter 4).(313)  
In our study mechanical dilation and botulinum toxin A (BTA) injections at the 
LES resulted in 100% perceived clinical improvement by owners as well as significantly 
increased body weight, body condition score, and significantly reduced regurgitant 
frequency.(313) These subjective and objective clinical assessments were supported by 
improved swallowing parameters as detected by VFSS. In these cases, improved gastric 
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filling and esophageal clearance were identified despite minimal improvement in 
esophageal motility further implicating the LES in the pathogenesis of disease for the 
subpopulation of dogs. Though effective, the results of this intervention were temporary 
which limits the use of mechanical dilation and BTA injections to the role of adjunctive 
diagnostic or as a stopgap measure in patients awaiting definitive treatment. A definitive 
approach was undertaken in a subpopulation of dogs who responded favorably to 
mechanical dilation and BTA injections at the LES. A Heller myotomy with Dor 
fundoplication was found to be similarly effective and may represent a long-term 
intervention in dogs with LES-AS.(313) The findings of this study provide hope for a 
population of dogs with a disease for which there have been historically very few 
therapeutic options.  
Though VFSS are beneficial for the detection of dysphagia and macroscopic 
aspiration events, they lack the sensitivity to detect small volume aspiration (i.e. 
microaspiration) events. Microaspiration is a significant contributor to the pathogenesis 
and progression of chronic respiratory disease in people and is frequently linked to reflux 
disease.(82, 234) Reflux scintigraphy has been used historically to reflux and cumulative 
aspiration in people and in our study was successfully adapted for use in dogs. (127, 130) 
Using reflux scintigraphy (Chapter 5), we identified that extra-esophageal reflux (EER) 
and pan-esophageal reflux, gastroesophageal reflux (GER) extending the length of the 
esophagus, occurred frequently in healthy asymptomatic dogs. These findings mirror 
results in people where healthy, asymptomatic people frequently have reflux events 
reaching the proximal esophagus with a smaller number of reflux events extending 
beyond the esophagus as EER. Interestingly and counter to the literature in people, 
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aspiration was not detected in any healthy dog. In this study, we successfully adapted a 
technique capable of detecting small volume and cumulative reflux events for use in dogs 
and provided normative data necessary for interpreting findings in patients with 
aerodigestive or AARS. Prospective studies in dogs with chronic respiratory disease 
would substantially contribute to our understanding of disease pathogenesis in dogs with 
aerodigestive disease.  
Other techniques used to detect extra-esophageal reflux and aspiration involve 
reflux biomarkers where digestive proteins are detected in sputum, oropharyngeal swabs, 
or bronchoalveolar lavage fluid (Chapter 6).(100, 122, 133, 280) This study utilized 
liquid chromatography mass spectrometry (LC-MS) to characterize the canine gastric 
fluid proteome and compare this to the oropharyngeal proteome in healthy dogs, 
vomiting/regurgitating dogs, and coughing dogs. This study found that pepsin A, a 
frequently used biomarker of reflux and aspiration in people, was a poorly abundant 
protein in canine gastric fluid.  Instead, canine gastric fluid was dominated in abundance 
by pancreatic proteins. This finding implies that gastroduodenal reflux is a frequent 
occurrence in dogs and that these pancreatic proteins may play a role in AARS and 
should be considered as potential biomarkers of reflux and aspiration. Importantly 
variability in protein abundance between dogs likely limits the utility of individual 
biomarkers though evaluation of biomarker panels is warranted. Of additional interest 
was that the oropharyngeal proteome differed in health and disease both in terms of 
individual protein composition as well as biological function.  These combined findings 
suggests clinical utility for protein biomarker panels for detection of reflux and aspiration 
in dogs encouraging future proteomic validation studies.   
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In addition to limitations in detection of patients with aerodigestive disease, 
assessing disease severity and monitoring response to therapy is a significant challenge. 
Historical methods for judging the frequency and severity have lacked sensitivity and 
carry significant risk of bias.(297) This study proposed an objective method of cough 
monitoring by evaluating cough acoustic waveforms and spectrograms  (Chapter 7).(301, 
303) This study demonstrated that cough and throat-clear, another airway protective 
behavior, generated reliable and consistent acoustic behaviors (AB) which were 
distinguishable from other common AB (e.g., lick, chew, drink, growl, bark, and whine) 
by objective parameters. Individual AB classification was able to be accurately and 
reliably performed by a trained investigator.  Objective monitoring of cough frequency 
has the potential to significantly impact clinical decision making allowing for more 
effective treatment and monitoring in patients with respiratory disease. This pilot study 
serves as a proof of concept for this novel monitoring strategy. Further studies evaluating 
automatically evaluated ambulatory devices are needed to increased utility in clinical 
patients. 
Future research investigation in aerodigestive diseases should involve prospective 
evaluation of clinically affected dogs or dogs belonging to specific at-risk populations. 
Animals with known aerodigestive disease are important for broader validation studies 
for biomarkers of EER and aspiration as well as for determining distinguishing criteria 
between health and disease using VFSS and reflux scintigraphy. At risk populations 
include brachycephalic dogs which are considered predisposed toward several 
aerodigestive diseases including reflux and aspiration pneumonia. Specific evaluation of 
these dogs by VFSS and reflux scintigraphy may provide additional insight into 
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aerodigestive disease through the use of brachycephalic dogs as an animal model of 
human disease.     
Aerodigestive and AARS are the result of discordant respiration and swallowing. 
Despite a high prevalence for such disorders in dogs presenting for respiratory signs these 
cases are likely under-recognized in dogs presenting for cough in clinical veterinary 
practice.  Advanced diagnostic and monitoring tools including VFSS, scintigraphy, 
biomarker analysis, and objective respiratory biometrics are needed to improve 
recognition and treatment of this population. Further, as both dogs and people have 
evidence aerodigestive disease, using a One Health approach will increase the 
opportunity for bidirectional advancement in research.  
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Appendix 
Figures  
 
Figure 1 
Figure 1: This figure summarizes airway protective mechanisms against aspiration.  
  
Resp/Swallow coordination 
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Figure 2 
 
 
Figure 2. The tracheal stripe is an endoscopic finding characterized by proximal erythema 
that dissipates distally toward the carina. Changes were noted prior to intubation. Oxygen 
was administered via red rubber catheter alongside the bronchoscope.  
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Figure 3 
 
Figure 3: Videofluoroscopic swallow study example of penetration (P) and aspiration (A). 
The head is oriented to the left and the tail to the right. A 1 cm size marker is denoted by 
*. A food bolus is present in the proximal esophagus (Prox E). In the left image, a piece 
of barium-extruded kibble is found between the epiglottis (E) and the arytenoids (aryt) 
but does not extend past the larynx. In the right image, a line of aspirated contrast (A) is 
present in the ventral trachea after drinking liquid containing iohexol. A scoring system 
for penetration-aspiration is displayed in Table 3.  
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Figure 4 
 
 
Figure 4: Final VFSS diagnosis for all patients evaluated by VFSS at the University MU-
VHC between April 2015-December 2017.  
  
121 
 
Figure 5 
 
Figure 5: Maximal Distal esophageal diameter (DeD) and the height of the T12 vertebral 
body are used to generate at DeD:T12 ratio. A comparison between this ratio (with >4.7x 
being 94% sensitive and 100% specific for ME) and subjective assessment of ME 
showed perfect correlation with a kappa coefficient of 1.  
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Figure 6 
 
Figure 6: Cranial (Left), Caudal (Right). Lateral projection of a still image from a VFSS. 
A baseline fluid line (arrow) is visible in the esophagus after a ≥12 hour fast prior to 
administration of oral contrast material. The top lip of the food bowl is marked by 
brackets. The dashed arrow points to a 1cm calibration marker worn around the patient’s 
neck.  
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Figure 7 
Figure 7: Cranial (Left), Caudal (Right). Fluoroscopic static image of the distal 
esophagus in a dog actively swallowing a pureed food consistency. This image 
demonstrates a narrowed contrast column resulting in an elongated taper through the LES 
(arrow). This appearance bears resemblance to a “bird beak” which is where this clinical 
feature received its name. 
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Figure 8 
 
Figure 8: Cranial (Left), Caudal (Right). (A) A narrowed distal esophagus is present 
(region displayed by brackets) that (B) partially increases in diameter with increased 
hydrostatic pressure/gravity as the dog is sitting down. This demonstrates that failure of 
the LES to relax is secondary to a functional obstruction and can be overcome with 
enough hydrostatic pressure.    
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Figure 9 
  
 
Figure 9: Balloon spanning the LES of a dog diagnosed with LES-AS. It is necessary for 
the balloon to span the entire LES for adequate dilation.(217)   
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Figure 10 a,b 
  
Figure 10 a,b: 2a) BTA (40 U/mL) is injected into 8 sites (4 U/site) circumferentially 
around the LES using an endoscopic injection needle. A small bleb should be visible after 
injection (black arrow).  2b) Four injections (Set 1, black arrowheads) are placed at 90° 
immediately adjacent to the LES. The remaining 4 sites (Set 2, white arrowheads) should 
be placed at 90° 1cm distal to Set 1.  Set 2 should be rotated 45° relative to Set 1.   
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Figure 11 a,b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 a,b: Still lateral image of a 6 year old female spayed mixed breed dog from a 
VFSS showing maximal gastric filling (arrows) in response to hydrostatic pressure before 
(11a) and after treatment with mechanical dilation + BTA. (11b).  Only a small amount of 
gastric filling was appreciated prior to intervention; after treatment, there was a large 
amount of gastric filling observed, indicative of improvement in the functional LES 
obstruction. 
11a 
11b 
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Figure 12 a-d 
 
 
 
Figure 12 a-d) Three view (A: right lateral, B: dorsoventral, C: left lateral) thoracic 
radiographs of an 8 week old MI Irish Wolfhound presenting for lethargy, regurgitation 
and decreased appetite after treatment with mechanical dilation and BTA. A large soft 
tissue opaque structure is present in the distal esophagus (arrows). The cardiac silhouette 
is obscured by the esophageal contents (white arrowhead, 8b).  8d) A still lateral image 
from a VFSS showing a gastroduodenal-esophageal intussusception with Type IV hiatal 
hernia. The dog is in sternal recumbency and freely consumed liquid containing 25% 
Iohexol (350/mg iodine/mL). Contrast outlines intestinal loops within the dilated distal 
esophagus (arrow).  
A B 
C 
D 
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Figure 13 
 
Figure 13a-b: Regions-of-interest (ROI) are drawn over dynamic images collected in 
dorsal (1a) and left-lateral (1b) recumbancy 30-min post-ingestion of a meal containing 
(3mCi) colloidal 99m-technetium phytate (99TcP). Lung ROI were not collected for dogs 
in lateral recumbancy due to summation of the right and left lung fields. Position markers 
at the level of the mandible and stomach are denoted by the arrowheads. Distal 
esophageal (E1) and pharyngeal (P) reflux are denoted by arrows in 1a and 1b 
respectively.  Distal 3rd of the esophagus (E1), Middle 3rd of the esophagus (E2), and 
proximal 3rd of the esophagus (E3), pharynx (P), Left lung field (LL), right lung field 
(RL), gastric (G).   
P 
E3 
E2 
E1 
LL RL 
G 
P 
E3 
E2 
E1 
G 
13a 13b 
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Figure 14 
 
 
 
Figure 14a-b: Time-activity-curves are displayed for the distal esophagus (E1) (14a) and 
stomach (14b) respectively. 2a) A discrete reflux event representing counts ≥ 200% 
background is present between frames 128 and 131 (*). Data were collected at 2 
seconds/frame. The duration of this reflux event is 3 seconds. This event corresponds to a 
decrease in gastric counts over the same time period (**) consistent with true 
gastroesophageal reflux.   
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Figure 15 
 
 
 
 
Figure 15: Representative reflux time-activity-curves (TAC) are depicted above. Reflux 
TAC are classified as one of the following; rising (reflecting repeated reflux events with 
failure of clearance), flat (no reflux or reflux events with return to baseline between 
events) or falling (reflux with delayed clearance). 
 
 
0
0.2
0.4
0.6
0.8
1
1 9
1
7
2
5
3
3
4
1
4
9
5
7
6
5
7
3
8
1
8
9
9
7
1
0
5
1
1
3
1
2
1
1
2
9
1
3
7
1
4
5
co
u
n
ts
Frames
Flat 
0
10
20
30
1 9
1
7
2
5
3
3
4
1
4
9
5
7
6
5
7
3
8
1
8
9
9
7
1
0
5
1
1
3
1
2
1
1
2
9
1
3
7
1
4
5
C
o
u
n
ts
Frames
Rising
0
5
10
15
20
1 9
1
7
2
5
3
3
4
1
4
9
5
7
6
5
7
3
8
1
8
9
9
7
1
0
5
1
1
3
1
2
1
1
2
9
1
3
7
1
4
5
co
u
n
ts
Frames
Falling  
132 
 
 
Figure 16 
 
 
 
 
 
 
 
 
 
 
Figure 16: Proteomic profiles as shown via principal component (PC) analysis of samples 
for all 4 samples sites: GF (yellow), normal OP (gray), cough OP (blue), and 
vomiting/regurgitation OP (purple). Similarities in proteomic profiles are demonstrated 
by overlapping regions on the PC1 versus PC2 plot. The ellipses represent 95% intervals.  
Gastric fluid (GF), Oropharyngeal (OP). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gastric Fluid 
Cough 
Normal 
Vomiting/Regurgitation 
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Figure 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: All groups were statistically dissimilar by ANOSIM based on biological 
function of identified proteins (p ≤ 0.001). This suggests the functional proteome differs 
by site (GF vs. OP) as well as between health and disease. The biological function profile 
for each group is displayed in the stacked bar chart above. Metabolic and immune 
proteins were over-represented in gastric fluid compared to normal dog OP swabs 
(p<0.05). Metabolic proteins were over-represented in vomiting/regurgitating dog OP 
swabs compared to healthy dogs (p <0.05), as were proteins with immunologic function 
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(p <0.05).  Coughing dog OP swabs had increased numbers of proteins involved cellular 
differentiation and stimulus response compared to normal and regurgitating/vomiting 
dogs (p <0.05). 
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Figure 18 
 
Figure 18: Representative positioning of a microphone at the level of the larynx (black 
arrow). The microphone was connected directly to a laptop computer equipped with 
bioacoustics collection and analysis software (RavenPro). Dogs were minimally 
restrained during data collection.    
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Figure 19 
 
Figure 19a-h: Representative acoustic waveforms (a-h) and spectra (a’-h’) are provided 
for a) cough b) chew c) lick d) bark e) whine f) drink g) growl h) throat-clear (TC). 
Waveforms describe amplitude over time. Median IQR waveform characteristics are 
provided in Table 2. Spectral plots show frequency on the x axis and dB on the y axis.   
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Tables 
Table 1 
Human Dogs 
• Laryngitis(314) 
• Laryngeal paralysis/dysfunction(28) 
• Large airway obstruction(28) 
• Bronchiectasis(315)  
• Diffuse aspiration bronchiolitis(316)  
• Aspiration pneumonia/pneumonitis(28) 
• Exogenous lipid pneumonia(317)  
• Interstitial lung disease(97)  
• Acute respiratory distress syndrome  
• Chronic cough(234) 
• Bronchiolitis obliterans syndrome(83)  
• Asthma(314)  
• Chronic obstructive pulmonary 
diseases(314)  
• Rhinitis/Sinusitis(314)  
• Otitis(318)  
 
• Laryngitis(12, 319) 
• Laryngeal paralysis/dysfunction(12, 
79, 106, 319)  
• Large airway obstruction(320)  
• Bronchiectasis(152)  
• Diffuse aspiration bronchiolitis(12)  
• Aspiration 
pneumonia/pneumonitis(12)  
• Exogenous lipid pneumonia(321)  
• Interstitial lung disease(12, 98)  
• Acute respiratory distress 
syndrome(12) 
• Otitis(77)   
 
 
Table 1: Aspiration associated respiratory diseases reported in the human and veterinary 
literature.  
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Table 2 
Table 2: Standardized VFSS scoring rubric for aerodigestive disorders in the dog. * 
Penetration-Aspiration scoring system displayed in Table 4. Reflux extending past the 
middle 3rd of the esophagus was considered pathologic.  
  
VFSS Metric Feature 
Oral preparatory phase Normal                         Abnormal  
Pharyngeal phase Normal motility           Hypomotile             Spastic  
Esophageal phase  Normal motility           Hypomotile             Spastic   
Megaesophagus  Present                         Absent  
Reflux   
Gastroesophageal reflux (GER)     
 Esophago-oropharyngeal reflux (EOR)    
Nasopharyngeal reflux (NPR)  
   
Present                  Absent              Consistency    
Present                  Absent              Consistency    
Present                  Absent              Consistency    
Distance of refluxate (GER) Distal 3rd of the esophagus   
Middle 3rd of the esophagus   
Proximal 3rd of the esophagus  
Lower esophageal sphincter achalasia-like 
syndrome  
Present                         Absent   
Hiatal hernia  Present                         Absent 
Laryngeal obstruction/defect  Present                         Absent 
Penetration* Present-Score: 2, 3, 4                  Absent 
Aspiration* Present-Score: 5, 6, 7                 Absent  
Aspiration/ penetration consistency  Liquid                    Puree                    Kibble 
Marked aerophagia  Present                         Absent 
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Table 3 
Criteria for evaluation Definition 
Respiratory   
• Upper airway  
o Airways proximal 
to the thoracic 
inlet 
 
Upper airway structures including the naso-, oro-, and 
laryngopharynx as well as the cervical trachea were evaluated 
for static or dynamic collapse during quiet breathing.  
• Laryngeal 
obstruction/defect (LO/D) 
Movement of the epiglottis with respect to swallow and 
respiration was evaluated. The larynx was also evaluated for 
appropriate rostral movement during pharyngeal swallow. 
• Laryngeal defects were considered to contribute to 
aerodigestive disease (AeroD) when there was 
concurrent evidence of penetration, aspiration, 
esophago-oropharyngeal reflux (EOR), or defect in 
pharyngeal swallow. 
• Lower airway  
o Airways distal to 
the thoracic inlet 
The intrathoracic trachea and main-stem bronchi (MSB) were 
evaluated for static or dynamic collapse/compression during 
quiet breathing.  
• Diaphragm and thoracic 
cage  
Movement of the diaphragm and ribs were evaluated for 
appropriate movement during quiet breathing.  
• Diaphragm: Flattening on inspiration  
• Ribs: Rostral movement on inspiration 
VFSS  
• Oral preparatory (O-P) 
phase 
Dogs were assessed for appropriate jaw excursion, mastication, 
and collection of the food bolus in the valleculae (between the 
base of the tongue and the epiglottis). 
• Pharyngeal phase  Dogs were assessed for appropriate pharyngeal constriction and 
conduction of a bolus from the pharynx through the upper 
esophageal sphincter (UES) into the proximal esophagus. 
• Greater than one swallow attempt per bolus or 
pharyngeal bolus discohesion (incomplete bolus 
clearance) for the majority of swallows was 
considered abnormal. Residual contrast in the pharynx 
during respiration was considered abnormal regardless 
of the number of swallow attempts or the presence of 
aspiration into the trachea.  
• Esophageal contraction 
and peristalsis 
These were defined as waves initiated by pharyngeal swallow, 
beginning in the proximal esophagus and capable of 
conducting the food bolus aborally towards the lower 
esophageal sphincter (LES). 
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• Megaesophagus (ME) Subjective assessment of esophageal dilation 
• Gastroesophageal 
reflux (GER) 
Orad movement of contrast from the stomach into the 
esophagus. 
• The maximal orad movement of contrast during GER 
was recorded: proximal 3rd of the esophagus, middle 
3rd of the esophagus, distal 3rd of the esophagus. 
Reflux extending past the middle 3rd of the esophagus 
was considered abnormal.(147) 
• Esophago-
oropharyngeal reflux 
(EOR) 
Orad movement of contrast from the esophagus into the 
oropharynx.  
• Nasopharyngeal reflux 
(NPR) 
Movement of contrast from the pharynx to the nasopharynx 
during pharyngeal swallow or with EOR.  
• Lower esophageal 
sphincter achalasia-like 
syndrome  (LES-AS) 
Dogs were assessed for a failure of the LES to relax in 
response to a pharyngeal swallow.(148)  
• Hiatal hernia (HH) Dogs were assessed for herniation of the stomach into the 
thoracic cavity through the esophageal hiatus either passively 
or in response to abdominal pressure.  
• During abdominal compression, a licensed 
veterinarian wearing appropriate personal protective 
equipment applied abdominal pressure to a standing 
dog in order to induce a sliding hiatal hernia. 
• Penetration-Aspiration (A-
P) 
 
Penetration: Material enters the airway but remains above the 
vocal folds 
Aspiration: Material enters the airway and extends past the 
vocal folds 
• Aerophagia  This was defined as the swallowing of substantial volumes of 
air. Aerophagia was considered “marked” if gas comprised > 
1/3 of the bolus volume and/or resulted in gastric distention (air 
accounting for >1/3 of the end gastric volume).   
Table 3: Standardized criteria for evaluation for respiratory fluoroscopy and 
videofluoroscopic swallow studies. Penetration-Aspiration scale is available in Table 4. 
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Table 4 
   
 
 
 
 
 
 
 
 
 
 
 
Table 4: Penetration-Aspiration Scale(322) describing entrance of liquid or food into the 
larynx and trachea. (Figure 3) 
  
  
Classification  Score  Description 
Normal  1 Material does not enter the airway  
Penetration 2 Material is in the supraepiglottic space, remains above the 
vocal folds but leaves the airway before epiglottis returns 
to rest position  
 3 Material is in the supraepiglottic space, remains above the 
vocal folds after epiglottis has returned to rest position 
 4 Material is in the supraepiglottic space, large amount 
remains in above the vocal folds after epiglottis returns to 
rest position 
Aspiration  5 Material passes bellow the vocal folds, and is actively 
ejected  
 6 Material passes bellow the vocal folds and is not ejected 
despite effort  
 7 Material passes below the vocal folds, no effort is made to 
eject  
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Table 5 
Respiratory Diagnosis Diagnostic Criteria 
Canine chronic bronchitis (CCB) ≥ 10% non-degenerate neutrophils ± ≥ 10% 
eosinophils on bronchoalveolar lavage fluid 
(BALF) cytology 
Eosinophilic bronchitis (EB) ≥ 10% eosinophils on BALF cytology 
Radiographic evidence of aspiration pneumonia (AP) Interstitial-alveolar pattern in dependent lung 
regions. A secondary bacterial infection was 
determined by the presence of intracellular 
bacteria noted on BALF cytology and/or a 
positive BALF culture 
Laryngeal paralysis (LarPar) The absence of laryngeal abduction on 
inspiration after treatment with doxopram 
 
Epiglottic retroversion (ER) Intermittent retroversion of the epiglottis on 
inspiration resulting in intermittent obstruction 
of the rima glottidis 
Bronchomalacia (BM) Static or dynamic collapse of the airways at the 
level of or distal to the principle bronchi by 
>50% 
Bronchiectasis (BE) Architectural remodeling resulting in airway 
dilation with failure of tapering of the lumen 
with distal progression 
Hypoplastic trachea Fixed narrowing of the trachea with a ratio of 
trachea to the 3rd rib of <2.0 
Table 5: Diagnostic criteria for specific respiratory diagnosis. 
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Table 6 
Demographic  Data  
Age: range (median (IQR)):  6mo-13 yrs (6 yrs (3-13 yrs)) 
Sex  
• Castrated Males: n=13 
• Intact Males: n=9 
• Spayed Females: n=8  
• Intact Females: n=1 
Breed  
• Mixed breed dogs: n=3 
• Golden retrievers: n=3 
• Labrador retrievers: n=2 
• French bulldogs: n=2 
• English bulldogs: n=2 
• Yorkshire terriers: n=2 
• German shepherd dogs: n=2 
• Staffordshire terrier: n=1 
• Miniature poodle: n=1 
• Pembroke Welsh corgi: n=1 
• Standard poodle: n=1 
• Doberman pinscher: n=1 
• Jack Russel terrier: n=1 
• Springer spaniel: n=1 
• Brittany spaniel: n=1 
• Wheaten terrier: n=1 
• Miniature schnauzer: n=1 
• Maltese: n=1 
• West Highland white terrier: n=1  
 
Head-conformation  
• Brachycephalic: n =6  
• Mesaticephalic:  n=19 
• Dolicocephalic: n=6 
Body weight (kg): range (median (IQR)): 1.4 kg-55.8 kg (23.4 kg(12.6 kg-31.3 kg)) 
Body condition score (9 pt): median (IQR): 5 (5-5) 
Presenting Complaint 
• Cough: n=31 
• Dysphonia: n=3  
• Sneezing/nasal discharge: n=2  
• Exercise intolerance: n=2 
• Reverse sneezing: n=2   
• Signs worse while eating and drinking: n=6 
• Paroxysms of cough with terminal retch: n=2 
• Recurrent aspiration pneumonia: n=3 
• Excessive panting: n=3  
• Increased respiratory effort: n=2  
Duration of clinical signs prior to presentation: range (median (IQR)): 2-43 mo (4 mo (2-8 mo)) 
Neurologic abnormalities* : n=4 
• Diffuse neuromuscular disease: n=2 
• Facial nerve paralysis: n=1 
• Peripheral vestibular disease: n=1 
Diagnostic Evaluation  
Thoracic radiographs (n=31) 
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• Unremarkable: n=11  
• Diffuse bronchial pattern: n=11  
• Radiographic evidence of aspiration pneumonia : n=7  
• Other  
o ME: n=3 
o Tracheal and main-stem bronchial collapse: n=1 
o Hypoplastic trachea: n=1 
o Bronchiectasis: n=1 
o Diffuse pulmonary osteomas: n=1 
o Cardiomegaly: n=1 
Laryngeal function examination (n=15: under propofol; respiration stimulated with doxapram) 
• Erythema: n=12 
• Laryngeal paralysis: n=7 
• Unremarkable: n=3 
• Laryngeal edema/swelling: n=1 
• Epiglottic retroversion: n=1 
• Laryngeal polyp: n=1 
Tracheobronchoscopy (n=13) 
• Diffuse erythema: n=7 
• Bronchiectasis: n=5 
• Bronchomalacia: n=5 
• Tenacious mucous: n=4  
• Increased tracheal vascularity: n=1 
• Tracheal stripe**w: n=1  
 
BALF cytology (n=13) 
• Neutrophilic: n=6 
o Non-septic: n=4 
o Septic: n=2 
• Eosinophilic: n=2 
• Mixed inflammation: n=3 
• Unremarkable: n=2 
BALF culture (n=13)  
• Negative: n=11 
• Positive: n=2  
o N=1: Beta hemolytic Streptococcus spp, Klebsiella oxytoca, E.coli, and 
Salmonella typhimuirium 
o N=2: Pseudomonas aeruginosa 
Table 6: Demographic (white) and diagnostic (grey) data from n=31 dogs presenting for 
cough in the absence of gastrointestinal signs.* Advanced diagnostics including MRI and 
electromyography (EMG) were not performed in dogs with neurologic disease. ** 
Tracheal stripe: proximal erythema of the trachea that dissipates toward the carina. 
(Figure 2) 
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Table 7 
 
Table 7:  Videofluoroscopic swallow study (VFSS) and respiratory abnormalities for all 
dogs. Dogs 1-2 (grey): No diagnosis was made despite standard respiratory workup and 
VFSS. Dogs 3-6 (white): A respiratory diagnosis was made with no concurrent 
alimentary abnormalities detected on VFSS. Dogs 7-14 (grey): Dogs were determined to 
have non-respiratory (alimentary cough) based on VFSS abnormalities and the absence of 
a concurrent respiratory diagnosis. Dogs 15-31 (white): Dogs had a respiratory source of 
cough in addition to VFSS abnormalities.  
* aspiration with both puree and liquid 
 Respiratory Diagnoses: (AP(rad)): radiographic dx of AP, (AP (bact)): radiographic 
Dog  Respiratory 
Dx 
VFSS  
Dx 
Loc. OP P- 
Cont 
LO/D A P NPR ME E-PP LES- 
AS 
Ref HH Aero 
1 None None None N Norm N N N N N Norm N N N N 
                
2 None None None N Norm N N N N N Norm N N N N 
3 CCB None Airway N Norm N N N N N Norm N N N N 
4 BE, BM None Airway N Norm N N N N N Norm N N N N 
5 EB None Airway N Norm N N N N N Norm N N N N 
6 AP(bact), 
LarPar 
None PP, Lar N Norm N N N N N Norm N N N N 
7 None EH Ali N Norm N N N N N Norm N N N N 
8 None EH, ME, 
LES-AS 
Ali N Norm N N N N Y EH Y N N N 
9 None OP, PH, 
P, NPR 
Ali Y PH N N Y Y N Norm N N N N 
10 None OP, PS, 
P, EH 
Ali Y PS N N Y N N EH N N N N 
11 None OP, Ref Ali Y Norm N N N N N Norm N Y N N 
12 None PH Ali N PH N N N N N Norm N N N N 
13 None PH, EH Ali N PH N N N N N EH N N N N 
14 None Ref Ali  N Norm N N N N N Norm N Y N N 
15 Airway collapse 
(Trachea/MSB) 
Aero Airway N Norm N N N N N Norm N N N Y 
16 CCB, BM EH, P, 
PH 
Airway N PH N N Y N N EH N N N N 
17 CCB PH Airway N PH N N N N N Norm N N N N 
18 CCB, LarPar HH, Ref, Airway, Lar N Norm N N N N N Norm N Y Y N 
19 CCB, LarPar, 
BM 
OP, P, 
Ref, PH 
Airway, Lar Y PH N Y Y N N Norm N Y N N 
20 EB, ER PH, LO/D Airway, Lar N PH Y N N N N Norm N N N N 
21 LarPar, BE, 
BM 
Ref, EH Airway, Lar N Norm N N N N N EH N Y N N 
22 CCB, LarPar, 
BE, BM 
Aero Airway, Lar N Norm N N N N N Norm N N N Y 
23 LarPar A, P, 
PH, OP 
Lar Y PH N Y Y N N Norm N N N N 
24 Lar. polyp Ref, A, 
LO/D 
Lar N Norm Y Y* N N N Norm N Y N N 
25 AP(rad) Aero, ME, 
EH 
PP N Norm N N N N Y EH N N N Y 
26 AP(rad) Aero, Ref, 
EH, 
PP N Norm N N N N N EH N Y N Y 
27 AP(bact), 
BE, BM 
Aero, Ref, 
PH, HH 
PP N PH N N N N N Norm N Y Y Y 
28 AP(rad), ER OP, LO/D PP Y Norm Y N N N N Norm N N N N 
29 AP(rad), 
HT 
EH PP, Airway N Norm N N N N N EH N N N N 
30 AP(sterile), 
BE 
Ref, ME, 
EH, MG 
PP, Airway N Norm N N N N Y EH N Y N N 
31 AP(rad), 
LarPar 
Aero, PH PP. Lar N PH N N N N N Norm N N N Y 
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evidence of AP with confirmed secondary bacterial infection, (AP (sterile)): radiographic 
evidence of AP without a secondary bacterial infection, (LarPar): laryngeal paralysis, 
(EB): eosinophilic bronchitis, (CCB): canine chronic bronchitis, (MSB): mainstem 
bronchi, (BE): bronchiectasis, (BM): bronchomalacia, (ER): epiglottic retroversion    
VFSS Criteria: (OP): oropharyngeal defect, (P-cont): pharyngeal contraction, (LO/D): 
laryngeal obstruction/defect, (A): aspiration, (P): penetration, (NPR): nasopharyngeal 
reflux, (ME): megaesophagus, (E-P): esophageal peristalsis, (LES-AS): lower esophageal 
sphincter achalasia-like syndrome, (Ref): reflux, (HH): hiatal hernia, (Aero): aerophagia, 
(Norm): normal   
VFSS Diagnoses: (Y): yes, (N): no, (PH): pharyngeal hypomotility, (PS): pharyngeal 
spasticity, (EH): esophageal hypomotility  
Disease localization: (Lar): laryngeal, (PP): pulmonary parenchymal 
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Table 8 
Lateral Views  
Obtain pre-feeding video sequence(s) of the thorax (pharynx to LES). 
• High resolution images of the larynx are recommended  
Slurry (Canned Pureed Food) 
• Obtain single video sequence consisting of 3 swallows focused on the upper esophageal 
sphincter (UES); follow 3rd-4th swallow to the LES 
• Focus on the LES while actively swallowing  
• Focus on the LES while the dog is not eating but is sitting or standing  
Liquid  
• Obtain a single video sequence from the UES (3-6 rapid swallows) panning to LES  
Kibble  
• Obtain a single video sequence that follows one kibble swallow from the UES to the 
LES; stay focused on the LES while the patient is actively swallowing  
• Focus on the LES while the patient is not eating (sitting or standing)   
• Repeat if necessary 
Application of abdominal pressure (induction of hernia or reflux): minimum of 1 video sequence 
focused on the LES 
Delayed Phase 
• Evaluate residual esophageal column height before and after 5 min of being held 
upright 
Dorsoventral Views  
Slurry 
• Focus on the LES while swallowing slurry  
• Focus on the LES while the patient is not eating  
Kibble  
• Focus on the LES while swallowing kibble 
• Focus on the LES while patient is not eating  
Table 8: Recommended minimum VFSS clips (video sequences) for a diagnosis of lower 
esophageal achalasia-like syndrome in dogs.  
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Table 9 
VFSS Metric Feature 
Baseline fluid line   Present 
Absent  
Subjective ME Present 
Absent 
Primary peristalsis (Contraction) Acontractile  
Hypomotile  
Hypermotile 
Normal  
Primary peristalsis (Propulsion) Effective Complete  
Effective Partial  
Ineffective  
Absent  
Primary peristaltic defect (Location) Focal  
Diffuse 
Secondary peristalsis (Contraction) Acontractile  
Hypomotile 
Hypermotile 
Normal 
Secondary peristalsis (Propulsion)  Effective Complete  
Effective Partial  
Ineffective  
Absent  
LES “bird beak”  Present 
Absent 
Narrowed/hypermotile distal esophagus Present 
Absent 
Entry of ingesta into the stomach With pharyngeal swallow  
With hydrostatic pressure  
Complete obstruction 
Normal  
Reflux  Present 
Absent 
Hiatal hernia  Present 
Absent 
Functional LES obstruction  Present 
Absent 
Consistency of food where achalasia was observed  Puree 
Liquid  
Kibble  
Inappropriate LES function  >50% of swallows  
<50% of swallows  
Collective impression to support LES-AS  Present 
Absent 
Subtype  Type 1 
Type 2 
Type 3 
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Pseudoachalasia  
Table 9: Standardized VFSS scoring rubric for LES-achalasia like-syndrome in the dog  
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Table 10 
VFSS Parameter LES-AS Control 
Failure of LES to open during 
pharyngeal swallowing 
19/19 0/20 
Abnormal LES relaxation 
>50% of swallows 
18/19 0/20 
Abnormal LES relaxation 
≥20%- <50% of swallows 
1/19 0/20 
Passage of ingesta from 
esophagus to stomach 
exclusively due to hydrostatic 
pressure 
13/19 0/20 
LES “Bird-Beak” 12/19 0/20 
Baseline Fluid Line 13/19 0/20 
Gastric Reflux 1/19 8/20 
Table 10: Frequency of VFSS abnormalities in LES-AS patients compared to normal 
controls.  
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Table 11 
VFSS Parameter Kappa  Standard Error  95% CI Degree of Agreement 
Presence of 
functional LES 
obstruction 
1.0 0.0 1-1 Perfect Agreement  
Timing of ingesta 
into the stomach 
(with pharyngeal 
swallow) 
0.7 0.2 0.5-1 Substantial Agreement  
Timing of ingesta 
into the stomach 
(from hydrostatic 
pressure) 
1.0 0.0 1-1 Perfect Agreement  
Baseline fluid line 1.0 0.0 1-1 Perfect Agreement 
Megaesophagus 
(presence or absence 
of ME) 
1.0 0.0 1-1 Perfect Agreement 
LES “Bird-beak” 0.7 0.2 0.4-1 Substantial Agreement  
Primary peristalsis 
(contraction) 
0.8 0.3 0-0.9 Substantial Agreement  
Primary peristalsis  
(propulsion) 
0.5 0.6 0.2-0.8 Moderate Agreement  
Hypermotile distal 
esophagus  
0.7 0.2 0.3-1 Substantial Agreement  
Consistency where 
LES-AS was noted  
0.9 0.1 0.7-1 Near Perfect Agreement  
Secondary peristalsis  0.8 0.1 0.6-1 Near Perfect Agreement  
Type of LES-AS 0.8 0.1 0.5-1 Near Perfect Agreement  
Reflux (abdominal 
pressure) 
1.0 0.0 1-1 Perfect Agreement  
Reflux (spontaneous)  0.9 0.1 0.8-1 Near Perfect Agreement  
Reflux (location) 0.9 0.1 0.8-1 Near Perfect Agreement  
Frequency of 
observed LES 
abnormalities  
0.3 0.3 0-0.9 Fair Agreement  
Table 11. VFSS parameters with kappa/weighted kappa (linear weighting) coefficients, 
standard error, 95% CI, and degree of agreement between the MU panel and an 
independent reviewer (CPG).  
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Table 12 
Clinical Outcome Parameters  VFSS Outcome Parameters  
Overall client perception of clinical improvement  Presence of ME (yes or no) 
Body weight  Esophageal motility and LES-AS subtype  
• Type 1 
• Type 2 
• Type 3  
• Normal motility  
Body condition score (9 point scale) Volume of gastric filling  
• Sitting or standing (small), medium, 
large) 
• After 5 minutes upright (small, medium, 
large) 
Frequency of regurgitation   
Duration of clinical improvement  
Complications  
Table 12: Clinical and VFSS outcome parameters for dogs having undergone mechanical 
dilation + BTA injections for LES-AS. Patients were evaluated a median (IQR) of 21 
days (14-25 days) post-treatment. 
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Table 13 
 Pre-Treatment  Post-Treatment  
Presence of ME 13/14 13/14 
Esophageal motility  Type 1: 7/14 
Type 2: 5/14 
Type 3: 2/14 
Normal: 0/14 
Type 1: 7/14 
Type 2: 5/14 
Type 3: 2/14 
Normal: 0/14 
Volume of gastric filling (sitting 
or standing) 
Small: 10/14 
Medium: 4/14 
Large: 0/14 
Small: 0/14 
Medium: 10/14 
Large: 4/14 
Volume of gastric filling (5 min 
upright) 
Small: 5/14 
Medium: 7/14 
Large: 2/14 
Small: 0/14 
Medium: 3/14 
Large: 11/14 
Table 13: VFSS outcome parameters for dogs with LES-AS pre- and post-treatment with 
LES mechanical dilation (pneumatic/bougienage) + BTA injections. For consistency, 
dogs were evaluated in the same position (sitting or standing) in their pre-treatment and 
post-treatment evaluations.  
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Table 14 
Region-of-Interest (ROI) Median (IQR)  
P 1.2% (0.6-1.6%) 
E3  0.8% (0.5-0.9%) 
E2 0.7% (0.6%-1.0%) 
E1 * 14.4% (7.7-27.4%) 
 
Table 14: Median (IQR) reflux volume displayed for esophageal (E1-E3) and pharyngeal 
(P) regions of interest (ROI). Volume is displayed as a percent of gastric counts.(243)  
The volume of refluxate in the E1 ROI was significantly increased compared to E2, E3, 
and P ROI. E1: distal esophagus, E2: middle 3rd of esophagus, E3: proximal 3rd of the 
esophagus, * statistical significance  
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Table 15 
 
Metabolic Protein Tissue of Origin Relative Abundance 
(Gastric Fluid) 
Double-headed protease inhibitor Salivary  1/230 
Pancreatic Lipase  Pancreatic  4/230 
Chymotrypsin-C Pancreatic  12/230 
Pancreatic alpha-amylase  Pancreatic  16/230 
Anionic trypsin  Pancreatic  19/230 
Chymotrypsin Pancreatic  37/230 
Pancreatic secretory granule protein  Pancreatic 42/230 
Chymotrypsin-like elastase Pancreatic 46/230 
Zymogen granule membrane associated 
protein 
Pancreatic  48/230 
Zymogen membrane granule protein Pancreatic 50/230 
Pancreatic triacylglycerol lipase  Pancreatic  54/230 
Gastric Lipase  Gastric  58/230 
Colipase  Pancreatic 63/230 
Bile salt activated lipase  Pancreatic  66/230 
Chymosin Intestinal 72/230 
Pepsin A Gastric  86/230 
 
Table 15: Metabolic proteins demonstrating increased abundance (GF vs. Normal) and 
relative abundance in GF based on normalized spectral absorbance factors (NSAF) are 
provided. Only proteins found within the 100 most abundant proteins are displayed 
above. Gastric fluid (GF) 
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Table 16 
Acoustic 
Parameter 
(units)  
Acoustic Behavior 
  Cough Chew Lick Bark Whine Drink Growl Throat-
clear 
Duration (sec) 2.1x10-1 
(1.5-
2.0x10-1) 
1.7x10-2 
(1.2-
2.4x10-2) 
2.8x10-2 
(2.0-
5.2x10-2) 
4.0x10^-1 
(2.2-
5.7x10-1) 
4.7x10-1 
(2.5-
5.8x10-1) 
5.0x10-2 
(3.3-
6.1x10-2) 
3.5x10-1 
(2.8-
5.3x10-1) 
1.5x10^-1 
(1.3-
.2x10-1) 
RMS amplitude 
(unitless)  
6.3x102 
(3.2-
9.9x102) 
4.7x102 
(2.3-
9.0x102) 
1.5x103(
8.3x102-
2.3x103) 
1.6x103 
(1.1-
2.x103) 
8.4x101 
(6.1x101 -
1.64x102) 
1.8x102 
(6.5x101-
2.3x102) 
2.3x102 
(1.8-
3.8x102) 
1.9x102 
(1.2-
5.5x102) 
Maximum 
amplitude  
(unitless) 
3.3x103 
(2.0-
6.3x103) 
1.7x103 
(9.1x102
-
1.2x103) 
4.7x103 
(3.7-
6.5x103) 
1.1x104 
(7.2x103-
1.3x104) 
6.2x102 
(1.2-
3.5x102) 
9.9x102 
(3.9x102-
2.4x103) 
8.8x102 
(6.1x102-
1.2x103) 
1.4x103 
(6.9x102-
2.9x103) 
Time to 
maximum 
amplitude (sec) 
6.6x10-2 
(5.5-
7.6x10-2) 
9.0x10-3 
(6.0x10-
3-1.4x10-
2) 
1.4x10-2 
(9.0x10-
3-6.3x10-
2) 
1.2x10-1 
(5.2x10-2-
1.7x10-1) 
3.2x10-1 
(1.2-
5.2x10-1) 
2.6x10-2 
(1.8-
3.5x10-2) 
1.5x10-
1(1.2-2x10-
1) 
4.9x10-2 
(2.1-
6.3x10-2) 
Slope  
(unitless) 
5.5x104 
(3.7-
9.0x104) 
1.9x105 
(1.1-
4.1x105) 
3.4x105 
(1.8-
6.7x105) 
1.1x105 
(6.8x104-
2.2x105) 
1.7x103 
(8.6x102-
6.2x103) 
1.4x104 
(7.1x103-
4.8x104) 
5.9x103 
(4.5-
8.1x103) 
2.8x104 
(2.2x104-
1.3x105) 
Inter-behavioral 
interval  
(sec) 
1.3 (1.0-
1.7) 
3.2x10-1 
(2.8-
3.5x10-1) 
2.6x10-1 
(1.8-
3.0x10-1) 
3.2x10-1 
(1.4-
9.6x10-1) 
2.4x10-1 
(2.8-
3.5x10-1) 
2.1x10^-1 
(6.6x10-2-
2.8x10-1) 
5.3x10-1 
(2.2-3.6 
x10-1)  
1.6 (1.1-
1.9) 
Maximum 
frequency (Hz)  
1.7x102 
(1.7-
3.5x102) 
3.5x102 
(1.7x102
-
1.0x103) 
3.5x102 
(1.7-
3.5x102) 
6.9x102 
(5.2x10^2-
1.0x103) 
5.2x102 
(5.2-
7.8x102) 
1.7x102 
(1.7-
3.5x102) 
1.7x102 
(1.7-
5.6x102) 
1.7x102 
(1.7-
3.5x102) 
Maximum 
power 
(dB) 
8.7x101 
(8.2-
9.0x101) 
7.7 (7.0-
8.3x101) 
9.1x101 
(8.6-
9.4x101) 
9.6x101(9.
4-9.9x101) 
7.2x101 
(6.7-
7.8x101) 
6.8x101 
(6.1-
7.4x101) 
7.7x101(7.
4-7.9x101) 
7.9x101 
(7.0-
8.7x101) 
Energy 
(dB) 
9.1x101 
(8.7-
9.9x101) 
8.2x101 
(7.5-
8.7x101) 
9.3x101 
(8.9-
9.7x101) 
1.1x102 
(1.0-
1.1x102) 
8.1x101 
(7.9-
8.7x101) 
7.2x101 
(6.7-
7.8x101) 
8.8x101 
(8.5-
9.2x101) 
8.3x101 
(7.9-
9.1x101) 
Table 16: Objective acoustic parameter (AP) data for each acoustic behavior (AB). Data 
are presented as median (IQR). Definitions for each AP are provided in Table 1. Hertz 
(Hz), decibel (dB), seconds (sec). Amplitude measures are unitless.  
Temporal Parameters: Duration: Time from start to the end of the AB; Root mean squared 
(RMS) amplitude: Effective amplitude of the AB, Maximum amplitude: Maximum of 
amplitude values in the AB, Time to maximum amplitude: Time to achieve maximum 
amplitude, Slope: Maximum amplitude / Time, Inter-behavioral interval: Time between 
AB  
Spectral Parameters: Maximum frequency: Frequency at which maximum power is 
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reached, Maximum power: Maximum power of the AB, Energy: Total energy within the 
bounds of the AB.  
  
158 
 
Table 17 
 Cough Chew Lick Bark Whine Drink Growl Throat-
clear 
Cough  0.0001 0.0001 0.0001 0.0001 0.0002 0.0001 0.09 
Chew 0.0001  0.0001 0.0001 0.0001 0.0001 0.0001 0.001 
Lick 0.0001 0.0001  0.0001 0.0001 0.0001 0.0001 0.0001 
Bark 0.0001 0.0001 0.0001  0.0001 0.0001 0.0001 0.0001 
Whine   0.001 0.0001 0.0001 0.0001  0.0001 0.04 0.001 
Drink 0.0002 0.0001 0.0001 0.0001 0.0001  0.0001 0.06 
Growl 0.0001 0.0001 0.0001 0.0001 0.04 0.0001  0.001 
Throat-
clear 
0.09 0.001 0.0004 0.0001 0.001 0.06 0.001  
Table 17: Analysis of similarity was performed for eight different AB with P<0.001 
considered significant. Behavior comparisons reaching statistical significance suggest 
that these behaviors are statistically dissimilar to each other. AB comparisons that did not 
reach statistical significance are highlighted in black.  Cough was found to be dissimilar 
to all other AB with the exception of throat-clear. (R: 0.50) Acoustic behavior (AB) 
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Table 18 
Acoustic Parameter AB distinguished from 
cough and TC 
P value 
Duration (sec) Chew, Lick, Drink  <0.001 
RMS amplitude  Whine, Drink, Bark <0.001 
Maximum amplitude   Whine, Drink, Growl, Bark <0.001 
Time to maximum amplitude 
(sec) 
Chew, Lick, Drink <0.001 
Slope  Chew, Lick <0.001 
Inter-behavioral interval (sec) Whine, Lick, Drink <0.001 
Maximum frequency (Hz) Whine, Bark <0.001 
Maximum power (dB) Whine Chew, Drink, Bark  <0.001 
Energy (dB) Whine, Chew, Drink, Bark <0.001 
Table 18: A one-way ANOVA on Ranks was performed to identify discriminatory 
acoustic parameters distinguishing respiratory from non-respiratory acoustic behaviors 
(AB). Respiratory AB, cough and throat-clear were distinguishable from all other AB by 
≥ 2 objective AP. P <0.05 is considered significant. TC: Throat Clear. Hertz (Hz), decibel 
(dB), seconds (sec)  
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Table 19 
A Cough 
(n=24) 
Chew 
(n=30) 
Lick 
(n=30) 
Bark 
(n=30) 
Whine 
(n=16) 
Drink 
(n=30) 
Growl 
(n=15) 
Throat- 
clear 
(n=8) 
Correct 
identification 
24 30 28 28 16 29 15 7 
Incorrect 
identification 
0 0 2 2 0 1 0 1 
Percent correctly 
identified  
100% 100% 93% 93% 100% 97% 100% 89% 
B Respiratory 
(n=32) 
Vocalization (n=75) Feeding (n=90) 
Correct 
identification 
32 73 90 
Incorrect 
identification 
0 2 0 
Percent correctly 
identified  
100% 97% 100% 
Table 19: A randomized sampling of waveforms were manually identified by a blinded 
trained reviewer according to AB (A) with a total accuracy of 96.5%. When grouped 
according to category (i.e. respiratory, vocalization, and feeding behaviors) (B), 
respiratory AB were correctly identified 100% of the time.  Accuracy was calculated as 
the percent of waveforms correctly identified. Strong reliability was calculated with a 
kappa coefficient of 0.76 for individual AB assignment, and perfect agreement was 
calculated for group assignment with a kappa of 0.97. When categorized by group, 
respiratory AB were correctly assigned 100% of the time.  
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